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Abstract 
In a pretargeting radioimmunotherapy system, monoclonal antibodies (MAbs) 
derivatised with a high affinity streptavidin receptor are used in a localisation step. 
Once tumour localisation has taken place and active or passive MAb clearance has been 
completed the final step is the administration of a radiotoxic radiopharmaceutical, 
which is a ligand to a high affinity receptor on the MAb. This technique maximises the 
tumour to background ratio and facilitates the use of much higher tumour radiation 
doses. 
Four pretargeting effector molecules were developed with a view to selecting the best 
performer for further pretargeting assays. When analysed for key characteristics, two 
of the novel.. DOTA-biotin conjugated effector molecules were selecxed for advanced 
testing in a pretargeting context. The other two effector molecules were not suitable 
for in-vivo use. Mouse biodistribution studies of indium-111 and yttrium-90 labelled 
effector molecules showed minimal organ retention and very rapid clearance. 
Herceptin was conjugated with streptavidin in the presence of stannous ions using UV 
irradiation to produce free suiphydryl groups. The free sulphydryls of the irradiated 
antibody were calibrated and stability of the conjug9te was tested. 
The Herceptin-streptavidin system was evaluated for cell binding potential with human 
breast cancer cells. Pretargeting studies were performed both in-vitro and in-vivo as 
were internalisation and externalisation assays. 
The two biotin derivatised effector molecules label well, have been shown to be very 
stable, and have a favourable biodistribution in murine models. The Herceptin- 
streptavidin conjugate has been produced with a 1: 1 stoichiometry to greater than 
99 % purity. Binding studies have been successful and show a very similar nature to 
Herceptin with albeit slower antigen association kinetics. Biodistribution and in-vivo 
pretargeting results are pending. With the results collected, it appears that the effector 
. fl 
molecules are promising agents for pretargeting, though final results must be collated 
before drawing conclusions on the antibody conjugate. 
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Chapter 1 The reasons for a pretargeting 
nuclear medicine therapeutic 
1.1 The case for Nuclear Medicine 
The choice of strategy in tumour therapy is critical in giving the patient the best 
possible prognosis. Surgery can often prove very effective in removing primary tumours 
but can do little in terms of micro-metastases and discovering small or inconspicuous 
neoplasms. Cancer radiopharmaceuticals are used at nanomole quantities and have the 
potential for a high degree of specificity delivered to targeted cells. By using 
appropriate radiation levels high quality images and/or targeted therapy can be 
achieved. This degree of specificity and versatility gives nuclear medicine a growing 
prospect in future therapeutic and imaging oncology and in other disease specialities. 
1.2 Aims and objectives 
Pretargeting has been identified as providing the best potential tumour to background 
radioactivity levels in a nuclear medicine therapeutic context. With this in mind, the aim 
of this study was to produce a pretargeting system by synthesising and evaluating four 
novel effector molecules and to synthesise and evaluate a trastuzumab-streptavidin 
conjugate. 
Four effector molecules were synthesised and evaluated with the aim of producing an 
improved effector molecule over current designs. Two (DLB and DBB) of the four were 
chosen for further pretargeting and testing, however two of the four candidate 
molecules did not label sufficiently well nor produce favourable biodistribution data. 
Below is a flow chart of the process undertaken to develop the effector molecules. 
Synthesis & 
purification of 
effector 
molecule 
Initial 
studies - 
radiolbbeling 
with 
alternativ® 
-> Ksnýtics 
-> Biodistribution 
Figure 1.1 Flow chart outlining the line of investigation taken with the 
development of the pretargeting effector molecules 
18 
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At each stage of the synthesis and evaluation, if the effector molecules were not 
considered suitable for further characterisation with the view to pretargeting 
applications, the experimentation would cease. It was for this reason that only two of 
the four molecules originally designed were fully characterised and assayed and these 
two are described in chapters 3 and 4. 
Further to the development of the effector molecules, a streptavidin derivatised 
antibody was synthesised using a novel photo-reduction method. The antibody used 
was trastuzumab due to its known success in the clinic. By contrast to conventional 
radioimmunotherapy, the pretargeting approach involves the administration of an 
unlabelled antibody-streptavidin conjugate, which when bound to the tumour can be 
targeted with a radiolabelled effector molecule for imaging or therapeutic purposes. 
Below is a flow chart detailing an overview of the trastuzumab-streptavidin conjugate 
synthesis and evaluation process. 
I IIn-vitro Syntheis of analysis of Future work trastuzumab- Iý the conjugate targeting Internalisation Biodistribuion 
streptavidin without Lstudles studies and murine 
conjugate ehr tumour studies jmolecules 
Figure 1.2 Flow chart describing the overall investigation strategy for the 
antibody-conjugate synthesis and pretargeting studies. 
With the exception of animal biodistribution and murine tumour studies, all of the 
above work was completed. The work henceforth introduces the subject of pretargeting 
and subsequently describes in detail the experimentation and characterisation of the 
streptavidin/biotin pretargeting system developed. 
1.3 Tumour associated antigens 
Many methods exist to specifically target tumours for detection and therapy, which may 
be used in combination or isolation. Unfortunately, all tumour-targeting methods 
cannot detect and provide therapy to malignancies in all circumstances. This is because 
almost all methods are not absolutely tumour-specific. Many tumour types in humans 
and animals express distinct cell surface antigens that distinguish them from other 
tissues 6-8. These "Tumour-associated antigens" (TAAs) are often used as targets for 
increasing the specificity of tumour diagnosis and therapy. TAAs are molecules that are 
found on the cell surface or within tumour cells that are either absent or in very low 
concentrations in normal cells 9. 
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TAAs are of clinical interest since they are a means by which the neoplasm may be 
targeted with therapy via a systemic administration. Some of these antigens are viral 8, 
10,11 but many more remain as yet uncharacterised. Numerous tumour cell-lines over- 
express cell-surface receptors that may be used for targeted therapy using antibodies 
as targeting vehicles to deliver the radioisotope to its desired tissue 12,13. The sensitivity 
of these targeting agents is dependent upon the in-vivo interaction of several variables 
such as the level and heterogeneity of receptor expression, the proportion of targeted 
cells, the tumour to non-target ratio and the attenuation by overlying normal tissue 14. 
TAAs can differ greatly in both their structure and number at the cell surface, in relation 
to the molecular species presented on normal cell surfaces 6, ', 15. TAAs can be 
categorised into two groups 16: heteroantibody and autoantibody identified (Humoral 
immunity) antigens form one group. The second group are those that can evoke a 
cellular immunity response, especially with respect to cytotoxic T lymphocytes (CTLs). 
This is observed by presentation of HLA (human leukocyte antigen) class II molecules 
on antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs). A 
number of TAAs are known which fall into both groups. One such example includes 
1' carcinoembryonic antigen (CEA) ' is 
The surface antigen expression by tumour cells is dependent upon two major limiting 
features. The first is that the age of the cell determines the concentration of the 
presented antigen. That is the older the cell the less antigen is expressed. Kufe et al 
presented in-vitro data showing the decline in surface expression with increasing 
passage levels 19. The second factor is that log growth phase cells express the highest 
number of cell surface antigens 20. Hence, the phase of the cell cycle determines 
antigen expression and thus imaging and therapeutic efficiency. 
Tumour cells are known to frequently shed HLA Class I molecules 21. HLA losses are 
detected when the primary tumour breaks the basal membrane, invades the 
surrounding tissues, and starts to metastasise. These altered HLA class I phenotypes 
probably constitute the major tumour escape mechanism facing anti-tumour T-cell 
mediated responses 22. Because of their difficulty in targeting as mentioned above, HLA 
Class I molecules at present are not suitable for tumour detection and therapy. 
However, because they are an excellent indicator as to the disease state and hence 
early therapy much emphasis is being placed on solving this problem. 
Tumours were thought to arise from one genetic clone, but in fact some tumours, as 
many as 10 %, are in fact bi-clonal 23. A feature of tumours is antigenic modulation, but 
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solid tumours. As efficacy is reduced with repeated administration of the same 
antibody, sometimes a heterologous mix of MAbs may be used instead. 
While immunohistochemistry shows some TAAs have a notable heterogeneity within 
tumours, other TAAs are expressed on all primary tumour derived cells 24. In order to 
generate a highly specific tumour-targeting drug, a scrutinised selection of viable TAAs 
is essential to derive the ideal targeting vehicle. 
1.4 Antibodies for tumour targeting 
For a long time antibodies (Abs) were known to bind to antigens with very high affinity 
and specificity. However, early purification fractions of Abs were very heterogeneous 
(Polyclonal antibodies) and the lack of specificity hampered suitable experimentation. It 
is noteworthy to mention that even at this stage, animal and clinical studies were 
undertaken demonstrating promising therapeutic value 25-30. Radiolabelling of polyclonal 
Abs first took place in the 1950's and 1960's 31-3`. The first antibodies targeted ferritin 
and human chorionic gonadotropin 27,35-3' In 1975 Georges Köhler and Cesar Milstein 
of the UK Medical Research Council's Laboratory of Molecular Biology fused myeloma 
cells to lymphocytes immunised with a specific antigen using polyethylene glycol (PEG) 
38. This procedure derived cell-secreted antibodies bound to antigen 38 ' 39. For the first 
time researchers were able to generate individual specific monoclonal antibodies 
(MAbs). From this discovery was born the vehicle to which radioactive isotopes could be 
attached with the accuracy to localise tumour and other diseased tissue targets. 
Figure 1.3 A ray-traced image of a human IgGi. The two heavy chains 
are in red, the two light chains are in yellow and the carbohydrate attached 
to the heavy chains is in purple. 40 
')l 
Successful radioimmunodetection (RAID) and radioimmunotherapy (RAIT) depends on 
the ability of the antibody to bind to TAAs highly selectively 27,37,41 . Hence, the choice 
of antigen target is vitally important in deriving an accurate image of the tumour or 
suspected growth. High-dose targeted radiation therapies using selected radioisotopes 
can also be used if acceptable localisation can be achieved. 
While radiolabelled MAb clinical studies were being carried out on CEA, it was observed 
that malignant breast tissue was targeted 36,37,41,4z. The low percentage binding of 
MAbs to the tumour site meant that computer processing was required to resolve the 
regions of greater radioactive uptake over the high background observed with the large 
amount of unlocalised radiolabelled antibody 43. Heterologous antisera would give a 
very low tumour to background ratio. MAbs derived from hyper-immune polyclonal sera 
could bind to tumours expressing the epitope but not tumours without the epitope. The 
potential for reducing background radiation and increasing specific binding was very 
important in the development of both improved immunoscintigraphy and therapeutics. 
1.4.1 Advantages of monoclonal antibodies 
The systemic injection of radiolabelled MAbs can lead to identification of metastases, as 
these are clonal cells". However, tumours derived from an entirely different origin may 
still be localised by the MAbs if they too express the same specific surface antigen 45. 
This information is important to ascertain, as not all neoplasms are individual in their 
surface antigen or surface protein presentation. 
Data has been published on the imaging of internalised antigens using radiolabelled 
MAbs. TNT-1 has been used for RAID and RAIT of human cervical carcinomas in mouse 
models to target intracellular antigens, which are integral structural components and 
are retained by degenerating cells 46. PSMA (Prostate-specific membrane antigen) is 
expressed at a high density on the cell membrane of all prostate cancers and after MAb 
binding, PSMA-MAb is rapidly internalised 47. The PSMA internal domain is the target of 
the well studied and successful prostatic cancer imaging agent Prostascint® 48. 
The major histocompatibility complex system may be deactivated in tumour cells so 
antigen presentation may be limited. For this reason, tumour lines that are selected for 
RAIT are those that have novel antigen presentation. Various high-throughput 
screening studies can be utilised to generate much of the binding data from various 
histological preparations. 
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localises to the cell nucleus 49. If external moiety binding is considered, then the 
knowledge of the shape of the cell is relevant to its potential to be sterilised due to the 
proximity of the radioisotope to the cell nuclei. MAb internalisation facilitates low energy 
Auger emissions to impose a high degree of cytotoxicity when using radioisotopes such 
as 1251 50 This could then allow isotopes with a longer half-life to be used, and render 
the cells damaged beyond nuclear repair. Normal tissue internalisation would definitely 
be undesirable. A study carried out by Welt et a/ proposed that 8% of '25I-radiolabeled 
TA99 MAb was internalised into a tumour xenograft in mice, and allowed imaging up to 
10 weeks later 51. However the method of RAIT employed determines whether this is a 
desired effect or not. Internalisation is probably immaterial in a RAIT context for all 
particles which are more energetic than Auger emissions. In a two-phase administration 
therapy of a MAb (Pre-targeting) and then a radiolabelled "Chaser" molecule 
internalisation of the MAb is not desired. Below is an example of an "'In-labelled PSMA 
antibody used for diagnostic imaging of prostatic cancer. 
Figure 1.4 Transaxial CT/Nuclear Medicine image (SPECT) fusion of'11In- 
Prostascint (PSMA MAb) indicating prostatic cancer seen at the pelvis level 
indicating a primary plus two lymph node metastases 
Tumour heterogeneity has a great impact upon the expression of TAAs. Different cells 
within a heterogeneous solid tumour may express varying levels of TAAs and thus 
another antigen must be targeted in order that a more uniform binding pattern is 
achieved, both in therapy and in imaging. In one study a combination of 5 variants of 
MAb were used and these had an improved localisation to the tumour over the single 
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another antigen must be targeted in order that a more uniform binding pattern is 
achieved, both in therapy and in imaging. In one study a combination of 5 variants of 
MAb were used and these had an improved localisation to the tumour over the single 
MAb application control 52. Another study proposed a ten-fold increase in localisation 
with two MAbs over a single MAb 53. This line of work is worthy of far more 
consideration. 
Regional injection of radiolabelled MAbs about the site of the tumour may aid the 
reduction or prevention of cross-reactivity and may increase tumour-uptake of 
specifically targeted MAbs. The spin-off would be increased performance in RAID or 
RAIT efficacy In a localised but not in a systemic context. Only a short period would be 
necessary between administration and imaging. Localisation times would be shorter 
and systemic doses would be expected to be much lower. Radioisotopes with shorter 
half-lives with high L. E. Ts could be used while still protecting more of the surrounding 
tissues. Tumour-radiation-dose should be at a maximum, concentrated at the site of 
Interest, while whole body dose would be limited. MAb injections into different regions 
of a large carcinoma could also ensure an improved distribution throughout the hypoxic 
core thus increasing the chance of a complete tumour-kill in one therapy. 
Subcutaneous and infra-lymphatic administration for lymphoscintigraphy studies have 
been carried out, yielding some good results s4,55. One drawback of this approach Is 
that identifying new metastases may be less effective. Intraperitoneal injections would 
also be appropriate for certain abdominal tumours as faster uptake and less systemic 
antibody could mean better sequestration 56. 
A growing number of studies have tried to develop MAbs with an increased specificity 
and lower human immunogenicity. Genetically recombinant MAbs such as chimeric 
MAbs, humanised MAbs and single-chain variable fragments (ScFv) are interesting 
potential vehicles of the future. It is becoming Increasingly easy to generate human 
MAbs to any human TAA using Crossbred TransChromo (TC) mice and the usual 
hybridoma techniques 57. A novel adaptive approach to using tumour targeted 
radiolabelled MAbs or Fab fragments is to use bi-specific Antibodies (BsAb) and bi- 
specific (Fab')2 haptens. These may be engineered to bind to TAAs and sequester a 
radiolabelled molecule that would thus Indirectly localise the tumour cell. 
Radioimmunoguided surgery (RIGS) is an area of growing interest and potential 58, 
allowing surgeons to remove radioimmunotargeted areas of disease of either primary 
carcinoma or metastases. A hand-held gamma detection probe is used for the purpose 
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of identifying the tumours 59. These areas may otherwise go undetected due to tumour 
size, location or morphology and may be curable by resection alone. RIGS is a very 
sensitive technique and providing the growth of interest can be accessed, it may be in 
some cases more sensitive than external camera imaging 60. This argument however 
becomes increasingly less relevant, the more that diagnostics and therapy improve, 
though a complete resection may be, in certain situations, a preferable choice, 
especially if the tumour is juxtaposed to a vital or radiosensitive structure. Many papers 
have been written on the subject detailing the use of RIGS for the treatment of various 
diseases 61'3. 
Despite Inefficient radioimmunotargeting of solid tumours, good clinical therapeutic 
results have been obtained in haematological tumour patients. B-cell lymphomas have 
been successfully treated with radiolabelled MAbs. Overall response rates of 60 - 70% 
have been reported in patients with non-Hodgkins lymphoma using radiolabelled anti- 
CD20 MAbs. The murine anti-CD20 MAb (C2B8) labelled with 90Y, designated as 
90Y-ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals Corp., San Diego, CA), has 
recently been approved for the treatment of relapsed or refractory low-grade follicular 
non-Hodgkin's lymphoma. 
1.4.2 Disadvantages of monoclonal antibodies 
Murine Mabs in humans can derive human-anto mouse antibodies (HAMA) 
Murine MAbs (mMAbs) were found to work well in rodent studies 1, but when applied 
to human systems they caused a rapid immunogenic response rendering them inactive 
64. In some rare cases fatalities emerged 64. It also became apparent that even when 
mMAbs were bound to an epitope, the mMAb heavy chains would not always trigger an 
immune response 65. 
MAbs may display cross-reactivity 
Many different MAbs that were originally intended to be used to target a specific 
tumour cell type have been found with a wide variation in cross reactivity. For example 
the MAb 115D8 was produced in response to a breast carcinoma antigen that is also 
recognised by the DF3 antibody. This antigen, CA 15-3, is a 300 kDa antigen present 
on the apical borders of secretory mammary epithelial cells. MAb 115D8 binds to 
breast, gastrointestinal tract, lung, kidney, urinary bladder and ovary cancers 66,6' 
However MAb 115D8 reacts also with most colon carcinomas but DF3 doesn't 68. Thus 
tumour pathology must be assessed and the specificity of a MAb known so that the 
tumour can be targeted to gain an accurate treatment plan. Distinct epitopes are 
expressed on tumour cell surfaces, which will allow specific tumour-type dependent 
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MAb generation. This would be especially important in the role of the radiolabelled 
antibody delivery because it must specifically localise the radiation dosage to the 
tumour site alone and non-specific sites should not be targeted. 
MAbs have slow binding kinetics 
One of the features of MAbs is that because they are large molecules, their localisation 
kinetics to TAAs are very slow when administered systemically. The binding affinity 
constant (Ka) can be expressed for every cell line under analysis. One study suggests 
that MAbs with a Ka of less than 108 per mole will not derive a satisfactory image due 
to insufficient localisation. This is supported by evidence from another group, which 
used different antibodies to the same CFA antigen 69. 
Antigen expression may not always be constant and may cycle often 
Many tumours may lack obvious novel surface proteins and are thus difficult to derive 
novel immunoglobulins to recognise them as tumour cells 70. A rapid cell growth rate 
may also cause a more rapid turnover of presented antigens on the plasma membrane 
rendering radioimmunotargeting results more variable. 
Therapeutic MAbs require stable tumour-associated antigens 
The significance of membrane-bound antigen stability is not as important for MAb 
imaging as it is for therapy. A lower concentration of TAAs at the site of interest is 
needed for imaging than for therapy as high backgrounds can be removed with 
software manipulation. Stable membrane TAAs are essential for therapeutic success as 
radiolabelled MAbs can only remain at the site of a tumour as long as TAAs are present. 
Once bound by MAb some antigens are thought to remain unaltered 71. However, some 
antigens may be internally modulated 72,73 or shed from the cell surface once bound 73. 
This factor may need to be investigated in long half-life ß-radiation therapy where 
maximum tumour-radiation-doses are desired. 
Binding affinity may be adversely affected by radiolabelling 
Binding affinity may be modified by radiolabelling the MAb and as such must be shown 
to have a sufficient Ka to produce a high-resolution image. Physiological conditions also 
moderate binding affinity 69, though the shift in binding affinity depends on the 
compound or metal(s) attached to the antibody. 
Mabs only deliver low tumour to background ratios 
One large problem in using radiolabelled MAbs is the relatively low radiation dose 
delivered to the tumour tissue over that of normal tissue. The accumulation of 20 % to 
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30 % of injected dose (i. d) per gram of murine tumour tissue is recorded in one study 
74, but in humans only between 0.001% and 0.1% of injected dosage is delivered to 
the tumour site. 
Mabs may not be able to localise tumours due to physiological barriers 
Between the circulation and tumour other physiological and physical barriers may 
restrict and/or prohibit larger amounts of MAb from binding cells 
75. High interstitial 
fluid pressures of tumours have been described 76, though it remains unclear as to how 
important this is in precluding targeting in clinical situations. In two studies, near 
complete saturation of surface-TAAs was achieved in animal models 
77,78 and one in a 
human trial 79 though high concentrations were required. Thus lowering the 
background radiation remains the objective in detection and destruction of tumours. 
Conventional RAIT may result in a heterogeneous binding pattern in solid tumours 
Using MAbs is not just restricted to micro-metastases, as solid tumours with good 
penetration can also be targeted. Deep tumour penetration of MAbs is critical for it is 
assumed that they won't bind in large amounts to every tumour cell within a solid 
tumour mass. The low degree of vascularisation of tumours reduces both capillary 
permeability and increases necrosis at the tumour's core also restricting MAb delivery to 
all the target cells. This gives rise to a non-uniform distribution and mainly peripheral 
binding of radiolabelled MAbs. This is due to a limited penetration, antigen-negative 
tumour cell variants and high levels of MAb clearance. 
MAb penetration into large tumour masses is often poor due to the low diffusion 
efficiency of large molecules. This may be overcome by using smaller molecules that 
retain the specific antigen binding necessary. Such molecules include Fab' fragments 
and engineered ScFv antibodies 80. Reduced specificity and stability is observed with 
these entities and is deemed unsuitable for RAIT 81 
The use of MAbs can produce adverse undesirable conditions 
MAb administrations have given rise to various systemic pathologies Including fever, 
chills, vascular instability and dyspnoea 82. These symptoms have been attributed to the 
clearing of MAb aggregates, the removal of MAb-circulating free antigen complexes and 
the binding of the MAbs to free haemopoeitic cells 83. Toxicity appears to be dose 
dependent, as Dillman demonstrated that doses of 3 to 6 mg of MAb derive symptoms 
82,83 
. However in some cases, doses of between 200 and 1000mg have been safely 
introduced over slow infusion 84, ss. 
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The administration of murine MAbs (mMAbs) may lead to the development of a host 
immune response observed by the formation of human anti-mouse antibodies (HAMA) 
86-88. However heterophilic MAbs (either MAbs against various animal proteins or auto- 
MAbs) have been discovered in patients who have never undergone mMAb 
administration 89-91. This cross-reaction may be due to the pharmaceuticals of animal 
origin according to Dahlmann and Bridlingmaier 92. Another possibility is that HAMA 
responses may be as the result of auto-MAbs (Rheumatoid factor and others) 89. All this 
points to the idea that mMAbs are immunogenic and that with successive applications, 
MAb to tumour localisation will become increasingly less successful. A study by Dillman 
suggests serious immune responses have resulted from the use of mMAbs 93. 
It seemed necessary to lead research in the direction of creating MAbs that derive a 
less immunogenic response to mediate increased efficacy as a drug and improved 
repeat-administrations. In one study by Abdel-Nabi et al, repeat-administrations of a 
mMAb gave rise to 16 % of patients presenting anaphylaxis 94. One problem with 
blood-HAMA presence is that serological tests that use mMAbs may produce errors. 
The production of HAMA can be controlled to some extent by immunosuppressive 
drugs, such as Cyclosporin A 95, although general immunosuppression of patients is 
undesirable. To overcome the problem of immunogenicity of mMAbs, chimeric MAbs 
constructed from the variable regions of the mMAb together with human constant 
regions have been produced and have shown reduced immunogenicity In man 96. 
Humanised MAbs have been constructed from only the hypervariable complementarity- 
determining regions (CDRs) of the mMAb built into the framework of a human MAb 97, 
9ß. HAMA is not detected with these new MAb variants however the reciprocal human 
anti-human antibodies (HAHAs) are produced 99. 
HAMA responses were diminished in patients receiving mMAbs for non-Hodgkin's 
lymphoma therapy who had received chemotherapy previously loo. However patients 
who had not undergone chemotherapy developed a significant HAMA response 101. 
MAbs undergo radiolysis when radiolabelled with high levels of fl-emitting isotopes 
It has been shown in several reports that radiolabelled MAbs undergo radiolysis after 
labelling and in storage, pre-administration 102-104. A damaged MAb cannot preferentially 
bind to tumour targets and would thus remain in the blood until clearance had taken 
place. However human serum albumin and ascorbic acid which are both free radical 
scavengers, have been shown to abrogate MAb radiolysis, by preventing free radical 
28 
attack 103, pos. Dilution has the same effect in reducing radiolysis and should ensure that 
radiolabelled moieties remain intact and tumour-bound for the maximum possible time. 
MAbs for all their disadvantages may still provide effective therapy 
A universal system must be applied to the therapy of solid tumours and metastases, 
whereby all possible tumours and derivatives can be found and destroyed in one 
application. A recent paper by J. M. Mattes argues that all these factors do not stop 
effective therapies being created even with tumour heterogeneity, in the light of 
current and future technology 1°6. 
1.5 Radioisotopes 
Correct radioisotope selection is essential for successful tumour imaging and 
subsequent therapy and for reducing whole body irradiation. The stability of the 
radiopharmaceutical molecule must exceed the radioisotope half-life in-vivo. Providing 
effective radiation doses to tumour cells in the context of therapy is a difficult but 
essential part of good therapeutic design. Thus isotopes with generally short half-lives 
107 are selected, typically 2 to 6 days 
The kinetics of the radiopharmaceutical should be matched to the properties of the 
radioisotope in any radiopharmaceutical design. Using this approach, highly destructive 
short-lived a-emitting radioisotopes could be used to radiolabel pharmaceuticals with 
very rapid kinetics such as astatinated pretargeting effector molecules 108, X09. Longer- 
lived radioisotopes could be used to radiolabel pharmaceuticals with slower binding 
kinetics such as 90Y-Fab fragments 110-112. Using this approach will enable the tumour 
dose to be maximised while reducing the level of normal tissue-damage. 
1.5.1 Imaging 
Imaging isotopes should have all the attributes described below. The radioisotope 
should be a pure y-emitter with little or no particulate emissions. It should have a 
suitable emission-energy (typically 100-250 keV). The radioisotope should be 
chemically reactive, allowing its incorporation into pharmaceuticals. The biological half- 
life of the radioisotope should be comparable or less than the half-life of the 
pharmaceutical. The radioisotope should be non-toxic and carrier free. 
The radioisotopes used for initial tumour imaging will not be the same as those used 
for therapy. However, therapeutic radioisotopes may be useful if they can produce 
emissions capable of being imaged. A radiopharmaceutical with the correct physical 
properties should be able to characterise a tumour in terms of size, locations and 
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degree of radioisotope uptake by patient imaging. Below is a short table listing some of 
the more commonly used radioisotopes in scintigraphy. 
Table 1.1 Half-lives of common y-emitting imaging radioisotopes 113 
y -emitting 
radioisotope 
Half-life 
(hr) 
Gamma energy 
(KeV) 
Abundance of 
y emission (%) 
111 In 67.2 247,172 90.5 & 94 
99m TC 6.02 140 88.9 
1231 13 159 82.8 
It is noteworthy to mention that for current imaging practices it is thought that ionising 
114 radiation doses to normal tissues are pathologically insignificant " 
1.5.2 Therapy 
The ideal properties of a radioisotope for the use in therapy remains unclear 
Comparing various studies that use different radioisotopes, it is rare that total tumour 
eradication is achieved by radiopharmaceutical tumour-delivery. Some exceptions are 
haematological malignancies such as non-Hodgkin's lymphomas 116. Tumour size, 
morphology and degree of vascularisation of the tumour in-situ all determine the choice 
of radioisotope to be used for therapy. 
Complete tumour-cell sterilisation is the desired effect to ensure no further cell 
differentiation will take place. Hence a uniformly dispersed and densely concentrated 
localised radioisotope is required for the best chance of therapeutic success. 
Measurement of the number of ionisations which radiation causes per unit distance as 
it traverses a cell or tissue is called the linear energy transfer (L. E. T) of the radiation. 
The concept involves lateral damage along the path, in contrast to path length or 
penetration capability. For single cell tumours, such as lymphomas and micro- 
metastases, a very short-range emission is required to ensure an effective high-ratio 
cell sterilisation. For large carcinomas, a longer-range medium L. E. T radioisotope is 
required. Below is a graph published by Pouget and Mather detailing a generalised dose 
versus survivability curve of cells using radiation sources with different LET values. 
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Figure 1.5 A generalised cell survival curve from LET radiation 
The responsiveness of cells to radiation particle induced cytotoxicity depends on the 
number of clonogenic cells in the tumour and the possible variations in their 
sensitivities 118. However, the uniformity of the radiation dose distribution is also 
important and a reduced total tumour radiation dose may result when the delivery of 
the dose is non-uniform. The variance in the energy imparted at the micro-dosimetric 
level to individual cell nuclei constitutes the ultimate limit of the variance in delivered 
dose at a given mean tumour dose. Considering all dosimetric variances it is shown that 
for low-LET radioisotopes, the conventional micro-dosimetric variance will dominate, 
while with high-LET radioisotopes in general the micro-dosimetric variance may 
contribute significantly to the observed dose-response relationship. As a result the 
radiation dose for tumour control and normal tissue complications with high-LET 
radiation will be reduced compared to that with lower LET radioisotopes. However it 
may be favourable to deliver a radioisotope with a lower LET to ensure a dose to all 
clonogenic tumour cell nuclei that is sufficiently high and uniform to achieve a high 
probability of tumour control 111. 
The most obvious and highest L. E. T radioisotopes that could be used are a-emitting 
isotopes. a-Particles travel a very short distance, and this ensures that the tumour cell 
receives a greater radiation dose. Geerlings in his 1993 review paper showed that 5% 
of a-particles were absorbed as opposed to 0.125% of ß-radiation in a mono-cellular 
model after respective radiopharmaceutical addition 119. The study proceeded to 
demonstrate that only 13 a-particles per cell were required to achieve a 0.63 kill ratio 
as opposed to 500 000 ß-particles 119. 
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A long-range ß-emitter is required to deliver high radiation doses to each cell in a large 
carcinoma to ensure the best chance of therapeutic success. As the L. E. T of a long- 
range radioisotope is low, it is important that the radiation-dose to the tumour is higher 
to ensure maximal sterilisation rate. The high number of tumour-specific binding sites 
may be in the order of 10 000 to 100 000 per cell 119 making a high density of tumour- 
cell bound radiopharmaceutical a feasible aim. Depending upon the avidity of such a 
localising complex, the maximum tumour absorbed dose could be very high ensuring 
maximum sterilisation. Wessels and Rogus indicated that the radioisotope half-life is 
best matched to its carrier when it is 1.5 to 3 times longer than the time it takes for the 
radiolabelled product to achieve the maximal tumour-to-non-tumour target ratio 114. 
Tumour cells irradiated by p-particles must absorb three times more energy than those 
irradiated by a-particles to achieve the same sterilisation ratio 120. Successful ß- 
radiation therapy is however still achievable in carcinomas, as the radiation dose per 
cell can be increased with the long localisation times associated with MAb binding. As 
long as the bound radiopharmaceutical has a very long half-life at the bound site and 
good uniform tumour distribution, then successful therapy may be likely. For small 
tumours, in the order of 0.5 cm or less, the viability of an effective ß- 
radioimmunotherapeutic becomes dramatically less with decreasing size (See table 
1.2). 
ß-emitters are the isotopes of choice for therapy at present as they are highly 
radiotoxic but not as cytotoxic as a-emitters; so slow localisation Is not detrimental. 
Iodine-125 (125I) is a low auger-emitter, which is extremely radiotoxic in very close 
proximity to nuclear structures. Internalisation of a 125I.. radiopharmaceutical must 
occur in order to achieve cell destruction. MAbs don't always internalise so 
radioisotopes that cause cell death from the exterior of a cell must be used with these 
MAbs. These radioisotopes may include copper-67 (67Cu), yttrium-90 (90Y), palladium- 
109 (109Pa), iodine-131, (131I), lutetium-177 (17Lu) and rhenium-186 ('86Re) amongst 
others. 131I has been under great study over the last 30 years even though In many 
respects it has undesirable y-emisions121. It has a half-life of 8.05 days and derives 
stable decay products. Hence, it has been used in both immunoscintigraphy and RAIT 
applications. 
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Table 1.2 Table of some commonly used ß-emitting radioisotopes 
P -Emitting Half- Type of Decay 
Gamma ptimal Range for a 
Radioisotope life and Particle Energy ure Probability of 
(hr) Energies (KeV) .9 (mm) 
(MeV) 
64 Cu 12.8 0.57(40%) 511 0.40 
0.65 (19 %) 1346 
EC (41 %) 
67 Cu 61 0.39 (57 %) 91 1.6-2.8 
0.48 (22 %) EC 93 
0.58(20%) 185 
364.5 
131 I 193.5 0.81 (3 %) 364 2.6-5.0 
0.34 (9 %) 636 
0.61 (87 %) 
177Lu 160.8 0.176 (7%) 110 1.2-3.0 
0.385 (3 %) 210 
0.498(90%) 
186 Re 90.48 0.934(23%) 137 7.0 -12.0 
1.07 (70 %) 
188 Re 16.94 1.96 (2 %) 155 23.0-32.0 
2.116(80%) 
105 Rh 36 0.565 319 2.0-3.6 
153 Sm 46.2 0.641(26%) 70 2.8-5.0 
0.694(53%) 103 
0.803(20%) 
161 Tb 165.8 0.52 49 ---- 
0.46 74 
90 Y 64.8 2.3 (100 %) 0 28.0-42.0 
Generally, low-range beta sources are isotopes that have a mean range of less than 
200 µm. Such isotopes include phosphorus-33, tin-121, lutetium-177, osmium-191 and 
gold-199. As mentioned earlier in this section the isotope is only good enough for the 
therapy intended if the carrier and target molecules are distributed uniformly 
throughout the tumour (molecular size dependent). Significant enhancements to local 
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energy deposition are achieved with emission of internal conversion electrons following 
p-decay emission and its reciprocal Auger electrons. 
Radioisotopes with a medium range may be classified by a ß-particle range of less than 
1mm but more than 200µm. Viable therapy sources in this category include such 
radioisotopes as scandium-47, copper-67, arsenic-77, rhodium-105, palladium-109, 
silver-111, iodine-131, praseodymium-143, terbium-161, and rhenium-186.1311 is the 
most frequently administered medium range isotope, being used in RAIT 122,123 with a 
considerable degree of success. In the case of iodine-131, it is clear from its physical 
characteristics that it certainly isn't optimal for RAIT, since two thirds of the absorbed 
dose is from gamma radiation and has a large escaping fraction from most primary 
tumours and their metastases. Investigations into palladium-109 124-126 and rhenium- 
1861Z', 128 are being carried out even though, from the list above they are the only two 
which are not available carrier free. 
ß-Emitters with a long range (greater than 1mm) are necessary for areas where 
penetration to tumour tissue is less vascularised, such as the core in large tumours. 
Such isotopes include phosphorus-32, yttrium-90 and rhenium-188. Yttrium-90 has 
been used extensively for therapy and many clinical patient studies have been 
undertaken 129,130.90Y has a 64-hour half-life and is used in many RAIT applications. 
One of the limitations with 90Y is its bone sequestration, yet its benefits are thought to 
outweigh the risks. 
a-Particles are densely ionising and have short path-lengths making them good for 
specifically targeted radiation therapy. However, rapid localisation is necessary In order 
to minimise doses to normal tissues. Thus if such highly destructive radiation is used, 
extremely high specificity to tumour-only sites must be achieved. This is the major 
concern using a-radiation therapy. For single cell sterilisations a-emitters are very 
good, but a large non-specific toxicity may ensue as demonstrated by in-vivo 
experiments 131. a-sources are rarely suitable for therapeutic isotopes because their 
high nucleon composition often derives unstable daughter products. a-recoil has a 
typical energy of between 100 and 200 keV. This is slightly more than the binding 
energy of a macrocyclic radiometal complex. In turn this may rupture the metal 
complex and may indeed disrupt the tumour cell-bound ligand to diffuse away from the 
tumour 132. Below is a table of a selection of a-emitters, which have been considered in 
RAIT that may prove effective in therapy. 
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Table 1.3 Table of some commonly used a-emitting radioisotopes 
a -Emitting Half- Type of decay and Gamma Optimal range for 
Radioisotope life particle energies Energy a cure probability 
(Hr) (MeV) (KeV) of 0.9 (mm) 
211 At"' 7.2 a5.9 (42%) 670 0.06 
EC 7.5 (58%) 
212 *Bi 1.0 a 1.36 (64 %) 727 (7%) 0.09 
a 6.1 (36%) 0.06 
213 Bi 0.78 a 5.8 440 0.06 
a 8.4 0.08 
A study by Bloomer et al involving the use of "'At as an a-particle emitting isotope 
shows successful therapy in an experimental ascites model 133. In two other studies 
MAbs have been labelled with 2"At while MAb specificity is retained 133,134. 
Zalutsky et al demonstrated an Astatine (211At) immunoconjugate distribution pattern in 
. mice which was then used to calculate human doses on the basis of organ uptake 
135 
The study concluded that the short half-life of 7.2 hours was too short for MAb-bound 
tumour delivery. Instead local administration was planned for a clinical trial in order to 
achieve clinically therapeutic doses. However a more recent study using the pre- 
targeting method shows that astatine is indeed a viable and effective Isotope for 
consideration in specialised forms of RAIT 136. 
1.5.3 Radiolabelling 
MAb radiolabelling techniques have developed over time to facilitate the attachment of 
different radioisotopes to different molecules. Some radiolabelling methods facilitate 
the radioisotope to react with the MAb alone, whereas others require a coupling 
molecule. These methods are known as direct and indirect labelling respectively. 
Radioactive iodine isotopes were the first isotopes to be used in radiolabelling MAbs. 
'III and 131I are both inexpensive though imaging and therapeutic properties are 
suboptimal (See section 1.5.1). Iodine labelling of proteins is performed using 
electrophilic substitution, whereby a positively charged iodous ion bonds to the phenolic 
ring of the tyrosine amino acid side chain. For clinical labelling applications, the 
Iodogen method is most commonly practiced 137 
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Technetium-99m (99mTc) is the most frequently used radioisotope in nuclear medicine 
138 and with its excellent imaging properties is the radioisotope of choice for 
scintigraphy. Direct labelling using 99mTc methods are unsuitable as the radiometal 
dissociates during the imaging period. Two labelling methods have been developed and 
both methods provide stable and clinically safe compounds. 
Sulphur containing amino acids can be radiolabelled with 99mTc to form stable 
complexes. Sulphydryl groups are normally oxidised and are unavailable for 
radiolabelling. After reducing the sulphydryl groups with a mild reducing agent such as 
stannous ions or mercaptoethanol, the MAb is purified to remove the mercaptoethanol. 
The MAb can then be labelled with 99mTc in the presence of stannous ions. 
Indirect labelling with 99mTc can be achieved with a bifunctional chelating agent (BFCA). 
A problem in radiolabelling arises when the 99'Tc ion bypasses the chelator and binds 
directly to the protein and later dissociates in-vivo. A solution to this problem is to label 
the BFCA prior to attaching it to the MAb. An example of such a BFCA is N2S2 described 
139 by Fritzberg et al 
A BFCA was later developed by Abrams et al which could be attached to a MAb before 
radiolabelling called hydrazine nicotinamide (HYNIC) 140. Radiolabelling of HYNIC was 
first applied in the use of MAbs 140, but has later been used with oligonucleotides 
and peptides 141,142. In contrast to N2S2 and the polycyclic acid derivatives used in 
indium-111 radiolabelling, HYNIC does not provide all the necessary coordination sites 
for full complexation. A co-ligand such as EDDA (ethylenediamine-N, N'-diacetic acid) 
must be used to complete the coordination sphere. HYNIC provides an efficient and 
stable platform to which a variety of pharmaceuticals can be attached. 
The coordination, analytical and radiopharmaceutical chemistry of indium-111 and 
gallium-67 has been reviewed in several papers 143,144. Both isotopes are found in 
group-IIIB of the periodic table. Under physiological conditions, the only oxidation state 
that either radiometal is found in is +3. Most chelating ligands complex the radiometals 
with oxygen, nitrogen or sulphur donor atoms. Indium III has a somewhat larger ionic 
radius than gallium III and thus prefers higher coordination numbers. Radiometal 
complexes in radiopharmaceuticals must be stable to hydrolysis and they should be 
more stable than metal-transferrin complexes. When radiolabelling with 67GaC13, 
90YC13, or "'InCl3 ligand exchange is necessary to prevent precipitation. This is 
performed with acetate or citrate, both weakly coordinating ligands. The weak 
coordination complex is then used to prepare complexes with far greater stability. 
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performed with acetate or citrate, both weakly coordinating ligands. The weak 
coordination complex is then used to prepare complexes with far greater stability. 
Within the last 10 years, a large amount of research has been undertaken to improve 
radiometal labelling of MAbs and proteins. Many radiometals can now be complexed to 
a bifunctional chelating agent (BFCAs), which both chelates the radiometal and has a 
functional group available for conjugation chemistry. A review by Schubiger et al 
describes some commonly used BFCAs for labelling with copper, technetium and 
rhenium radioisotopes las. BFCAs which can chelate indium, yttrium and rhenium have 
146, been reviewed in two further reviews , 14'. 
1.5.4 Bifunctional chelators 
The first BFCAs were analogues of EDTA and DTPA 148-151. Several improvements have 
been made since as described in Gansow's review 152. DTPA (shown in figure 1.6) has 
Inferior binding and in-vivo stability to modern BFCAs and its suitability in-vivo with a 
number of radiometals is becoming increasingly questionable. With the advent of DOTA 
(See below) the use of DTPA in radiolabelling is becoming increasingly less used. 
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Figure 1.6 Diethylenetriaminepentaacetic acid (DTPA) 
When DTPA was complexed with 90Y or with radiolanthanides, the complexes were 
unstable resulting in deposition of the radionuclide in normal tissue, in this case bone 
being the natural accretion site for such elements 111. 
A new bifunctional chelating agent (BFCA) was developed by Meares and co-workers 
known as 1,4,7,10-tetraazacyclododecane-N, N', N", N"'-tetraacetic acid (DOTA) 154. 
DOTA Is used to label monoclonal antibodies (MAbs) and peptides with an increasing 
variety of radioisotopes in the +3 oxidation state Including 64Cu, 67Cu, 90Y, "'In and 
177Lu. DOTA is clearly superior to DTPA with regards to kinetic stability when chelating 
lanthanides, especially 90Y 15s. In fact DOTA forms the most stable lanthanide 
complexes studied so far, log K (H20) = 22.86 - 29.2 156, DOTA allows the generation 
of clinically useful stable metallic radio-conjugates for the diagnosis and therapy of a 
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variety of tumours. Some patient studies would benefit from the possibility to image 
pre- and post-therapy. To image a tumour and then use a therapeutic dose using the 
same pharmaceutical is possible with the DOTA bifunctional chelating agent. Below are 
two diagrams detailing firstly the chemical structure of DOTA and secondly the 
conformation adopted when complexed to the Y3+ ion. 
HO OH 
O_NO 
ONNO 
HO OH 
Figure 1.7 DOTA (1,4,7,10-tetraazacyclododecane-N, N', N", N"'-tetraacetic 
acid) 
Figure 1.8 DOTA-9°Y ball and stick model 157 (White atoms are hydrogen, 
grey atoms are carbon, blue atoms are nitrogen, red atoms are oxygen and 
green atom is yttrium-90) 
Harrison et al described the comparisons of in-vivo inertness of 90Y-DTPA and 
90Y-DOTA chelated MAbs in murine models 158. Measurements of the levels of 90Y in the 
shafts of the femurs from DOTA-complexes were 7% of the amount found when 
DTPA-conjugates were used. Their findings demonstrated the greater inertness and by 
implication the greater suitability for immunotherapy of the 90Y-DOTA complex 158 
The BFCA CHX"-DTPA (figure 1.7) has also received considerable attention primarily in 
the use of bismuth III isotopes (213Bi and 212Bi) 159 though more famously in the use of 
Zevalin, an 90Y labelled ibritumomab. 
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Figure 1.9 CHX-A" DTPA chemical structure 
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CHX-A" DTPA has been shown to be a far more favourable BFCA than DTPA and 
compares well with other BFCA's such as DOTA. For example Milenic reports of greater 
stability and pharmacokinetic data with 177Lu-CHX-A" than with 177Lu-DOTA 160. Stimmel 
et al report of similar positive findings on comparing 90Y-CHX-A" with 90Y labelled DOTA. 
Few clinical trials have taken place using a radiopharmaceutical radiolabelled with a 
"cocktail" of radioisotopes. New chelators are being developed and although the 
stability of DOTA is excellent with a variety of radiometals, it does not chelate many 
potentially excellent radioisotopes. However DOTA has by far the broadest isotope 
chelation library to use in nuclear medicine and remains to varying degrees very stable 
with all of them. Using a mix of different radioisotopes would yield a more complete 
therapeutic regime 132. This is because radioisotopes with both high and low LET's have 
a much greater tumour control probability by increasing the chances of cytotoxicity to 
closely located cells as well as cells more distantly located due to poor targeting of the 
radiopharmaceutical. One advantage with using radioisotopes with three different 
emission types is that a, ß and y radiation can be used to increase the energy 
deposition within the tumour as well as image the localised compound. Alternatively 
radioisotopes which emit the same particles but have different LI=T's could be used for 
increased therapeutic efficacy such as 90Y and "'Lu thus penetrating tissue with 
different ranges. 
1.6 Pretargeting 
Anti-cancer MAbs have been used in RAIT studies for more than two decades 161. A 
recent resurgence of interest in the field of RAIT MAbs has been developed since 
clinical trials in non-Hodgkins lymphoma gave very encouraging results 101,162-167, Solid 
tumours however have been less responsive as higher radiation doses are required. As 
"necessity is the mother of invention", novel approaches have been developed in an 
attempt to improve the delivery of therapeutic radioisotopes and provide a more 
uniform dose of ionising radiation to tumours. 
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1.6.1 The need for pretargeting 
Imaging and therapy using directly and indirectly radiolabelled MAbs and their Fab 
fragments have been successfully used in animal models 168 and patient diagnostics and 
therapies 169 with various tumour types. The high degree of specificity of MAbs can give 
excellent imaging resolution and specificity 170. MAbs are radiolabelled with lanthanides 
by using the bifunctional chelator, DOTA, by indirect labelling methods 171 . 
Antibodies accrete slowly into tumours and are removed slowly from the circulation 172. 
Unacceptable levels of bone marrow toxicity generally limit conventional RAIT 173. It is 
possible to give bone marrow support in such situations, but such toxicity increases the 
cost and complexity of treatment 174. Because of the long time required for tumour 
1'5 localisation, the potency of the therapeutic-isotope-labelled MAb is reduced 
To achieve an effective treatment, a therapeutic method is needed whereby tumour 
doses can be maximised and systemic doses minimized. Such a system must retain 
tumour cell specificity but be capable of delivering higher doses than can be achieved 
176 with radiolabelled MAbs 
1.6.2 Pretargeting studies by Goodwin 
Sixteen years ago Goodwin et al proposed the pretargeting concept, by using dual 
specificity bifunctional MAbs or MAb-avidin conjugates 177,178. The concept of 
pretargeted RAIT was proposed as an alternative in the light of the limitations of 
conventional RAIT 1,179-181. In these systems MAbs derivatised with a high affinity 
receptor are used in a localisation step. The MAb derivative is administered at tumour 
saturating doses and allowed to localise for 24 - 48 hours i82. This results in 
homogenous targeting of the tumour 183. Once tumour localisation has taken place and 
active or passive MAb clearance has been completed the final step ensues. The final 
step comprises of the administration of a radiotoxic radiopharmaceutical, which is a 
ligand to a high affinity receptor on the MAb. This technique maximises the tumour to 
background ratio and facilitates the use of much higher radiation doses 184" 
The use of a "clearing agent" designed to bind and remove any remaining circulating 
MAb or Fab' can be administered before the radiolabelled ligand. Goodwin et al used an 
i. v. "Chase" (transferrin 21T-BABE-Co(II) chase) which increased the tumour to blood 
ratio by removing competitive binding of circulating MAb and leaving the bound 
tumour-MAb intact las. Although the tumour to blood ratios were greatly Increased over 
conventional RAIT, the shortcomings with this study were that a considerable reduction 
of the MAb injected dose was found at the tumour. 
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Despite any downfalls in the Goodwin study, the significant increase in tumour: blood 
(Background) ratio led to the subsequent development of two and three-step pre- 
targeting strategies in both diagnosis and therapy 169,166. This line of investigation 
enabled the use of tumour specific pretargeting MAbs or Fab' fragments, where the 
184 
same protocol for both diagnostic and therapeutic regimes could be used v 
1.6.3 Basic concepts of pretargeting 
The three-step pretargeting approach is based upon two experimental observations 
187. 
The first observation is that MAb-tumour localisation reaches its maximum 24 - 48h p. i, 
well before the complete clearance of circulating MAb 188. The second observation is 
that these circulating MAb-streptavidin conjugates can be rapidly removed via the 
liver after complexation with a clearing agent 189. Rapid localisation by a small 
radiolabelled compound to the tumour-bound streptavidin follows the clearance phase, 
circumventing the dose-limiting toxicity associated with covalent delivery of 
19o-19s radioisotopes by MAbs 
1.6.4 Pre-localisation phase 
The slow pharmacokinetics of long-circulating large targeting-molecules such as MAbs 
produces a relatively low tumour concentration but a high degree of specificity and 
stability at the site of binding 196. The greatest concentration of tumour-localised MAb is 
at two days however still the largest fraction of MAb remains in the circulation 197. By 
developing a MAb-streptavidin conjugate, a tumour can be avidinylated and a 
radiolabelled biotin moiety can be subsequently localised to the tumour. 
Avidin is a minor constituent of egg white of reptiles, amphibians and birds. It is a 
glycosylated and positively charged protein that can bind up to 4 molecules of vitamin 
H, D+ biotin. Streptavidin, a protein derived from Streptomyces avidinii bacteria, was 
also found to bind to D+ biotin with great avidity (e. g., KA of 1015 M"1) 198 with a 
valency of 1: 4 199. The deduced amino acid sequence of streptavidin shows several 
interrupted blocks of homology with the amino acid sequence of chicken egg-white 
avidin 200. Biotin-streptavidin affinity is 1x 106 fold higher than that of host antigen- 
MAb interactions 199. Streptavidin has a lower normal tissue retention than that of 
avidin 201,202" The half-life of avidin in-vivo is much shorter than that of streptavidin, 
indicating that streptavidin is a superior choice for avidinylating tumours 199. 
Most pretargeting studies set out to exploit the extremely high affinity of streptavidin 
for biotin 198. Mice and rabbits have been studied using biotinylated MAbs as the first 
step and radiolabelled avidin as the second step 203,204. These studies proved that 
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radiolabelled avidin could accumulate at a biotinylated target. Several different 
protocols using streptavidin attached to MAbs were used to localise to the tumour 
. site(s)1,179,20S 
Figure 1.10 Computer generated model of the avidin-biotin binding site. 
Viewed from the entrance, the model shows the peptide backbone only plus 
the amino acid side chain residues lining the binding site. The model was 
calculated by superimposing the crystallographic coordinates of streptavidin 
to the amino acid sequence ofavidin. 1 
When preparing biotinylated MAbs 206,207 or streptavidin conjugated MAbs 208 210, it is 
important to ensure that the MAb-epitope binding remains specific with a high affinity. 
Pretargeting MAbs must not cause premature shedding of the receptors or internalise 
along with the receptor but remain present on the exterior of the tumour cell. The 
advantage of the streptavidin/biotin system is that up to four radiolabelled-biotin 
molecules can bind a MAb-conjugate with high affinity 211. Biotinylation increases the 
molecular mass of the complex only very minimally and does not affect plasma kinetics 
or diffusion 184. When conjugated to MAbs, streptavidin increases the RMM by 
approximately 25-33%. Thus the pharmacokinetics and possibly tumour uptake will be 
reduced. This is clearly demonstrated in a study by Breitz et al who showed superior 
pharmacokinetics when using 186 Re-NR-W-10 over streptavidin derivatised 186Re-NR- 
LU-10 212. 
Bi-specific antibodies (BsAbs) are made up of two separate MAbs chemically cross- 
linked to the other 213. As pretargeting has become increasingly popular as a method of 
both imaging and therapy 213, the use of BsAbs has become a popular method of 
choice. This in the main is due to fewer pharmaceuticals being required to be 
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developed and possibly also a reduction in administration protocol complexity. Below is 
a generalised schematic showing the steps followed in a bispecific antibody pretargeting 
protocol. 
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Figure 1.11 Schematic of bi-specific antibody pretargeting 
One of the arms of the BsAb is specific for the TAA and the other is specific to a 
radiolabelled peptide v', 178 Administration of the BsAb is usually 1-2 days prior to 
radiolabelled peptide administration to facilitate tumour localisation and passive 
205 clearance 
1.6.4 Clearance phase 
After the MAb-conjugate component has localised to the site(s) of the tumour, a 
considerable proportion remains in the serum 199. Since the administration of the 
second radiolabelled "effector" component would give rise to very high levels of 
systemic radiation a clearing agent is required 199. Once clearance has taken place, the 
effector molecule will be able to rapidly localise to the relatively high concentration of 
MAb at the tumour site and systemic radiation will remain low 199. 
The first proposed clearing agents were in the main only able to clear MAb derivatives 
189 from the serum . Polyvalent macromolecular constructs were initially used, and these 
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cleared MAb-derivatives from the serum, to the reticuloendothelial system in the liver 
iss. From the graph below it is demonstrated that active conjugate clearance is far 
more effective than passive clearance. The clearance phase ensures that both imaging 
and therapy possess very low background radiation. 
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Figure 1.12 Blood clearance of MAb-streptavidin by HSA clearing agent 
A more recent design of clearing agent employs the Ashwell receptors found on 
hepatocytes 215. These receptors internalise their ligands for degradation 216. Ashwell 
receptors have a high affinity for asialoglycoprotein and function even at sub- 
nanomolar concentrations Z". Terminally clustered galactosyl or N-galactosaminyl 
residues interact with the triplex receptor 218. Most clearing agents developed towards 
the Ashwell receptor have been biotin derivatised residues, which will complex the 
circulating streptavidin complexes 218. These residues are then coupled to galactosyl or 
N-galactosaminyl residues for high affinity binding to Ashwell receptors 216. 
Pretargeting strategies using streptavidin or avidin have been described as successfully 
reducing blood: background levels of radioactivity 181. Both species have been used 
either as the radioisotope carrier to a biotinylated MAb pretargeted tumour 219,220 or as 
the clearing agent for biotinylated MAbs before administration of the radioisotope in 
221 three-step pretargeting , 222 
Both avidin and streptavidin are efficient in the use as clearing agents for radiolabelled 
biotinylated MAbs, reducing the amount of radiolabelled MAb that normally remains in 
the circulation 187, zzs, This results in significantly higher tumour to blood ratios 224, 
which are essential to reduce myelotoxicity while still permitting effective RAIT 225, 
The streptavidin-biotinylated MAb complexes are cleared by the reticuloendothelial 
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system and persistent spleen activity has been observed when radiolabelled species are 
224 used 
In a recent human trial, the use of a clearing agent in combination with the 
pretargeting system demonstrated removal of greater than 95% of excess circulating 
antibody, tumor-to-blood ratios of 65: 1, visualization of all tumors and minimal toxicity 
226. Human Serum Albumin (HSA) was derivitised with around two d-biotin residues per 
HSA protein to provide a clearing agent. 
1.6.5 Radio-targeting phase 
Investigators soon realised that the slow kinetics of radiolabelled streptavidin 
localisation to biotinylated MAbs bound at the site of the tumour was a major hindrance 
to obtaining high tumour to background ratios 219. This drawback could be 
circumvented by first administering a MAb-streptavidin conjugate and after an 
appropriate delay period exploiting the rapid kinetics of biotin as a radiolabelled effector 
molecule 179. In the streptavidin/biotin system the effector molecule is based around 
the metal chelate system and a biotin moiety for targeting the streptavidin complex 183. 
The molecule should be as small as possible to maintain rapid kinetics 183. A low 
hydrophobicity is also necessary to ensure low serum protein binding and good delivery 
of the radioisotope to the tumour 183. The rate of loss of the radiometal from the BFCA 
depends on the rate at which other ligands may be exchanged 158. Dissociation rates of 
the radioisotope are element dependant and are strongly influenced by the molecular 
structure of the BFCA 158. 
The use of DTPA a, w-bis biocytinamide in initial pretargeting therapeutic studies 
resulted in a loss of 5% of the 90Y in-vivo, yielding a considerable additive radiation 
dose to the red marrow 227. It is worth noting that antibody modulation will affect how 
long the antibody remains bound to the tumour cell before internalising or down- 
regulating intrinsic signalling pathways 228. Thus the correct antigen must be selected in 
order that the radiolabelled effector molecule can reach its target 229. Hence the fate of 
the radiolabelled compound and its catabolism will also affect the radioisotope 
selection. 
As discussed earlier, the stability of DOTA-radiometal complexes far exceeds that of 
DTPA-radiometal complexes 158. The biodistribution of radiolabelled DOTA conjugates 
has been studied several times and is excellent for use In nuclear medicine 160,215 
Rapid renal excretion is observed (t1/2 15 min) in normal mice with no normal organ 
displaying an uptake of more than 2% 215. It is for the reasons mentioned above that 
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DOTA is widely used, not just in conventional RAID and RAIT but importantly in 
pretargeting effector molecules 227" Radiolabelled DOTA-biotin was first described by 
Hnatowich in 1992 where he showed that "'In-DOTA-biotin localised pretargeted MAbs 
with a significantly greater tumour: background ratio than with conventional RAID. 
DOTA-biotin has a favourable biodistribution, excellent binding kinetics properties and a 
212 high affinity constant with streptavidin 
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Figure 1.13 Schematic of three-step pretargeting 
The rapid localisation of the radiolabelled biotin means that a shorter-lived radioisotope 
can be used to greater effect. Altogether, pretargeting allows a greater radiation dose 
to be deposited in a more specific area(s), and reduces the overall systemic dosage 230. 
1.6.5 Limitations 
The streptavidin/biotin system like others depends upon the binding affinity of the 
primary targeting agent (MAb to TAA). Thus the high binding affinity of biotin to 
streptavidin may not be enough to compensate for an inefficient MAb binding. 
Streptavidin and avidin are foreign proteins and have produced in many patients 
considerable immunogenicity in-vivo, thus reducing the efficacy of repeat 
administrations 231 
4F 
With the streptavidin/biotin system, the clearing stage introduces another level of 
complexity to a multi-step approach. An increased number of visits to the treatment 
clinic would be required in order to fulfil the therapeutic regimen. Without this step, it 
remains to be seen whether such a system would have any advantage over 
radiolabelled MAbs. 
Biocytin (biotin-lysine) cleavage by biotinidase is another problem encountered when 
using biotin-lysine derivatised effector molecules 136. Cleavage will reduce the amount 
of radioisotope localised to the MAb-conjugate and the amount of time it remains 
227 resident at the tumour 
Endogenous biotin, an essential vitamin (H), has the potential to bind to streptavidin 
and reduce the opportunity for radiolabelled biotin to bind 168, although Kalofonos et al 
demonstrated that circulating MAb-streptavidin conjugates were not saturated with 
endogenous biotin even after 3 days 232. Some degree of radiolabelled biotin blocking 
was expected, as 1.5 µg of biotin was present in the patient's serum and 0.3 mg of 
streptavidin was administered capable of binding around 3-4 µg of biotin 232. Bearing in 
mind that a large proportion of MAb-conjugate will be cleared and will not be tumour- 
bound, in-vivo streptavidin-ligand competition remains poorly understood. 
1.7 Aims and objectives 
Pretargeting has been identified as providing the best potential tumour to background 
radioactivity levels in a nuclear medicine therapeutic context. With this in mind, the aim 
of this study was to produce a pretargeting system using the clinically proven MAb, 
trastuzumab. 
An effector molecule with a favourable biodistribution and biotinidase resistance is 
essential for an effective pretargeting regimen. Trastuzumab (Herceptin®) has been 
shown to possess significant ADCC (Antibody Dependent Cellular Cytotoxicity) activity 
and was viewed as a potentially excellent pre-targeting modality. Below are a set of 
objectives that were pursued in this work: 
" development of improved effector molecules in terms of stability, kinetics and 
biodistribution in normal animals 
" use of alternative radioisotopes 
" development of a novel trastuzumab-streptavidin conjugate using a 
photoreduction method 
" pharmacokinetic analysis in normal animals 
" tumour targeting in nude murine xenografts 
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Chapter 2 Materials and methods 
2.1 Materials 
2.1.1 Radioisotopes 
Indium chloride (111InCl3) was sourced from Mallinckrodt Medical b. v (Petten, 
Netherlands). Yttrium chloride (90YC13) was ordered from MDS Nordion (Fleurus, 
Belgium). Lutetium chloride ("'LuCl3) was sourced from Perkin Elmer Life Sciences, Inc. 
(Boston, Massachusetts). Sodium iodide (NaI125) and cobalt chloride (57CoC12) were 
sourced from ICN (Basingstoke, Hamps, UK). 
2.1.2 HPLC & ITLC solvents 
HPLC solvents were all supplied by Sigma-Aldrich (Dorset, England) and were HPLC 
grade. Gelman Sciences (Ann Arbor, Michigan) supplied ITLCTM paper. Ultra High Purity 
(UHP) water was obtained from an Elga Purelab Maxima water purification system 
(Buckinghamshire, England). All prepared buffers were filtered using a 0.22 µm pore 
Steritop® filter unit (Millipore, Bedford, MA). 
2.1.3 Phosphate buffer 
The phosphate buffer used for conjugation reactions consisted of 61 mM di-sodium 
hydrogen orthophosphate and 44 mM sodium dihydrogen orthophosphate and 2 mM 
EDTA ( pH of the solution at room temperature was 7.4). 
2.1.4 TSMZ 
The TSMZ buffer contained 80.2 mM triethanolamine, 98.9 mM sodium chloride, 1 mM 
magnesium chloride and 0.1 mM zinc chloride pH corrected to pH 7.3 with concentrated 
sodium hydroxide. 
2.1.5 Human breast tumour cells 
The cell line used for immunoconjugate binding studies and mouse xenografts was 
SKBR3. SKBR3 cells were obtained from Cell Services at Cancer Research UK (ATCC 
designation: HTB 30). SKBR3 are derived from a human breast adenocarcinoma, 
malignant pleural effusion, of a 43 year old female Caucasian with blood type A+. 
Culturing breast tumour cells has been reviewed in detail by Trempe 233. Cells were 
cultured In E4 media with 10% foetal calf serum and 2.4 mM glutamine. 
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BT-474 cells were obtained from Cell Services at Cancer Research UK (ATCC 
designation: HTB 20). BT-474 cells are derived from a human ductal carcinoma of a 60 
year old Caucasian female. Isolation and immortalisation is described by Lasfargues 234. 
MDA-MB-361 cells were obtained from Cell Services at Cancer Research UK (ATCC 
designation: HTB 27). MDA-MB-361 cells are derived from a human brain 
adenocarcinoma of a 40 year old Caucasian female with blood type 0+. 
Characterisation is described by Siciliano et al who also describes many other 
235 metastatic breast carcinoma cell lines et al 
MDA-MB-435S cells were obtained from Cell Services at Cancer Research UK (ATCC 
designation: HTB 129). MDA-MB-435S cells are derived from a human brain 
adenocarcinoma of a 31 year old Caucasian female. The characterisation of MDA-MB- 
435S is described by Siciliano et al 235. 
2.16 Animal models 
Murine models were BALB/c and were used in all animal biodistribution experiments. 
2.17 Reagents 
A complete list of the reagents used during the experiments listed in this volume is 
listed below. 
Table 2.1 Reagents used 
Chemical name Supplier Grade Abbreviation 
Acetonitrile Sigma-Aldrich HPLC MeCN 
2-p aminobenzyl-1,4,7,10- 
tetraazacyclododecane-1,4,7,10 
tetraacetic acid 
Macrocyclics Synthesis p-NH2-Bz- 
DOTA 
Ammonia Fisons Analytical NH3 
Ammonium acetate BDH AnalaR NH4Ac 
Ammonium bicarbonate Sigma-Aldrich Sigma 
Benzaldehyde-2-sulphonic acid Fluka Pract (95%) T BA2SA 
Biotin (d+) Sigma-Aldrich Sigma d-Bio 
Biotin (1+) Commisioned I-Bio 
Bovine serum albumin Sigma-Aldrich Sigma BSA 
Dichloromethane Sigma-Aldrich 99.6 % DCM 
Dicyclohexylcarbodiamide Sigma-Aldrich - DCC 
Diisocarbodiimide Sigma-Aldrich Sigma DIC 
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Dimethylformamide Sigma-Aldrich Sigma DMF 
Dimethylsulfoxide Sigma-Aldrich Sigma DMSO 
Disodium hydrogen 
orthophosphate anhydrous 
BDH AnalaR Na2HPO4 
5,5 Dithio-bis-(2-nitrobenzoic acid) Perbio Analytical DTNB 
DTPA a, w-bis biocytinamide Sigma-Aldrich Sigma DTPA-Biotin 
Ethanol Sigma-Aldrich HPLC EtOH 
Ether Sigma-Aldrich Sigma CH3OCH3 
Ethylenediamine tetraacetic Acid Sigma-Aldrich ACS EDTA 
Ethylenediamine tetraacetic Acid 
(0.097M) 
Sigma-Aldrich ACS EDTA 
Standard 
Ethylenediamine-N, N'-diacetic Acid Sigma-Aldrich ACS EDDA 
Fmoc-Lys(Mtt)-Wang resin Calbioch. 
Novabioch. 
N/A 
Foetal Calf Serum Sigma-Aldrich Sigma FCS 
Glutamine CR-UK CR-UK Glu 
Glycine Sigma-Aldrich Sigma Gly 
Hydrochloric acid BDH AnalaR HCI 
1 Hydroxybenzotriazole / N-Methyl- 
2 Pyrrolidone (1M) 
Applied 
Biosystems 
Peptide 
Synthesis 
HOBT/NMP 
Immobilised iminobiotin slurry Perbio Analytical 
Immobilised streptavidin beads Sigma-Aldrich Sigma 
5-Iodoacetamidofluorescein Sigma-Aldrich Analytical 5-IAF 
Iodo-Gen Perbio Pierce 
Isopropanol (Isopropyl alcohol) Fisons Analytical IPA 
L-Cysteine Sigma-Aldrich Min. 98 % L-Cys 
Magnesium Chloride Sigma-Aldrich Sigma MgCl2 
Medronate II Amersham Pharmaceutical MDP 
2 Mercaptoethanol Sigma-Aldrich Sigma ME 
Methanol Sigma-Aldrich HPLC MeOH 
N, N-Diisopropylethylamine Sigma-Aldrich Sigma DIPEA 
N-Hydroxybenzotriazole/ N-Methyl- 
2-Pyrrolidone 
Applied 
Biosystems 
Peptide 
Synthesis 
HOBt/NMP 
N-Hydroxysuccinimide Sigma-Aldrich Sigma NHS 
Ninhydrin-ethanol Applied 
Biosystems 
Peptide 
Synthesis 
Solution C 
N-methylpyrrolidine Sigma-Aldrich Sigma NMP 
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Phenol/ethanol Applied 
Biosystems 
Peptide 
Synthesis 
Solution A 
Phosphate buffered saline pH 7.4 Cancer 
Research UK 
N/A PBS 
Piperidine/DMF Perseptive 
Biosystems 
Peptide 
Synthesis 
Pip/DMF 
Potassium cyanide/pyridine Applied 
Biosystems 
Analytical Solution B 
Potassium ferricyanide Sigma-Aldrich Sigma FeK3(CN)6 
Saline (0.9%) Steri-Amp Injection NaCI(aq) 
Sodium Chloride Sigma-Aldrich ACS NaCl 
Sodium dihydrogen 
orthophosphate 1-hydrate 
BDH AnalaR NaH2PO4 
Sodium dihydrogenorthophosphate BDH AnalaR NaH2PO4 
Sodium hydroxide Sigma-Aldrich AnalaR NaOH 
Streptavidin (Streptomyces avidinii) Sigma- Aldrich Sigma SAVD 
Streptavidin (Streptomyces avidinii) ICN ICN SAVD 
Sulfosuccinimidyl 4-(N- 
maleimidomethyl) cyclohexane-1- 
carboxylate 
Perbio Pierce Sulfo-SMCC 
1,4,7,10 tetraazacyclododecane- 
N, N', N", N"'-tetraacetic acid 
Macrocyclics Synthesis DOTA 
Tin (II) chloride dihydrate Sigma-Aldrich ReagentPlus SnCI2 
Trastuzumab Roche Clinical 
Tricine Sigma-Aldrich Sigma Tric 
Triethanolamine Sigma-Aldrich Sigma TEA 
Trifluoroacetic acid Sigma-Aldrich Sigma TFA 
Triisopropylsilane Sigma-Aldrich Sigma TIS 
Ultra-high purified water Elga < 18.2 MQ UHP 
Zinc chloride Sigma-Aldrich Sigma ZnCI2 
Methods 
2.2 Radiolabelling 
2.2.1 Radiolabelling of DOTA biotin derivatives 
The radiolabelling of the DOTA compounds with 90Y3+1"'In3+ and '"Lu3+ were carried 
out under the same reaction conditions. Typically, a volume of 10 µ1 (7 MBq) of the 
radioisotope was added to a 1.8 ml cryo-vial (Corning Incorporated, NY), followed by 
an equal volume of 2M ammonium acetate, pH 5.4 236. This was followed by 5 µI of a1 
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mg/ml solution of DLB in UHP water. Finally the volume was made up to 100 µl using 
UHP water. The reaction vial was sealed and placed in a boiling bath for 30 minutes 
before being analysed by RP-HPLC. 
During the course of a week period radiolabelling of conjugates, the efficiency of 
labelling became increasingly poor. By pre-treating the pipette tips in 1M HCI for 24 
hours, then rinsing the tips with UHP water and drying in a heated cabinet, labelling 
efficiency was only mildly reduced instead. It was found that the 90YCI3 source was far 
more affected by un-treated tips than 111InCl3 was. This was suspected to be due to 
metal contamination of the disposable plastic pipette tips. Labelling efficiency was 
dramatically improved and retained after dilute hydrochloric acid was used to wash 
them (Section 3.4.3). 
2.2.2 Radiolabelling of proteins with iodine-125 
Radiolabelling of the immunoconjugate was performed using the Iodogen® method. 
Iodogen® tubes were purchased from Perbio, Tattenhall, Cheshire. A 20 pl sample of 
trastuzumab-streptavidin conjugate (1 mg/ml) was diluted to 100 pl with 0.1 M pH 7 
Phosphate buffer. The solution was added to a dry Iodogen tube and a1 pl (6 MBq) 
aliquot of Na 1251 was added and the tube was gently vortexed all in quick succession. 
The solution was incubated for 30 minutes at room temperature prior to use and 
purified using a sephadex PD10 column. The column was equilibrated with 0.5 % BSA 
in PBS and the radiolabelling reaction mixture was added to the column. Fractions of 1 
ml each were collected and then quantified in a dose calibrator. Invariably the fourth 
fraction was by far the largest and the amount of protein in the fraction was 
determined as a percentage of the total radioactivity eluted from the column. 
2.3 Chromatography 
2.3.1 Reverse Phase (RP) High-Pressure Liquid Chromatography (HPLC) 
RP-HPLC analysis was carried out using two different HPLC systems. The first consisted 
of a Beckman 125 solvent-module pump system with a Beckman 166 NM single 
wavelength UV detector (Beckman, High Wycombe, England). The second system 
consisted of a Beckman 126 solvent-module pump system with a Beckman 168 diode 
array detector collecting UV absorbance readings from 190 nm to 600 nm. Both 
systems had a sodium iodide flow through radiochemical detector attached to a Raytest 
gamma radioactivity monitor. A Galaxy Jupiter analytical 5µ C18 column, 300 A; 4.6 x 
250 mm l. d was used with each system (Phenomenex, Cheshire, England) along with a 
SecurityGuardTM HPLC pre-column filter (Phenomenex, Cheshire, England). Data 
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collection was handled by a PC running System Gold® Nouveau (Beckman, High 
Wycombe, England). 
2.3.2 Size exclusion HPLC 
Size-exclusion HPLC was carried out using a Bio-SEC-S 3000,300 x 7.80 mm Ld column 
(Phenomenex) connected to a Beckman 125 solvent-module pump system with a 
Beckman 166 NM single wavelength UV detector. Data collection was handled by a PC 
running System Gold® Nouveau (Beckman, High Wycombe, England). Pre-column 
filtering was performed using an Anachem A101X rep frit (Anachem, Luton, 
Bedfordshire) in a frit receiving connector. 
2.3.3 Semi-preparative RP-HPLC 
Purification took place using an Agilent Zorbax 300SB-C8 preparative column (21.2mm x 
25cm). The packing consisted of silica chemically bonded to diisopropyl N-octyl. 
2.3.4 Trastuzumab-streptavidin purification by size-exclusion HPLC 
Purification of the trastuzumab-streptavidin conjugate was performed using an ÄKTA 
Explorer connected to a Frac 950 fraction collector connected to a PC running Unicorn 
v 4.12 (Amersham Biosciences, Amersham, Bucks). The size exclusion column used 
was a HiLoad' 16/60 Spuredextm 200 60 cm column. The column was equilibrated and 
run with a 0.1 M phosphate buffered saline, pH 7.4 mobile phase. The flow rate was 1 
ml per minute. The 1 ml fractions were collected using an intrinsic fraction collector into 
a 96 x 2ml well plate. 
2.3.5 Reverse-phase HPLC method 1 
Reverse phase purification was performed on a C8 preparative column. Two buffers 
were made as follows: Buffer A: 0.08 % TFA, 1% ACN, 98.92 % UHP water. Buffer B 
consisted of 0.08 % TFA, 90 % ACN 9.92 % UHP water. The gradient was 5- 60 % 
Buffer B over 20 mins with a flow rate of 8 mis per minute. 
2.3.6 Reverse-phase HPLC method 2 
Analytical reverse phase high-pressure liquid chromatography (RP-HPLC) was carried 
out using mobile phases of 0.05 % TFA (Trifluoroacetic acid)/water (Solvent A) and 
0.05 % TFA/acetonitrile (Solvent B) and a flow rate of 1 ml/min. The column was 
equilibrated with 95 % solvent A, 5% solvent B and after Injection the percentage of 
solvent B was held for 6 minutes. Solvent B was then increased to 30 % over 20 
minutes. After this the gradient was increased to 100 % over 10 minutes before 
returning to 5% solvent B over 4 minutes. The total run time was 41 minutes. 
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2.3.7 Reverse-phase HPLC method 3 
Analytical reverse phase high-pressure liquid chromatography (RP-HPLC) was carried 
out using mobile phases of 0.05 % TFA (Trifluoroacetic acid)/water (Solvent A) and 
0.05 % TFA/acetonitrile (Solvent B) and a flow rate of 1 ml/min. The column was 
equilibrated with 95 % solvent A, 5% solvent B and after injection the percentage of 
solvent B was held for 6 minutes. Solvent B was then increased to 20 % over 10 
minutes. The percentage of acetonitrile was then held for 9 minutes at 20 %. After this 
the gradient was increased to 100 % over 10 minutes before returning to 5% solvent 
B over 5 minutes. The total run time was 41 minutes. 
2.3.8 Size-exclusion HPLC Method 
For size exclusion chromatography a sodium phosphate buffer solution (2 mM 
disodium-EDTA, 61 mM disodium-hydrogen-phosphate, and 44 mM sodium dihydrogen 
phosphate, brought to pH 7.4 with conc. NaOH) was used as the mobile phase. SE- 
HPLC was run under isocratic conditions until all of the peaks had been eluted. 
2.3.9 Fraction collection 
Radioactive HPLC fractions were collected using a Pharmacia Frac-100 fraction collector 
(Pharmacia, Milton Keynes, England). Each HPLC system could be connected to the 
Frac-100 via the outlet tubing. Metered fractions were collected In gamma counting 
tubes and analysed by a 1282 Compugamma CS Universal gamma (Compugamma, LKB 
Wallac, Finland). This was connected to an Apple Macintosh computer running the 
analysis software (Utmac v1.2, Wallac, Finland). 
2.3.10 Instant Thin Layer Chromatography (ITLCTM) 
In all systems silica gel ITLC Strips (ITLCTM SG, GelmanSciences) were taken and a 
pencil line drawn 1.5 cm from the bottom of a9x1.5 cm strip. A cross was made at 
the centre of this line and this is where 2 µL of the labelled sample was placed. A felt 
pen mark was made 1.5 cm from the top of the strip in order to determine the 
completion of chromatography upon ink separation. 
Using clean forceps the dried ITLC strips with either the 111In or 90Y samples applied 
were placed into 1.5 ml of a 10 % NH40H/50 % Methanol solution in an ITLC bottle. 
When the solvent had reached the felt pen mark the strips were extracted from the 
bottles and allowed to dry. After drying, the strips were imaged on a storage phosphor 
imaging system (CycloneTM, Packard). The images were then quantified using 
compatible analysis software (OptiQuant v. 3.00, Packard). 
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2.3.11 Indium/yttrium-DOTA ITLC analysis 
Below is a table detailing the species analysed by ITLC and the relative Rf (relevant 
front) value obtained. 
Table 2.2 Table of Rf values obtained with different compounds 
Species Mobile Phase Rf Value 
DOTA-Biotin 10%NH4OH, 50% MeOH 0 
Indium acetate 10%NH4OH, 50% MeOH 0 
Indium chloride 10%NH4OH, 50% MeOH 0 
Indium a, u -bis (Biocytinamide) 10%NH4OH, 50% MeOH 0 
Indium EDTA 10%NH4OH, 50% MeOH 1 
Indium DOTA 10%NH4OH, 50% MeOH 1 
Indium DTPA 10%NH4OH, 50% MeOH 1 
2.4 DOTA Biotin chemical syntheses 
2.4.1 (DLB) Bio-Iys(DOTA)-OH (d- and I- isomers) 
Below is the reaction scheme adopted for the synthesis of DOTA lysine d-biotin 
synthesis. 
Fmoc Removal 
MTT 20% Piperidine MTT Biotinylation MTT 
II 
Fmoc-NH-Lys-Resin NH2-Lys-Resin 
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Figure 2.1 DOTA-Lysine Biotin reaction scheme 
The ninhydrin test was performed after each conjugation stage to determine whether 
the functional amine group was available or had been completely reacted with the 
activated biotin (Section 2.5.6). If the reaction hadn't gone to completion a further 
addition of the reagents was made. 
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2.4.2 (DBB) Bio-Lys [Bio-Lys (DOTA)]-OH (d- isomer only) 
Below is the reaction scheme adopted for the synthesis of d-bio-lys [bio-lys (DOTA)]-OH 
synthesis. 
MTT 
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MTT 
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Fmoc-NH-Lys-Resin NH2-Lys-Resin BIOTIN-Lys-Resin BIOTIN-Lys-ResinI 
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Figure 2.2 Bio-Lys [Bio-Lys (DOTA)]-OH reaction scheme 
The ninhydrin test was performed after each conjugation stage to determine whether 
the functional amine group was available or had been completely reacted with the 
activated biotin (Section 2.5.6). If the reaction hadn't gone to completion a further 
addition of the reagents was made. 
2.4.3 Deprotection of the Fmoc group from the lys-resin 
This procedure was carried out in a fume hood. A volume of 3 ml of 20 % 
piperidine/DMF along with 50 mg of peptidyl resin was added to a 1.5 ml microfuge 
tube. The tube was placed on a mixer for an hour to promote efficient reaction. The 
reacted sample was centrifuged on an MSE Microcentaur at 6500 rpm for 1 minute to 
collect the beads at the bottom. The supernatant was removed and replaced with a 
further 3 ml of 20 % Piperidine/DMF to ensure complete reaction. The supernatant was 
removed, and the uncapped tube was placed in a Savant SpeedVac® Plus and the 
solution was evaporated to dryness. The resin was washed with 1 ml of 
dimethylformamide three times, and after shaking for 1 minute the tube was 
centrifuged in a microfuge at 13000 rpm and the supernatant aspirated off by pipette. 
The resin was then washed with 1 ml of DCM twice in the same way. Once the Fmoc 
Sf 
protection group was removed from the lysine residue and the resin had been washed. 
The Ninhydrin test was performed (Section 2.5.6) on these dry beads. 
2.4.4 Ninhydrin test (Applied Biosystems kit) 
A Ninhydrin kit (Applied Biosystems, Foster City, CA) was used for the purpose of 
quickly determining whether free NH2 groups were made available for reaction or 
whether they remained protected. This procedure was carried out in a fume hood due 
to the harmful nature of the reagents. To each of two 12 x 75 mm glass test tubes the 
following was added: 75µI Solution A (phenol/ethanol), 100 µi Solution B (potassium 
cyanide/pyridine), 75 µl Solution C (Ninhydrin/ethanol). 
Approximately 50 Lys-resin beads were placed in one of the glass test tubes; the other 
was used as a negative control. Both were incubated at 100 °C for 5 minutes. The 
tubes were then allowed to cool. The bead colour and supernatant colours were 
compared. If the beads were blue and the supernatant was blue then the active NH2 
groups were deprotected and free for reaction. If the solution was yellow and/or the 
beads were either clear or partially clear or colourless, the Fmoc deprotection step was 
not complete and had to be repeated. 
2.4.5 Biotinylation of peptide resins (0.1mM scale) 
The deprotected lysine resin beads were pre-swollen with 250 µl of NMP, and the 
excess supernatant was removed. A 4: 1 molar ratio of d-biotin (0.1 mM) to lysine 
(Resin-lysine concentration according to Novabiochem) was weighed out. A volume of 1 
ml of DMSO and 400 µl of NMP was added to the biotin and was left to dissolve 
completely. Then 200 pl of 1M HOBT in NMP was added to the d-biotin solution and left 
for 3 minutes. A volume of 200 µl of diisopropylcarbodiimide activator (1 M In NMP) 
was added to the d-biotin solution and reacted for 30 minutes. The activated d-biotin 
solution was then added to the resin, and the microfuge tube was rinsed with 2x 200 
µl of NMP. This mixture was agitated continuously overnight on a 411T-rocking table 
(Luckham, Ltd., Burgess Hill, UK). The next day the beads were washed 3 times with 
1.5 ml NMP. A volume of 500 pl of DCM was used to shrink and dry the beads. A 
Ninhydrin Test (Section 2.5.6) was performed where colourless beads and a pale yellow 
supernatant indicated a successful reaction. 
2.4.6 Removal of the MTT protection group 
An 8 ml sample of resin wash solution, comprising 1% TFA, 5% TIS and 94% DCM was 
prepared, 2 ml was added to the resin and left to stand for 3 minutes. The supernatant 
was removed by pipette and the application was repeated three more times. The 
solution became a fluorescent yellow colour indicating the MTT (3-(4,5-dimethylthiazol- 
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2-yl)-2,5-diphenyl-2/itetrazolium bromide) in solution. Washing continued until the 
wash solution became colourless again. The beads were washed in DCM. The Ninhydrin 
test was executed and a successful reaction gave a blue supernatant and blue beads. 
(See Sec 2.5.6). 
2.4.7 DOTA conjugation 
This procedure was carried out in a microfuge tube. After ensuring that the NH2- 
protecting group was removed from the resin bound amino acid; the resin was dried in 
a SpeedVac. The resin beads were then preswollen with 200 µl of NMP. A mass of 115 
µg (0.2 mmols) (4x excess) of DOTA-tris(t-butyl ester) (Macrocyclics, Dallas, USA) was 
placed in a microfuge tube and 700 µl of DMF was added and left on the spiramix until 
completely dissolved. 
A 200 µl aliquot of 1M HOBT in NMP was added to the DOTA-NMP solution and left for 
3 minutes after a fast mix on a MS2 Minishaker (Staufen, Germany). After adding 50 µI 
of diisopropylcarbodiimide (1 M in NMP) to the DOTA Solution, the solution was 
incubated at room temperature for 30 minutes to activate. 
The "Activated DOTA" was added to the swollen resin. The tube was sealed and placed 
on a rotator overnight. The resin beads were filtered and washed with at least 5-6 
washes of DMF. Subsequently two DCM washes were performed. The Ninhydrin Test 
was carried out on the beads, where a complete reaction produced greyish beads and 
pale yellow solution. Where a partial reaction or no reaction occurred then the DOTA 
addition procedure was repeated. It is important to note that DOTA is a strong 
chelating agent and as such no glass or metal must be used. In addition if a metal 
needle must be used then it must be pre-treated with TFA. 
2.4.8 Cleavage of DOTA biotin from the resin 
The cleavage mix (2.5 % water, 2.5 % TIS, 95 % TFA) was made (10 - 25ml per gram 
of resin) and iml was added to a filtering microfuge tube allowing gravity filtration over 
2 hours. This was done in two filtered microfuge tubes and collated later. The solute 
was precipitated with 1 ml of diethyl ether cooled on ice. The solution was mixed, 
centrifuged for 1 minute and the supernatant removed. A second volume of ether was 
added to further wash the compound before centrifugation. Again the excess ether was 
removed and the compound was lyophilised. The resultant solid was weighed in a 
microfuge tube on a Sartorius analytical balance (Goettingen, Germany). The solid was 
then dissolved in water to a concentration of 1mg/ml for analysis. 
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2.4.9 Mass spectrometry 
Matrix-assisted laser desorption/ionisation time of flight (MALDI-TOF) mass 
spectrometry was used to verify the correct molecular mass of the effector molecules 
DLB and DBB. Analysis was performed by technicians at the Cancer Research UK mass 
spectrometry services department. A 20 pl sample of a1 mg/ml stock solution in UHP 
water of each effector molecule was placed in a labelled microfuge tube and sent for 
analysis. 
2.4.9 Purification 
For the purification of DOTA-biotin conjugates, RP-HPLC on a C8 column was used. 
Approximately 20 mg of conjugate was dissolved in ultra-high purified water. The 
mixture was loaded onto the system using a TFA treated needle and a plastic syringe 
and run according to the method detailed in Section 2.3.3. Collection of peaks was 
performed manually in a 15 ml falcon tube, the solute was precipitated with 2 ml of ice- 
cold ether, the supernatant discarded and the product was lyophilised in a Modulyo 
lyophilizer (BOC Edwards Pharmaceutical Systems, NY, USA). 
2.5 Effector molecule analysis 
2.5.1 Indium/yttrium-DOTA ITLC pH stability assays 
Five 5 µL samples of "'In-DOTA labelled products were added to five 45 t AL samples of 
0.1 M glycine solutions of pH 1,2,3,4,5 for 30mins at 37 °C. At 30 minutes 50 µL of 
pH 6.4 sodium di hydrogen phosphate 0.1 M was added to each tube and mixed. A 1µL 
sample was then analysed by ITLC as described above in section 2.3.11. This assay 
was based upon the paper by Stimmel et al 237. 
2.5.2 Sep-Pak® purification of radiolabelled biotin 
Radiolabelled biotin preparations were purified using Sep-Pak® C18 Cartridges (Waters, 
Milford, MA, USA). Passing 5 ml EtOH through by syringe over a one-minute period 
activated the cartridges. This process was then repeated at the same rate with UHP 
water. To a small quantity of radiolabelled compound 2ml of ultra-purified water was 
added and taken up in a2 ml syringe. This was slowly pushed through the column. A 
sample of 2 ml of water in a fresh syringe was then used to wash the column. The 
column was then washed with 30 % acetonitrile / 0.01 % TFA. Fractions of 500 p1 were 
taken. Invariably the first fraction contained the radiolabelled biotin which was analysed 
by RP-HPLC and further used for experimentation. 
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2.5.3 Immobilised streptavidin beads-d-DLB binding assay 
To a microfuge tube an excess (100 pl) of immobilised streptavidin beads (Sigma) (1.2 
mg streptavidin/ml) was added, then 390 pi of PBS followed by a 10 pI (0.5 pg) sample 
of indium labelled d-DLB typically 0.1 MBq/ pl to make the final volume of 500 µl. The 
reaction vial was then incubated at room temperature on a Spiramix for 30 minutes. At 
30 minutes the microfuge tube was centrifuged for 1 minute, and the supernatant 
removed and placed into a fresh-labelled microfuge tube. The beads were then washed 
with 500 µl of PBS and then centrifuged as before. The supernatant was removed and 
placed in a fresh-labelled microfuge tube. This last wash was then repeated. 500 µI of 
PBS was added to the beads and all four tubes were analysed on a universal gamma 
counter (window setting level no. 150 - 190). The same assay was repeated at 4 °C 
and 37 °C, either In a cold cabinet or in an incubator. 
2.5.4 Streptavidin- d-DLB binding assays 
(1) Stoichiometry of binding of d-DLB to streptavidin 
A set of concentrations of a solution of streptavidin ranging from 0.2 pM to 2 pM in 500 
pl of PBS were prepared and indium-111 labelled d-DLB was added to a final 
concentration of 26 nM. The reaction mixture was incubated at 37 °C for 30 minutes 
(unless otherwise specified). Analysis was performed using G50 Spin Columns 
(MicrospinT'"' G50, Amersham Biosciences). Two G50 spin columns were taken, their 
tops rotated a quarter turn and the bottoms snapped off. The columns were then 
placed in an empty microfuge tube and centrifuged at 2000 g for 1 minute. A 100 µl 
sample of the reaction solution was placed in the centre of each of the G50 spin 
Column resins. After centrifugation at 2000 g for 1 minute, the two components of each 
column were placed in gamma-counting tubes and measured In a gamma-counter. The 
filtrate contained the high molecular weight streptavidin bound moiety while unbound 
labelled biotin remained on the resin column. DLB was labelled with 2.6 MBq of "'In 
and the final concentration of DLB was maintained at 20.88 I. M. The reaction volumes 
were 100 µl and dilutions were done with PBS. 
(2) Biotin stability assay 
An excess (ten-fold) of streptavidin (650 ng) was added to 10 ng of "'In-labelled 
DLB/DBB in a total volume of 200 µl. Samples of 12 µl at defined time points were 
taken and analysed by G50 microspin columns as described above. The time points 
were at 0,0.5,1,2,6 and 24 hours. 
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2.5.5 Determination of the d-DLB concentration by cobalt-57 
1 ml of a stock 169.68 mM 57CoC12 solution was combined with 5.787 g of H2O in a 
metal free vial to give 6.787 ml of a nominal 25 mM Co solution. A 2.0 ml aliquot of the 
resulting solution was added to the entire vial of 57Co solution contained in 19µI volume 
to give a solution with a concentration of 1.5 x 106 dpm/µI. A 0.0997 M EDTA (Sigma) 
standard was diluted 25-fold with 0.1 M PBS pH5.5 to produce a 3.988 mM EDTA 
solution. 
To seven metal free vials labelled 1-7,5 µI of Co solution was added. Subsequently 5, 
10,15,20 and 25 µl of EDTA standard were added to vials 1-5 successively. 95 µl of 
ammonium acetate, 0.5 M pH 5.5, was added to vial number 7. Vials 1-6 were made up 
to 100 µl with PBS (dilution factor for the standards was 20). The mixtures were swirled 
and incubated for 1 hour at room temperature. 
A2 pl sample from each vial was spotted 1 cm from the bottom of seven 9x1.5 cm 
ITLC strips and allowed to dry. The strip was developed in 1.5 ml of 50 % ammonia, 
50 % methanol. In this system, 57Co-EDTA has an Rf of 1 and 57CoC12 an Rf of 0. The 
strips were cut in half and counted in the y-counter. A standard curve was constructed 
with EDTA concentration plotted against the fraction of 57Co which was EDTA bound 
from which a final Cobalt-57 concentration of 30.444 mM was calculated (P < 0.0001). 
A DOTA-lysine-biotin (DLB) solution was radiolabelled with Co in order to determine its 
molarity. A parallel labelling with "'In was performed to check the labelling success. 15 
µl, 20 µl and 40 µl of a theoretical 66.66 µg/ml and 100 µg/ml DLB stock solution were 
added to 10 µl of Co and 10 µl ammonium acetate mixture. The three vials were then 
made up to 100 µl with H2O and boiled for 25 minutes. 
A2 µl sample from each vial was spotted 1 cm from the bottom of seven 9x1.5 cm 
ITLC strips and allowed to dry. The strip was developed in 1.5 ml of 10mM EDTA In 0.1 
M ammonium acetate. The strips were cut in half and counted in the y-counter. A 
straight-line graph was constructed with Co concentration plotted against DLB 
concentration. From this graph an observed DLB concentration ratio of 1.583 times the 
expected DLB concentration was calculated (P <0.0001). 
2.5.6 Biotinidase assay 
A5 pg sample of d-DLB and I-DLB were radiolabelled with indium-111 and yttrium-90 
(30 MBq) and DTPA a, ca-bis biocytinamide was radiolabelled with indium as a control. 
The volume after labelling was made up to 280 µ) with water. In the case of the 90Y 
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labelled compound 100 pL of 100 mg/mI Ascorbic Acid 105 was added and made up to 
280 µl. A1 ml sample of fresh human serum was diluted to 10 ml with 0.1 M PBS. For 
each compound, five 450 µl samples of fresh human serum were taken and added to a 
microfuge tube. 50 µl of labelled compound was added to each of the five tubes and 
sealed before placing in an incubator at 37 °C on a spiral mixer for 0,1,2,6 and 24 
hours. At the specified time, 100µI of the serum was analysed by RP-HPLC to determine 
any degradation of the product. 
2.5.7 Protein binding analysis 
Radiolabelled DLB (1 µg/20 µl) was incubated in 480 µl of serum for 24 hours at room 
temperature. A G50 spin column was taken, its top rotated 0.25 turns and the bottom 
snapped off. The column was then placed in an empty microfuge tube and centrifuged 
at 2000 g for 1 minute to remove the liquid. The columns were then placed in fresh 
microfuge tubes. A 20 µl sample of the reaction solution was placed in the centre of the 
G50 spin column resin. The samples were centrifuged at 6500 rpm for 60 seconds. The 
filtrate containing the protein bound moiety determined the amount of the radiolabelled 
compound bound to serum proteins. The two column components were placed in 
gamma-counting tubes and measured in a gamma-counter. 
2.5.8 Biodistribution assay 
Labelling of both the I- and d-isomers took place under standard conditions as 
described above using 5 µg of DOTA-biotin and 10 MBq of 90Y or 111In. A sample of 1.1 
MBq of the labelled tracer was placed in a 10 ml vial and made up to a volume of 
600 pl with phosphate buffered saline (PBS). A 100 µl sample of 0.2mg/ml ascorbic acid 
solution was added to the radiolabelled 90Y labelled DOTA-biotin solutions, 20 pl of 50 
mM EDTA and 80 pl of PBS to the "'In-labelled samples. 
24 YA BALB/c female mice (bred in-house at Cancer Research UK) were separated into 
six equal groups. Groups 1-3 and 4-6 were injected In the tail vein with 50 µl of either 
90Y labelled d-DLB or I-DLB solutions respectively. Groups 1 and 4 were sacrificed at 2 
hours post-injection (p. 1), groups 2 and 5 were sacrificed at 6 hours p. 1 and groups 3 
and 6 were sacrificed at 24 hours p. i. After each sacrifice, the animals were dissected 
and a sample of their blood, a sample of muscle, a femur, both kidneys, the liver, the 
complete intestine, the spleen and the tail from each animal were placed in pre- 
weighed gamma counting tubes and sealed. 
The tubes were centrifuged briefly to collect the tissues at the bottom of the tubes. 
Each tube was then weighed and the weight of the tube deducted from the final weight 
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to give a tissue weight, which was recorded in a spreadsheet. This was done for all 
mice, and the tubes were placed in a gamma counter and counted for four minutes 
using the 90Y or'11In calibration setting (window setting level no. 85 - 220 or 150 - 190 
respectively). Indium-111 produces a photo-peak which is between 150 and 190 keV 
whereas yttrium-90 does not produce a true-photo peak but instead bremsstrahlung 
emissions are measured which also interact with the sodium-iodide detector. One thing 
to be cautious of is that the bremsstrahlung emmisions interact with lead to produce X- 
rays which also interact with the sodium-iodide detector to produce a measured count. 
Thus the gamma photons produce much higher signal to noise ratios than 
bremsstrahlung emmisions thus maximising the amount of yttrium-90 activity is 
important to reduce errors. 
Standards were made by taking three universal tubes and labelling them appropriately. 
The first was placed on a Sartorius L2200P micro-balance (Goettingen, Germany) and 
zeroed. A 20 µl sample was taken from the injection material and placed at the bottom 
of one tube. The tube was then made up to 10.00 g with water. The cap was replaced 
on this tube and mixed. 1 ml of the volume from the first tube was added to the 
second on a newly zeroed balance. The tube was then made up to 10.00 g with water. 
This process was then repeated for the third tube. One 1 ml of each sample was 
counted in a gamma-counting tube at the beginning, the middle and the end of the 
tissue analyses. The counting data was entered into the same spreadsheet and the 
percentage injected-dose (I. D) per gram of tissue was calculated for each study. 
The t-test was performed on two populations (C and T) of data (Initial 90Y-d-DLB and 
repeat "'In-d-DLB data) in order to disprove the null hypothesis that there was no 
significant difference between the initial and repeat d-DLB biodistribution data. The 
results were calculated using Microsoft ° Excel 2003 ° and verified by hand using the 
formula below for the two populations C and T. X bar represents the mean of the 
population data, the variable is represented by var for each data point and n is the 
number of data points in the data population. 
XT-Xc 
Var,. 
+ 
VarT 
nT nC 
The bone samples of 90Y-DLB were analysed for the attenuation of bremsstrahlung 
emissions by dissolving the bones in 1 ml of 1M HCI at 371C in the original scintillation 
tubes for two hours until the bone had been almost dissolved. The tubes were allowed 
to cool and then 4 ml of scintillant (Fisons Chemicals, Loughborough, UK) was added to 
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the solution and inverted to enable mixing. The tubes were then incubated at 40C in the 
dark for 24 hours before counting in a 1215 Rackbeta liquid scintillation counter (LKB 
Wallac). 
2.5.9 90Y Stability assay 
5 µg of both d-DLB and I-DLB were radiolabelled in a final volume of 100 µl with 30 
MBq of 90Y or 111In as described in section 2.3.1. This volume was made up with either 
400 µl water, or 300 µl water and 100 µl of 500 mg/ml sodium ascorbate, similar to Liu 
et al's work238 and supported by Chakrabarti in their monoclonal antibody study of 
radiolysis los. The solutions were incubated at room temperature for 72 hours and 
analysed by RP-HPLC. Radiolytic degradation products eluted from the column at the 
start of the chromatogram. 
2.5.10 Low & high molecular weight separation by gel filtration spin column 
Analysis was performed using G50 Spin Columns (Microspintm G50, Amersham 
Biosciences). One G50 spin column per sample was taken, the top rotated a quarter 
turn and the bottoms snapped off. The columns were then placed in an empty 
microfuge tube and centrifuged at 2000 g for 1 minute. A 25 µl sample of the reaction 
solution was placed in the centre of each of the G50 spin column resins. After 
centrifugation at 2000 g for 1 minute, the two components of each column were placed 
in gamma-counting tubes and measured in a gamma-counter. The filtrate contained 
the high molecular weight protein bound moiety while unbound labelled biotin 
remained on the resin column. 
2.6 Herceptin-streptavidin derivatisation 
2.6.1 Photoactivation of the MAb 
Exposing the sulphydryls of the MAb in order to conjugate it to the maleimide 
derivatised streptavidin was performed by photoactivation as described by Stalteri and 
Mather 239. A typical irradiation was performed as follows. 2000 µl of 10 mg/ml 
Herceptin® MAb in PBS or TSMZ was taken by syringe and needle and injected into a 
sterile 10 ml nitrogen-filled borosilicate glass vial with a rubber septum (Incstar Ltd., 
Wokingham, Berkshire., Uk). Concurrently an MDP II kit (Amersham, Amersham, UK) 
was reconstituted with 2 ml of PBS or TSMZ and the entire volume was drawn and 
placed into the MAb containing vial to form a5 mg/ml MAb solution. The vial containing 
the MAb solution was placed on a large upturned glass beaker centralised In the lamp 
unit of a Rayonet RMR 3000 photochemical reactor (Southern New England UV 
Company) with eight UV lamps and irradiation of the MAb was performed for known 
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time periods. If a sample was to be frozen 100 pl aliquots were placed in microfuge 
tubes and stored at -40 °C. 
2.6.2 Conjugation reaction of reduced trastuzumab with streptavidin-SMCC 
A5 pl aliquot of streptavidin solution (20 mg/ml) was mixed with 0.84 pi Sulpho-SMCC 
(4 mg/ml) and incubated at room temperature for ten minutes. Concurrently, a frozen 
UV-irradiated MAb sample was removed from the -40 °C freezer for defrosting. After 
ten minutes the streptavidin-SMCC reaction mixture was combined with a UV-irradiated 
MAb preparation in order for cross reaction to occur. For small preparations this was 
performed by slow pipette mixing at the beginning of the reaction for one minute. In 
the case of a large preparation the antibody solution being the larger volume was 
continuously stirred in a 10 ml vial with a magnetic stirrer and stirring bar at a very 
slow revolution rate. To this 10 pl of the SMCC-derivatised streptavidin was dropped in 
at a time over a two minute period to ensure the best possible mixing. Purification was 
performed as described in section 2.3.4 and after analysis of each 1 ml fraction the 
pure conjugate samples were combined and used in further studies. 
2.6.3 Sulphydryl assay - Ellman's reagent and 5-iodoacetamidofluorescein 
The number of free suiphydryls per antibody was determined using two separate 
suiphydryl quantitation assays. One assay using Ellman's reagent, DNTB 240-243, and the 
other using 5-IAF (5-Iodoacetamidofluorescein) 2. 
2.6.3.1 Ellman's assay 
A 10 mM solution of DTNB stock solution was made up and stored in the fridge until 
use. 250 µl samples of a5 mg/ml solution of trastuzumab In PBS were injected into 
sealed 10ml nitrogen-filled borosilicate glass vials with a rubber septum. To the vials, 
250 µl of an Amerscan Medronate II Kit reconstituted with 2 ml of degassed 2 mM 
EDTA in 0.1 M phosphate buffer pH 7.0 was added. The vials containing the 
trastuzumab-Medronate II mixture were irradiated as described in section 2.7.1 for 0, 
5,10,20 minutes. At the irradiation end-point, 250 µl of DTNB stock solution 4 mg/ml) 
were added to each of the vials and the vials were momentarily swirled. The solutions 
were placed on a rotator in an incubator set at 37°C, for 20 minutes. During 
experimentation the stock solution was kept under the same conditions as the assays 
samples at all times. After the DTNB Incubation period was completed the antibody was 
separated from any free DTNB or stannous ions as described in section 2.2.2. 
A cysteine standard curve was constructed by performing the same assay on a range of 
cysteine concentrations up to 200 µM in 0.1 M PBS. The absorbance's of all the 
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solutions were measured at 412 nm on a Beckman DU 600 general purpose UV/Vis 
spectrophotometer with a 100 µl micro-cuvette. A 100 µl sample of the pH 7 0.1 M PBS 
was used as the blank. Sulphydryl concentrations were calculated by dividing the 
concentrations of experimental readings by the known concentration of trastuzumab. A 
graph was plotted using Origin 6.0 (Microcal Software Inc, Northampton, MA) and an 
equation derived by plotting a linear fit. 
2.6.3.2 5-lodoacetamidofluorescein assay 
An 8mM stock solution of 5-IAF was made up in a2 ml cryo-tube covered in aluminium 
foil to exclude the light and stored in the fridge until use. 250 µl samples of a5 mg/ml 
solution of trastuzumab in PBS were injected into sealed 10 ml nitrogen-filled 
borosilicate glass vials with a rubber septum. To the vials, 250 µl of an Amerscan 
Medronate II Kit reconstituted with 2 ml of degassed 2 mM EDTA in 0.1 M phosphate 
buffer pH 7.0 was added. The vials containing the trastuzumab-Medronate II mixture 
were irradiated as described in section 2.7.1 for 0,5,10,20 minutes. At the irradiation 
end-point, 250 µI of 5-IAF stock solution were added to each of the vials and the vials 
were momentarily swirled. The solutions were placed on a rotator in an incubator set at 
37 °C, for 20 minutes. During experimentation the foil was removed from the stock 
solution and was kept under the same conditions as the assays samples at all times. 
The samples were purified by size-exclusion chromatography using a Sephadex G25 
PD-10 column and PBS/EDTA as a mobile phase. Sixteen 0.5 ml fractions were 
collected. A 200 pI sample of each of the fractions was placed in a 96 well white plate. 
200 pl samples of blanks of phosphate/EDTA buffer and aliquots from a 5-IAF dilution 
series also added to the plate. 
The samples in the 96-well white plate were measured on a SpectraMAX Gemini 
microplate reader: a dual-monochromator spectrofluorometer system 
(Molecular Devices). The data capture and analysis software, SoftMax Pro 4.3 was 
used on an Apple Macintosh computer. A 5-IAF standard curve was constructed 
using a range of 5-IAF concentrations up to 200 M. The graph was plotted in Origin 
6.0 (Microcal Software Inc, Northampton, MA) and an equation derived by plotting a 
linear fit. From this standard curve the molar extinction coefficient was then calculated 
to measure the suiphydryl concentration of the antibody samples and hence the 
number of suiphydryl groups per antibody. 
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2.6.4 Dialysis of trastuzumab with EDTA/phosphate or TSMZ buffer 
A3 ml sample of a5 mg/ml solution of trastuzumab in its original buffer was injected 
into a pre-whetted Slide-a-Lyzer® (Pierce, Woburn, MA) dialysis cassette with a5 ml 
syringe and 23-gauge needle. Any air in the cassette was drawn out using the same 
syringe without re-introducing the needle. The cassette was attached to the float 
provided and suspended in a2 litre volume of either EDTA/Phosphate or TSMZ buffer 
pre-cooled to 4 °C. The dialysis solution was covered and incubated over a weekend at 
4°C. The dialysed solution was withdrawn from the cassette using a5 ml vial and 23- 
gauge needle and placed in a 10 ml nitrogen filled borosilicate vial. The MAb solution 
was stored at 4 °C until use. 
2.6.5 Iminobiotin purification of trastuzumab-streptavidin 
The immobilised iminobiotin was purchased from Perbio and was mixed by inverting the 
bottle before aliquoting 2 ml of the suspension into a gauze-plugged 5 ml syringe body 
without the plunger which acted as a filtration column. The column was equilibrated 
with five column volumes of the binding buffer (50 mM ammonium carbonate buffer, 
pH 11, containing 500 mM NaCl) and then plugged with a rubber blind-hub. A2 ml 
volume of 50 mM pH 11 ammonium carbonate buffer was added to the iminobiotin 
support and a1 ml sample of trastuzumab-streptavidin (1 mg/ml) was added to the 
system. The mixture was incubated for thirty minutes and after each five minute the 
slurry was agitated by pipetting up and down a1 ml volume of the mixture. 
After the thirty-minute incubation period, the blind-hub was removed and the solution 
was allowed to pass through the gauze leaving the iminobiotin support on the surface 
of the gauze. Fractions of 100 pl were collected and Individually analysed by SE-HPLC. 
The column was then washed with five column volumes of binding buffer. The 
Immunoconjugate was then washed off the column with 5 ml of elution buffer (50 mM 
ammonium acetate buffer, pH 4.0, pH adjusted with 0.1 M acetic acid). The pH of the 
eluate was adjusted to neutrality to avoid any loss of activity resulting from extended 
exposure to acid pH values. The purified protein was then concentrated on a Centricon- 
30 column and buffered in 1 ml of PBS. 
2.6.6.1 Molecular weight determination by size-exclusion HPLC 
Molecular weight standards were obtained from BioRad (Hercules, CA) with proteins of 
several different molecular weights. The proteins consisted of thyroglobulin (670 000 
Da), bovine gamma-globulin, (158 000 Da), chicken ovalbumin (44 000 Da), equine 
myoglobin (17 000 Da) and Vitamin B12 (1 350 Da). Using the system described in 
section 2.3.2, a 10 µl standard of each was injected onto the column and the retention 
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times of each peak noted. A standard curve was produced plotting retention time 
against the log of the molecular mass. The retention time of analytical samples was 
then used to calculate the molecular mass of eluted species by reference to the 
standard curve. 
2.6.6.2 Tryptic digest and mass spectrometry 
In order to separate proteins of different molecular weights and obtain a protein 
without any impurities a SDS PAGE gel was run and the protein bands were isolated for 
analysis. A Pierce Precise 8- 16 % 10 well acrylamide gel (Perbio, Tattenhall, Cheshire) 
was fixed into place in a BioRad Mini Trans Blot tank. A packet of BupHTM Tris-HEPES- 
SDS Running Buffer (Pierce) was dissolved in 500 ml of UHP water and added to the 
tank to cover the sample wells. To a 10 pl sample of 5 mg/ml protein a 15 pl amount of 
premixed running buffer (Pierce) was added and gently mixed. A 15 pl amount of the 
protein/running buffer sample was applied to each well. A 10 pl sample of BioRad's All 
Blue protein standard solution was used as a marker. Streptavdin, trastuzumab and 
trastuzumab-streptavidin were separated in two lanes per sample. The gel was run for 
approximately 90 minutes at 90 volts using a BioRad power supply unit. 
Bands were cut out from the acrylamide gel using a clean scalpel and placed in a clean 
0.5 ml microfuge tube. A 180 pl sample of 25 mM ammonium bicarbonate solution was 
added to the tube to cover the gel-fragments. After a half-hour incubation the tubes 
were vortexed and centrifuged to ensure adequate reaction and the subsequent 
collection of the protein. The process was repeated, typically twice, to remove the 
Coomassie stain. The supernatant was then removed and a 180 pi aliquot of 
acetonitrile was added. The tubes were centrifuged and the gel observed for significant 
shrinkage and the microfuge tubes were centrifuged to collect the pellet and the 
supernatant was removed and placed in a SpeedVac for at least 45 minutes. A 200 ng 
trypsin in ammonium bicarbonate solution (final volume 500 pl) was used to rehydrate 
the gel fragments. The samples were incubated In ammonium bicarbonate for 4 hours 
at 37 °C The reaction was stopped by placing samples on dry ice for 5 minutes. The gel 
fragments were placed in formic acid were placed In a sonicating water bath for 15 
minutes, before being dried in a SpeedVac. The protein was re-suspended in 20 ml H2O 
and dried down in Speed Vac twice. Mass spectrometry was then performed 
immediately by a Cancer Research UK mass spectrometry technician at Lincolns Inn 
Field, London. Each sample was reconstituted in 5 pi 50 % ACN / 0.1 % TFA v/v with 
0.3 pl loaded on to the target plate with a 0.3 pl mixture of 3 mg/ml a-cyano matrix 
and Angiotensin I (25 fmol). Peptides were analysed using a 4700 Proteomics Analyser 
(Applied Biosystems) in MS Reflector Positive mode. The collated MS and/or MS/MS 
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data was used to search the NCBI database using Protein Prospector with a mass 
accuracy of 20 ppm. 
2.6.6.3 UV Spectrophotometry of streptavidin 
A5 µi sample was diluted to 1000 µl with 0.1 M PBS. A blank was made using 0.1 M 
PBS. The absorbance of the solutions was measured at 280 nm on a Beckman DU 600 
general purpose UV/Vis spectrophotometer with a 1250 µl quartz micro-cuvette and the 
spectrophotometer zeroed after equilibration. 
2.6.6.4 SDS PAGE (Phastpage) 
A Pharmacia (Upssala, Sweden) PhastSystem separation and control unit is a single unit 
with a temperature control bed with electrode arms which can be positioned to come 
into contact with a polyacrylamide gel. Gels were available in 7.5 %, 12.5 % and 20 % 
polyacrylamide varieties and were supplied ready to use. These were placed on the 
PhastSystem and SDS buffer strips were placed into contact with the gel. The 
electrodes were then aligned onto the buffer strips and the bed was cooled to 15 °C. 
Meanwhile the 10 pl (1mg/ml) protein samples were incubated with 15 PI of (100 mM) 
sample buffer (2 % SDS, 10 % glycerol, 0.08 M Tris-HCI pH 6.8,0.1 M DTT, 50 % 
water) for 15 minutes at 100 °C. After cooling down the protein samples, 10 pl of each 
of the samples was placed in a template containing 8 wells. BioRad All Blue® molecular 
weight markers were placed in one or more wells. A comb with eight ridges and 
capacity for 4 pl of liquid was placed Into the eight wells to take up the samples. The 
comb was then placed in the insert of the Phastsystem poised above the gel. The 
program run had a setting of 12.5 mA value and 3.5 V and the gel was run for typically 
half an hour before staining. Staining was performed in a Petri dish with Fast 
Coomassie stain (30 % methanol, 10 % acetic acid and 60 % distilled water with 2g of 
Brilliant blue 250 (Sigma) dissolved in 1 litre and filtered using double layer Whatman 
54 filter paper) and left overnight on a rotator. Destaining involved using the same 
solution as the staining solution without the brilliant blue stain. The Petri dish was 
replaced on the rotator where several changes of the solution were required until the 
gel had resolved adequately. The gel was dried by leaving it In the lid of the Petri dish 
on a bench for overnight. 
2.6.7.1 Concentration of protein solutions by Centriprep column 
With large protein preparations (> 2 000 - 15 000 pl) the protein in solution could be 
concentrated by using a Centriprep column (Millipore, Billerica, MA). The protein 
solution (typically 5 ml) was placed in the bottom of the cylinder and the filter insert 
was replaced. The column was centrifuged at 3000 g in an AllegraTm 21R centrifuge 
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(Beckman Coulter) using a S4180 swing-out rotor (Beckman) for the length of time it 
took to concentrate it to a desired concentration. If de-salting of the buffer was 
required the protein solution would be concentrated and then PBS would be added to 
the protein solution to 15 ml. The column would then be centrifuged again until the 
same original volume was reached. This would be repeated four times. 
2.6.7.2 Concentration of protein solutions by Centricon-30 column 
For small volume protein concentration protocols (< 2 000 NI) a Centricon-30 was used. 
The filter column was placed into its complementary buffer collection cylinder. The 
protein solution (typical volume 1 ml) was then placed on the filter. The column was 
then centrigued using a F0850 fixed angle rotor (Beckman) in an AllegraTM 21R 
centrifuge (Beckman Coulter) (To ensure that the filter remained wet). If more protein 
was to be concentrated in the same sample a further sample was added to the filter, 
the buffer flow-through discarded and the re-assembled column was centrifuged again 
until only a small volume of around (100 pl) remained. To reclaim the protein the filter 
cylinder was inverted and placed into a fresh collection tube and the column was 
centrifuged upside-down for ten minutes. 
2.6.8 Oxidation of reduced MAb suiphydryls using tetrathionate. 
Re-oxidation of the MAb free sulphydryls produced by the reduction with stannous ions 
in the presence of UV light was performed by the addition of a final concentration of 
5 mM sodium tetrathionate to the reaction solution after a two hour incubation period. 
The solution was stirred for a further 10 minutes before placing the reaction solution at 
4 'C. 
2.7.1 Radioimmunoassay for measurement of immunoreactivity 244 
Two confluent flasks of SKBR3 cells were trypsinised by covering the cells with 
0.025 % trypsin in versine solution and incubating the flask at 37 °C for five minutes. 
The cell suspension was taken up in a pipette and placed in a 15 ml falcon tube and 
centrifuged at 1500 rpm for 5 minutes. The supernatant was aspirated off and the cells 
were re-suspended in 5ml of cold 1% BSA/ 0.1 M PBS pH 7.4 in a universal tube. The 
universal tube was centrifuged at 1500 rpm for 5 minutes, and the resulting 
supernatant discarded. The cell pellet was then re-suspended in 3 ml of cold BSA/PBS. 
The cell clumps were broken-up by passing the solution though a hypodermic syringe 
with a 22 gauge needle. A 100 pI sample of the cell suspension was diluted to 10 ml 
with BSA/PBS. The cell concentration was measured using a haemocytometer and a 
Bausch and Lomb Balplan light microscope. The cell number was determined by 
counting the number of cells seen within the 25 large squares of the haemocytometer 
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and then multiplied by 10 000 to obtain the number of cells per ml. Two rows of 5 
microfuge tubes were set up and 0.5 ml of cold BSA/PBS pipetted into tubes 2-5 of 
each row. A 0.5 ml sample of the cell suspension was aliquoted into tubes 1 and 2 of 
each row. Tube 2 was briefly vortexed and 0.5 ml of the solution was transferred to 
tube 3. This serial dilution process was continued to tube 5. A 0.5 ml sample was taken 
from tube 5 and discarded to produce equal volumes (0.5 ml) in all samples. The 
remaining concentrated cell suspension (1 ml) was divided between two further 
microfuge tubes. The tubes were labelled NSB (Non-specific binding). To each of the 
NSB tubes, 50 pl of unlabelled MAb (10 mg/ml) was added and briefly vortexed. The 
'25I-radiolabelled conjugate was diluted to a final concentration of 50 ng/ml with cold 
BSA/PBS and mixed well. A 250 pl aliquot of the diluted radiolabelled conjugate was 
pipetted into tubes 1- 10, both NSB tubes and two further empty microfuge tubes 
(Total Activity). The lids of all tubes were closed and then placed into 4 sterilin 
universal tubes and incubated at room temperature on a Spiramix for two hours. All the 
tubes were centrifuged for 2 minutes at 13 000 rpm in a microfuge. The supernatant 
was carefully removed being careful not to disturb the cell pellet. A 0.5 ml aliquot of 
BSA/PBS was placed into each tube and vortexed to re-suspend the cell pellet. The 
tubes were then centrifuged and washed again. The tubes were then placed in a 
gamma counter and counted using an 1251 specific program (window setting level no. 
37-102). The total counts in the sample were divided by the counts which were cell- 
bound. These data points were plotted against the cell-dilution factor for each sample. 
The y- intercept value was determined automatically by the Origin graphing software 
and the reciprocal of this value multiplied by 100 to produce the immunoreactive 
fraction. 
2.7.2 Cell-binding kinetics assay 
Five six-well plates were seeded with approximately 700 000 SKBR3 cells per well and 
incubated overnight to obtain cells which were 60 - 80 % confluent in each well. The 
media was aspirated off and replaced with fresh media to remove any unbound cells. 
The plates were then placed on a bench and allowed to equilibrate to room 
temperature. A 30 pI aliquot of a2 pg/pI stock solution of 125I-labelled streptavidin 
conjugated trastuzumab was placed in three adjacent wells After the desired incubation 
time the media was removed and placed in a labelled gamma counting tube. The cells 
were washed with another 1 ml of media which was again placed In a labelled gamma 
counting tube. A1 ml aliquot of 1.0 M sodium hydroxide was placed on the cells and 
the plate was put on a Thermalyne Maximix III shaker (Boston, MA) to aid removal of 
the cells from the plate. Once the cells had been displaced the solution was taken up 
with a pipette and placed in a gamma counting tube. Another 1 ml of 1.0 M sodium 
71 
hydroxide was added to the wells, mixed and placed into the same gamma counting 
tube as the last aliquot. These steps were repeated for all time points required. As a 
control, 125I-labelled MAb was assayed in exactly the same way as the conjugate. A 
repeat assay was carried out at 4 °C. Non specific binding was determined by 
quenching the receptor binding sites with 100 pg of trastuzumab an hour prior to the 
assay. Excess cold MAb was washed off with the first media replacement. After all the 
tubes had been compiled, the tubes were counted on a gamma counter, with a 
program set-up optimised for 1251. Total counts were averaged and the cell-bound 
counts at each time point was divided by the total counts to give a final figure of 
percentage of the conjugate or MAb bound to the SKBR3 cells. 
2.7.3 Cell-internalisation assay 
Five 6-well plates (Falcon, Tissue Culture treated, Becton Dickinson) were seeded with 
SKBR3 cells and grown to confluency. The assay was performed in triplicate so 6 wells 
per time point were required. Three of the wells were designated for cold (i. e. 
unlabelled) trastuzumab added, and the other three wells were designated to be 
without trastuzumab. On the day of the experiment the media was removed and the 
cells washed twice with ice-cold internalisation media (E4 plus 20 % Foetal Calf 
Serum). To each well 1.2 ml of internalisation media was added and 150 pl of 1251- 
radiolabelled conjugate (250 ng/ ml). At the same time 150 pI of PBSA/0.5 % BSA was 
placed in three wells and 150 pI of trastuzumab (400 pg/ ml) in PBS/0.5 % BSA was 
placed in the other three wells. Three 150 pI aliquots of radiolabelled trastuzumab were 
placed in three microfuge tubes to provide a measure of the total radioactive counts for 
the assay. The five plates were incubated at 370C for 20,40,60,90 or 120 minutes. 
The reaction was stopped by removing the media and rinsing each well twice with 1 ml 
of Ice-cold internalisation media. A1 ml sample of 0.05 M glycine-HCI acid wash buffer 
(pH 2.8,2.3 or 1.8) was placed in each well and incubated at room temperature for five 
minutes. The supernatant (membrane-bound radio-ligand fraction) was collected and 
retained. A further wash with internalisation media and then acid wash buffer was 
performed as before, and the supernatants combined for counting. The cells were then 
rinsed with 1 ml of PBS/ 0.5 % BSA. A1 ml aliquot of NaOH was added to the cells and 
incubated for 15 minutes at room temperature to lyse the cells. The solution was then 
transferred to counting tubes and counted to obtain the internalised radioligand counts. 
The percentage of Internalised activity was then calculated for each time point. 
2.7.4 Externalisation assay 
Five 6-well plates (Falcon, Tissue Culture treated, Becton Dickinson) were seeded with 
SKBR3 cells and grown to confluency. The assay was performed in triplicate so 6 wells 
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per time point were required. Three of the wells were designated for cold (i. e. 
unlabelled) trastuzumab added, and the other three wells were designated to be 
without trastuzumab. On the day of the experiment the media was removed and the 
cells washed twice with ice-cold internalisation media (E4 plus 20 % Foetal Calf 
Serum). To each well 1.2 ml of internalisation media was added and 150 NI of 125I- 
radiolabelled conjugate (250 ng/ mi). At the same time 150 pl of PBSA/0.5 % BSA was 
placed in three wells and 150 pl of trastuzumab (400 pg/ ml) in PBS/0.5 % BSA was 
placed in the other three wells. Three 150 pl aliquots of radiolabelled trastuzumab were 
placed in three microfuge tubes to provide a measure of the total radioactive counts for 
the assay. The five plates were incubated at 370C for 1,2,2.5,3,4 or 6 hours. After 
the two-hour time point, the media was taken off and replaced with fresh pre-warmed 
cell media and incubated for up to a further four hours. At each of the time points, the 
reaction was stopped by removing the media and rinsing each well twice with 1 ml of 
ice-cold internalisation media. A1 ml sample of 0.05 M glycine-HCI acid wash buffer 
(pH 2.8,2.3 or 1.8) was placed in each well and incubated at room temperature for five 
minutes. The supernatant (membrane-bound radio-ligand fraction) was collected and 
retained. A further wash with internalisation media and then acid wash buffer was 
performed as before, and the supernatants combined for counting. The cells were then 
rinsed with 1 ml of PBS/ 0.5 % BSA. A1 ml aliquot of NaOH was added to the cells and 
incubated for 15 minutes at room temperature to lyse the cells . The solution was then 
transferred to counting tubes and counted in the gamma-counter to obtain the 
internalised radioligand counts. The percentage of internalised and externalised activity 
was then calculated for each time point and the data plotted. 
2.7.5 Pretargeting assay 
SKBR3 cells were seeded in five six-well plates as described in section 2.7.1 and on the 
morning of the assay, the supernatant was removed and fresh media was added. The 
assay was performed at 37 °C and the fresh media was pre-warmed before replacing 
the old media. 10 pg of cold TSA was placed In a 15 ml Falcon tube and diluted in PBS 
to 5 ml. Samples of 150 pl were added to each well and allowed to bind to the cells In 
the Incubator. After two hours, the media was replaced with fresh media. To the fresh 
media 150 pi aliquots of 6.6 pg/ml of "'In-labelled effector molecule (DLB or DBB) was 
added. The plates were then replaced in the incubator for another three hours to 
ensure compete reaction. At the end of set time periods (0.3,0.6,1,2 or 3 hours) 
three wells per time point were analysed for radioactivity associated with the cells. 
Firstly the media was aspirated and retained, the cells were then washed and the 
supernatant added to the first fraction. Lastly, the cells were removed from the plate by 
adding 2 ml of iM NaOH and incubating the cells for 15 minutes. The cell fraction and 
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the supernatant fractions were placed in counting tubes and analysed with the gamma- 
counter. The percentages were obtained from each fraction and the data was plotted. 
2.7.6 Cell microscopy 
Cells were imaged using a Nikon Eclipse E600 microscope with a digital camera 
attachment (DXM1200F) (Nikon, Kingston upon Thames, UK). The imaging device was 
connected to a PC running Nikon ACT-1 version 2.62 data collection software. A 750 ml 
flask of confluent cells were harvested using trypsin/versine and re-suspended in PBS. 
The volume was aliquoted into four microfuge tubes and the cells centrifuged for 5 
minutes at 13 000 rpm. The supernatant was removed and the pellets were incubated 
in 0.05 M glycine-HCI acid wash buffer (pH 2.8,2.3 or 1.8) at 37 °C for twenty 
minutes. A 20 pl aliquot was placed in an equal volume of Trypan Blue and mixed 
gently before incubating for five minutes. At five minutes an 8 pl aliquot of the cell 
solution was placed on a haemocytometer and Imaged with the microscope. 
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Chapter 3 Synthesis and evaluation of a 
pretargeting effector molecule (DOTA- 
lysine-biotin) 
3.1 Introduction 
Two-step and three-step pre-targeting have been shown to be a successful and safer 
method of delivering radioisotopes to tumours than conventional radioimmuno- 
targeting 245,246. In the two-step method 246, the rapid clearance of the non-localised 
radiolabelled effector molecule reduces background radiation dose and increases target 
to background ratios 1,222,247. The aim of the work described in this chapter was to 
create an effector molecule that will be able to localise a pretargeted MAb derivative 
effectively. 
Since the intention was to use the streptavidin-biotin interaction as the means of in- 
vivo capture, a radiolabelled biotin construct was required as the effector molecule. 
Accordingly, a molecule that combines biotin and DOTA, separated by a lysine linker, 
was designed as shown in figure 3.1. The most widely used method of radiolabelling 
such a molecule is by using a BFCA (bi-functional chelating agent), such as DOTA. 
In 1990 "'In-diethylenetriamine pentaacetic acid (DTPA) o, cw-bis biocytinamide (lysine- 
biotin) was used by Kalofonos et al to successfully image squamous cell lung tumours 
with a streptavidin conjugated MAb 232. Previous experience has shown that biotin 
derivatives must be stabilised against enzyme degradation 248. In this study, DOTA was 
used as it forms a more stable complex with 3+ metal ions than DTPA. The construct 
was made as described in the materials and methods section, using a lysine-bound pre- 
loaded resin. Both dextro (d) biotin and laevo (I) biotin isomers were used. Below is a 
diagram detailing the chemical structure of DLB. 
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ON 
ýO 
NH 
HN 
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DOTA LYSINE BIOTIN 
Figure 3.1 Chemical structure of DLB (DOTA-Lysine-Biotin) 
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3.2 Synthesis of DOTA-Lysine-Biotin (DLB) 
A lysine-bound pre-loaded resin with two different functionalised active groups 
derivatised with blocking groups was used as the basis of the reaction as shown in 
figure 3.2. Removal of the FMOC blocking group from the a amino group of lysine 
facilitated the addition of the d- or 1-biotin molecule. The MTT blocking groups were 
then removed and tris-butyl-DOTA was added to the lysine linker. After washing off the 
reagents, DOTA was deprotected and the peptide cleaved from the resin with 95 % 
TFA and precipitated with ether. The compounds were washed and dried before being 
dissolved in ultra-high purified water. The yield was determined by mass of the dried 
product as 81 %. For a detailed description of DLB synthesis consult section 2.5. 
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l 
BIOTIN-Lys-COOH 
Section 2.5.10 
BIOTIN-Lys-Resin BIOTIN-Lys-Resin 
Section 2.5.9 
Figure 3.2 DOTA -Lysine - Biotin Reaction Scheme 
3.3.1 DLB analysis by RP-HPLC 
The products obtained were both purified by RP-HPLC and 50 pg of d-DLB and 100 pg 
of I-DLB were analysed by RP-HPLC (Reverse-phase high pressure liquid 
chromatography). This was to verify whether a single species had been isolated from 
any reagents and reaction intermediates. Below are the UV-chromatograms of both 
isomers indicating their purity. 
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Figure 3.3 RP-HPLC analysis of d-DLB showing the purified product 
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Figure 3.4 RP-HPLC analysis of I-DLB showing the purified product 
Both UV-chromatograms show a single defined peak with no shouldering and baseline 
resolution. Small amounts of other contaminants were seen at various time points but 
these are no more than 7.5 % in either compound. Although a greater degree of purity 
was hoped for (i. e. greater than 95 %), further characterisation was performed on the 
premise that DLB's performance may not be impeded by a low degree of impurity. 
3.3.2 Mass spectrometric analysis of DLB 
The synthesised product was first analysed by matrix-assisted laser 
desorption/ionisation time of flight (MALDI-TOF) mass spectrometry to verify the 
correct molecular mass of 759 amu. Below are the analyses of both isomers. 
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Figure 3.5 Mass spectrometry analysis of d-DLB purified product 
T" 374 
i 
Figure 3.6 Mass spectrometry analysis of I-DLB purified product 
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Although other species are present, an excellent signal is given from the peak at 759 
amu. Thus combining the data from the post-synthesis UV-chromatogram with this set 
of data, we can be almost certain that we have synthesised the predicted molecules 
with acceptable purity. 
3.4.1 Radiolabelling of DLB 
Both DLB isomers were radiolabelled with 111In3+, 90Y3+ and "'Lu3+ using the procedure 
described in section 2.2.1. By radiolabelling the compounds it was possible to 
determine the level of pure DLB compound and to see whether any other impurities 
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were radiolabelled. To determine their purity, the products were then analysed by RP- 
HPLC. Below are two graphs showing the labelled products of d-DLB and I-DLB 
analysed by RP-HPLC as detailed in section 2.3.5. 
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Figure 3.7 d-DLB radio-chromatograms combined to demonstrate the 
labelling patterns with different radio-metals 
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Figure 3.8 I-DLB radio-chromatograms combined to demonstrate the 
labelling patterns with different radio-metals 
Radiochemical purity was determined by analysis of the areas under the curves in each 
radiochromatogram which were automatically integrated using the Beckman HPLC 
software, 32 Karat. Each radiolabelling with a different isotope gave its own distinct 
labelling patterns with different retention times but all having just a single peak. It is 
noteworthy to mention that both isomers, when labelled with the same metal, produced 
the same retention times. No other radiolabelled peptide peaks resulted from labelling, 
and only a small amount (typically less than 1 %) of "In-EDTA eluted at the solvent 
front. The single labelled peaks were sharp and without shoulders indicating a single 
labelled product when analysed on a shallow gradient (section 2.3.5). These 
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clean sharp peaks indicated that any of the impurities visualised on the mass 
spectrograph and HPLC do not influence the radiolabelling yield and were thought not 
to impact on any future experiments performed. 
3.4.2 The labelling efficiency of DLB using different times of boiling 
The initial labelling procedure involved a thirty-minute incubation in boiling water. This 
method was used from previous investigators experiences of labelling in the laboratory. 
However to determine whether the labelling yield was susceptible to Increasing 
incubation times a study to determine these questions was performed. 
The time of boiling of the labelling reactants was increased in 15-minute increments up 
to one hour. This was performed in order to determine whether the time of incubation 
was critical to successful radiolabelling. A typical radiolabelling assay was set up to 
determine the percentage of "'In-d-DLB formed after a 30 minute labelling (see 
section 2.2.1). 
After 15 minutes of boiling the reaction mixture, the labelling yields was determined to 
be 96.23 %±1.3 % as determined by RP-HPLC and automatic software peak 
integration. On average the degree of radiolabelling was 99.37 ± 0.6 % at thirty 
minutes. At sixty minutes 98 %±0.74 % of the activity was bound to the DLB with 
only 2% found at the solvent front. Therefore the thirty minute radiolabelling practice 
was kept and all future radiolabelling work with DLB was performed with the same 
method. 
As seen from this assay, the consistency of labelling does not alter greatly over the 
hour period. Therefore specific incubation times for radiolabelling reactions were not 
critical, as labelling Incubations up to an hour produced acceptable results. Importantly, 
the compound does not break down over the hour period of boiling, Indicating its 
inherent thermostability. 
3.4.3 Labelling efficiency decreases over time 
During the course of radiolabelling the conjugates over a week period using the same 
vial of i11InCl3, the labelling efficiency became Increasingly poor. ITLC analysis showed 
a higher proportion of the ""'In-EDTA" migrating to the solvent front in both organic 
and aqueous solvents suggesting that it had been complexed by an unknown agent. 
Below Is a radio-chromatogram showing typical reduction In labelling efficiency after 
three or four days. 
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From a hypothesis that the pipette tips may be contaminating the "'InCl3 solution, the 
pipette-tips were pre-treated with 1M hydrochloric acid for 24 hours, and then rinsed 
in ultra-high purified water before drying in a heated cabinet. When using the pre- 
treated pipette-tips, labelling efficiency only mildly declined over the week. 
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Figure 3.9 ""'in and 90Y poor labelling efficiency due to contamination 
introduced from pipette tips 
When labelling with 90Y3+, it was observed that once pipette-tips had entered the 
solution, the following day labelling efficiency was less than 10 %. The degree of 
reduction in labelling efficiency was much greater than that of "1In3+ 
The pre-treated pipette-tips increase the length of time that the radio-metal solution 
remains viable for labelling, even up to a week after first use. This would be the typical 
useful life of the source to ensure that specific activity was kept high and sufficient 
radiolabelling yields were maintained. 
A question remained as to what the radiolabelled compounds formed were, though this 
was deemed purely academic as a solution to the reduced labelling yield of the peptides 
had been found. Consistent and high labelling yields were always produced when 
labelling with the pre-treated pipette-tips was performed. 
3.5.1 Immobilised streptavidin beads binding assays 
To determine the ability of the "'In-labelled DLB to bind to streptavidin, an excess of 
immobilised streptavidin beads was diluted in PBS (phosphate buffered saline) and 
'111n-d-DLB was added and incubated for 30 minutes to facilitate maximal binding. 
R1 
After centrifuging the beads, the supernatant and two further washes in PBS were 
recovered and counted to determine what percentage of d-DLB was bound to the 
beads. Competitive binding studies, performed with cold d-biotin, were carried out to 
determine the degree of non-specific binding. Below are the results of the binding assay 
(details are provided in section 2.5.3). 
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Figure 3.10 Immobilised streptavidin beads as a substrate for d-DLB 
binding 
These initial binding studies of d-DLB with immobilised streptavidin beads in PBS 
showed that almost 80 % of d-DLB bound to the streptavidin. The negative control 
result demonstrates that the degree of non-specific binding was almost 12 %. 
The I-biotin DLB analogue did not bind to streptavidin beads and the activity bound to 
the beads was the same as those for biotin saturated streptavidin. The technique was 
relatively fast to perform and the results indicated a respectable level of binding was 
achieved, with non-specific binding being relatively low. 
3.5.2 d-DLB association at different temperatures 
An assay was performed under the same conditions as that in section 3.5.1, but at two 
alternative temperatures to see whether a variation in temperature would affect d-DLB- 
streptavidin association over the same 30-minute period. 
The temperatures chosen were 37 °C and 4 °C and both sets of reaction vials were 
placed on rotators at either temperature to ensure adequate mixing of the reaction 
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solutions. Below are the results of the thirty-minute binding study including the two 
subsequent PBS washes performed to remove any unbound radiolabelled d-DLB. 
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Figure 3.11 Streptavidin binding assay at cold and warm temperatures 
As can be seen above no significant difference was observed between the assays at 
either of the temperatures. From this result we can conclude that d-DLB binding 
kinetics is rapid, because within half an hour maximum binding has occurred even at 
the lower temperature of 4 °C, where under such conditions binding kinetics are greatly 
reduced. However, although binding of the labelled biotin to the streptavidin beads was 
generally in the region of 80 %, on repeating the assay several times it was observed 
that the percentage bound to the beads compared to the supernatant was very 
variable. 
Variability was thought to be due to the fact that the amounts in the aliquots taken 
from the suspension of streptavidin beads were very variable. A new assay was 
therefore required to determine a more accurate result. 
3.5.3 Binding of DLB to streptavidin in solution 
Because of the variability of results derived from streptavidin beads, it was decided to 
use a soluble streptavidin system where concentrations of streptavidin could be more 
easily controlled. Size-exclusion gel-filtration spin-columns were to be used which 
separate high molecular weight components from the low molecular weight 
components by retaining the small molecules in the resin and allowing the high 
molecular weight components to elute from the column. Thus streptavidin-bound "In- 
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DLB eluted from the column and the free "'In-DLB was retained in the column resin 
(described in greater detail in section 2.5.4 (2)). 
Using this system a1 pg amount of "'In-radiolabelied d-DLB was incubated in a PBS 
solution containing 100 pg of free streptavidin per sample. After completion of the 
elapsed incubation times, spin columns were used in order to separate the high 
molecular weight compounds (i. e. any streptavidin-bound-DLB) from the low molecular 
weight component. Both fractions were then analysed using a gamma counter and the 
percentage of "'In-DLB bound to streptavidin was plotted as a percentage of the total 
activity of DLB found in the sample counting tubes. 
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Figure 3.12 Binding of 1111n-d-DLB to streptavidin in solution 
Greater than 96 % of "'In-d-DLB bound to streptavidin in 30 minutes. After 30 
minutes, binding increased steadily to 97 % after twenty-four hours. This confirms that 
the great majority of the labelled d-DLB Is biologically active though the reason a value 
close to 100 % was not obtained may be related to the sample purity described in 
section 3.3.1 or simply because of the heterogeneity of the streptavidin. Interestingly, 
92 % of the activity was found to be streptavidin-bound at time "zero", allowing for 
time of experimentation this time probably equates more closely to 2 minutes indicating 
very rapid binding of most of the conjugate. 
Because the rate of binding "'In-d-DLB to excess streptavidin is rapid, at this stage of 
experimentation its potential use as a pre-targeting effector molecule remains viable. 
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3.5.4 57Co/60Co study to attempt a more accurate quantification of DLB 
concentration DLB - 57Co proportionation 
Concentration dependent studies such as binding studies and radiolabelling assays 
require that the concentration of effector molecule is accurately known. In order to 
determine whether the concentration of d-DLB was correct, a 57Co assay was 
performed (section 2.5.5). Cobalt-57 has a long half life of 270 days, thus reducing any 
calculation errors and is chelated by DOTA in the same way as lanthanides are. 
The assay involves a technique known as back-titration whereby the reaction of a fixed 
concentration of 57Co3+ with a changing concentration of an accurately known 
concentration of EDTA solution produces a defined concentration of cobalt-57. 
Estimated amounts of DLB were then radiolabelled with known amounts of cobalt-57 
which could then be related to d-DLB. After the radiolabelling of d-DLB with 57Co3+, 
ITLC analysis was performed to determine the range of labelling yields. The 
concentration of bound 57Co was then plotted against the concentration of DLB to 
produce the graph seen below. 
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Figure 3.14 Standard curve of 57Co labelled DLB in EDTA to derive the true 
DLB concentration 
The plot forms a good straight line of best fit, passing through the origin with little 
error. A d-DLB concentration which is the same as the predicted concentration will have 
a slope of 1. However the 57Co3+ concentration is 1.56 times greater than that of the 
predicted d-DLB value indicating that the real DLB concentration was 1.56 times higher 
than that initially estimated. 
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Though quite a high degree of error in measured over expected DLB amounts was 
exposed by the cobalt-57 assay, it was necessary for further concentration dependent 
studies that the DLB concentration was known exactly. The cobalt-57 assay produced 
accurate data which was used to produce a stock solution of known concentration. 
3.5.5 "'In-DLB-free streptavidin binding and separation assay 
A study was designed to quantitatively determine the molar ratio of binding of d-DLB to 
streptavidin. Knowing the binding relationship between "'In-DLB and streptavidin 
provides further characterisation of DLB and highlights whether any instability or 
undesirable interactions prevent DLB from binding in the same way as biotin does. 
To determine the concentration of streptavidin required for the saturation of biotin 
binding sites by a fixed concentration of d-DLB, a series of different concentrations of 
streptavidin was used. After incubation and reaction with "'In-d-DLB the reaction 
mixtures were placed on G50-sephadex spin columns. On centrifugation the high 
molecular weight component (streptavidin and any bound radiolabelled biotin) were 
separated from the low molecular weight component (unbound "In-d-DLB). The 
methodology for this assay is also described in section 2.5.4. Below is the graph 
constructed from the data produced from the sample analysis by y-counter and used to 
derive DLB: streptavidin binding stoichiometry. 
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Figure 3.13 Chart showing 10 ng d-DLB binding to streptavidin over a 
range of different concentrations 
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As expected the curve is sigmoidal and ranges from 1.5 % to 99 % of DLB binding to 
streptavidin. It can be seen that a 4: 1 ratio of DLB to streptavidin (0.25 on the x-axis), 
corresponds to a binding efficiency of 93 % and is close to the plateau ultimately 
reached of 97 % binding. This indicates that DLB does bind to streptavidin with a 
stoichiometry of about 4: 1, in the same way as biotin itself. 
Although this estimate is not very accurate, because of the very shallow slope of the 
curve at this point, it does give reassurance that the functionality of the DLB has not 
been adversely affected by the conjugation and labelling procedures. 
3.6 d-DLB stability in human serum 
Biotinidase is a ubiquitous mammalian enzyme found at high concentrations in the liver, 
serum, and kidney. The primary function is to cleave biotin from biocytin Z4, as shown 
in figure 3.15, preserving the pool of biotin for use as a cofactor for biotin dependent 
enzymes, namely the 4 human carboxylases 249. Several investigators have provided 
solutions to the potentially cleavable biotinamide bond by introducing various blocking 
groups 136,25o-252 From literature research it is clear that biotin derivatives must be 
resistant to biotinidase metabolism in their chemical design 252-254. It may be important 
to note for future drug design that Zempelni et al report that biotinidase is not specific 
255 for cleaving the biotinamide bond in biocytin 
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Figure 3.15 Biotinidase cleavage site shown in DTPA a, w- biocytinamide 
Wilbur et al report that by introducing a N-methylbiotinamide structure (figure 3.16), 
stability was increased but an increased rate of dissociation from streptavidin occurs 252. 
These observations are explained by undesirable molecular interactions at the 
biotinidase active site caused by the derivative. However if a molecule (such as an 
amino acid) is conjugated to an unaltered biotin moiety, then dissociation rates are only 
252 minimally affected 
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Figure 3.16 N-Methylblotinamide bond to prevent biotinidase cleavage 
Our effector molecule was designed by considering these factors along with the need 
for a 6-atom spacer to facilitate a good binding profile to streptavidin. To counter 
biotinidase activity the lysine linker was oriented with the a-carbon conjugated to the 
biotin and the c-carbon conjugated to the DOTA carboxyl group. In this configuration it 
was hoped that the carboxyl group would block biotinidase activity as the configuration 
252 is similar to that described by Wilbur 
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Figure 3.17 Example of a biotinidase resistant effector molecule 
To determine the susceptibility of the conjugate to biotinidase, "'In 3+ -labelled d- and I- 
DLB were incubated separately in fresh human serum for seventy-two hours and 
analysed by HPLC (section 2.5.6). The experiment was conducted at 37 °C (Human 
body temperature) to ensure enzyme activity was comparable to that in-vivo. DTPA 
a, w-bis biocytinamide was used as a control as it was expected to be susceptible to 
biotinidase catabolism. RP-HPLC analysis was performed at various time-points and the 
areas under the curve were determined by automatic software integration. The table 
below details the percentages derived from the results of the analyses of the RP-HPLC 
peak integrations. 
RR 
N-Methylbiotinamide bona 
Table 3.1 Table showing the stability of DLB and biotin derivatised DTPA 
in human serum 
Percentage 
radiolabelled Time (Hours) 
Compound 0 1 2 3 4 5 6 24 72 
d-DLB N100 -100 -100 -100 -100 -100 -100 -100 N100 
I-DLB «100 -100 -100 -100 -100 -100 -100 -100 -100 
DTPA a, w-bis 
biocytinamide 
-100 95 89 88 87 85 71 44 0 
The data after seventy-two hours incubation demonstrates that no degradation of 
either of the "'In-DLB conjugates was seen. However "'In-DTPA a, w-bis biocytinamide 
was completely degraded over the same time-period. The data is very clear in showing 
that both isomers of DLB are resistant to biotinidase for up to 72 hours. On the other 
hand DTPA a, w-bis biocytinamide is not resistant to biotinidase activity and is gradually 
catabolised over the 72-hour period. 
Because "'In-DTPA a, w-bis biocytinamide was broken down by biotinidase it acts as a 
positive control demonstrating that biotinidase is active in the serum. Importantly DLB 
was shown to be completely resistant to biotinidase indicating its potential as a 
therapeutic. 
3.7.1 DLB-serum protein binding analysis by SE-HPLC 
Pharmaceuticals that are injected systemically can bind to proteins by Van der Waals 
forces and electrostatic forces, especially if the compound is more lipophiilic. However 
this mechanism renders the fraction of the drug that has bound incapable of specific 
ligand recognition and will be circulated before being cleared by the liver. Therefore the 
degree of protein binding should be kept low, especially in the case of 
radiopharmaceuticals to maximise therapeutic efficacy and reduce systemic dose. 
To determine how much DLB was binding to serum proteins, '11In-d-DLB was incubated 
with fresh human serum at room temperature for 48 hours. A sample was then passed 
down a size exclusion HPLC column where large molecular mass molecules elute faster 
than small molecular mass molecules, thus any protein bound activity will elute first 
and unbound activity will elute later. Fractions were collected at one-minute intervals 
were analysed by a y-counter and the results can be seen below in the chromatogram 
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Figure 3.18 Size-exclusion analysis of serum protein binding to d-DLB 
The small peak with a retention time of around 16 minutes represents 11In-d-DLB- 
serum protein binding. The unbound "'In-d-DLB is identified as the large peak and 
shares the same retention time as the "'In-d-DLB control (without serum). The 
problem using this assay for quantitative analysis was that the percentage radioactive 
recovery from the column was very low (22 %), giving a potentially inaccurate figure 
for the degree of protein binding. 
SE-HPLC analysis was thus not very effective for determining the percentage of serum 
protein-DLB interaction. Thus an alternative technique was sought to derive an accurate 
figure of serum protein binding percentages. 
3.7.2 DLB-serum protein binding analysis by resin spin column 
In order to overcome the problem of low SE-HPLC column recovery and gain a more 
accurate percentage of the amount of radiopharmaceutical that was protein bound, gel- 
filtration spin columns were used. The advantage of spin-column over SE-HPLC columns 
is that a small volume of protein solution can be used and the affinity of the resin for 
protein is lower than that of the column theoretically providing a greater yield and a 
more accurate result. 
DLB was radiolabelled with indium-111 and incubated with fresh human serum at 37 °C 
on a rotator to constantly agitate the solution. After a 24-hour incubation of the total 
radioactivity, "In-d-DLB was separated from the serum protein-bound "In-d-DLB by 
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using gel-filtration spin columns. The two fractions were then placed in counting tubes 
and analysed by y-counter (section 2.5.10). 
The serum protein-bound fraction contained 5% of the activity representing the 
amount of serum-protein bound DLB. Results from this assay were reproduced twice 
and were consistent. 
The degree of protein binding is somewhat higher than expected and this level of 
serum-protein binding would be considered sub-optimal for a therapeutic effector 
molecule. Nevertheless, serum-protein binding was considered low enough to pursue 
its further characterisation. 
3.8 DLB stability with relation to other chelators 
DOTA will chelate different lanthanides but will also complex other cations too. One 
feature of the radiolabelled product is that the metal and the chelators are in reversible 
equilibrium and competition for the DOTA chelating site by endogenous metal ions can 
occur. The DLB molecule uses one of the DOTA carboxyl groups which is normally used 
to help complex the metal-ion, to bond to the lysine linker. Therefore a study was 
called for to determine whether the reduction in number of carboxylate arms used in 
radiometal chelation negatively impacts radiometal stability. Under normal conditions, 
the rate of exchange of the radio-metal from DLB is slow, but by reducing the pH of the 
aqueous environment then hydronium ions have an increased competition for 
complexation. Because of this feature it is possible to determine the stability of 
complexes by testing them at a range of pH values. 
The assay was performed using 0.1 M glycine-buffered solutions brought to the correct 
pH using hydrochloric acid. A sample of the labelled conjugate was incubated in a large 
excess of the buffer and the reaction was allowed to proceed for 30 minutes before 
being re-buffered with an equal volume of 0.1M sodium dihydrogenphosphate pH 6.4. 
The mixture was then analysed by ITLC and counted in the gamma counter. Below is a 
graph showing the stability of the 11'In3+ and 90Y3+ labelled DLB compounds plus DTPA 
a, w-bis biocytinamide as well as two labelled un-conjugated chelators, DOTA and 
DTPA. 
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Figure 3.19 DLB pH stability assay 
From this experiment it became clear that DLB is as stable at retaining the metal 
chelate as DOTA itself. Not only that, the stability of the DOTA/metal complex at very 
low pH is extremely high, even at pH 0.5 less than 5% of radiometal is lost. It is also 
very interesting that even with different radiometals the complex remains just as stable. 
DTPA and a, w-bis biocytinamide are shown for comparison, and show a very much 
lower stability at low pH, though at pH values closer to physiological pH, all appear just 
as stable. Interestingly DTPA has a greater degree of stability than a, W-bis 
biocytinamide as nearly all of the DTPA remains radiolabelled at pH 2 whereas a, w-bis 
biocytinamide has the same level of radiolabelling at pH 4. 
This assay clearly demonstrates the high stability of DLB and its superior stability to 
DTPA and its derivatives. With only seven points of bonding rather than eight it was a 
concern as to whether DOTA in the DLB molecule would have a reduced radiometal 
association over the increasing hydronium ion concentration. As the pH stability assay 
firmly suggests in the data set above, this does not appear to be the case under the 
conditions assayed for. 
3.9 Yttrium-90 DLB stability and radiolysis 
90Y-labelled products undergo radiolysis very quickly in concentrated solutions 256 
Where the local radiation dose from the ß-emission is high under these conditions, 
compounds are quickly broken down by nucleophilic attack, from hydroxyl radicals. 
Ascorbate is well known to scavenge free radicals and abrogate radiolysis. 
Q1) 
To assess the factors influencing stability of 90Y- and "'In-labelled DLB a concentrated 
stock solution was made, either with or without ascorbate (section 2.5.9). A5 pg 
amount of effector molecule was radiolabelled with 30 MBq of yttrium-90 or indium-111 
and all of the solutions was made up to a final volume of 400 pl with PBS. A 100 pI 
aliquot of a1 mg/ml solution of ascorbate solution was added to the radioactive 
effector molecule solution and the vials were incubated for designated time-periods. 
RP-HPLC analysis was performed on the samples at different time points in order to 
determine the percentage of original product remaining. Any activity that was not found 
in the labelled product peak was found at the solvent front in the form of hydrophilic 
90Y-species. 
Table 3.2 Table detailing the stability gains of 90Y-DLB in the presence of 
ascorbic acid 
Radiolabelled Time (Hrs) 
compound remaining 0126 24 48 
%/% 9 i-labelled d-DLB in "100 -100 «100 -100 -100 -100 
ascorbate 
90Y-labelled d-DLB -100 86 63 000 
without ascorbate 
1111n-labelled d-DLB -100 -100 «100 «100 -100 -100 
in ascorbate 
oho "'In-labelled d-DLB -100 -100 100 -100 -100 -100 
without ascorbate 
It is quite clear from the data presented above that ascorbate has a dramatic ability to 
abrogate radiolysis due to its scavenger properties. By six hours DLB has been 
completely degraded In the absence of ascorbate but retains the radiolabel to nearly 
100 % in the presence of ascorbate. Even after two days, the assay demonstrates that 
ascorbate is still providing complete protection of the 90Y-labelled DLB from radiolysis. 
It is clear that in the situation of storing this radiopharmaceutical prior to in-vivo 
administration, ascorbate should be added to the 90Y-labelled compound. This was 
therefore performed in the biodistribution studies performed in this work. 
3.10 Biodistribution of 90Y3+ labelled d- and I-DLB 
To determine how the effector molecule might behave in the body and to determine if 
it localises to any particular organ, a murine biodistribution study was undertaken. Such 
a study is critical to discovering a successful drug, as incorrect or poor localisation will 
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result in unacceptable imaging and/or therapy, but also normal tissue radiotoxicity. 
Some tissues are dose limiting (e. g. bone marrow), so low uptake in these organs is the 
goal. 
90Y-labelled d-DLB was injected into 12 mice, in three time groups, and at two hours, 
six hours and twenty-four hour intervals, four animals were sacrificed. Each organ was 
isolated and its radioactivity counted. An identical experiment was carried out for the (- 
isomeric form radiolabelled with 1.1 MBq of yttrium-90 (section 2.5.8). Below are the 
results of the 90Y3+-labelled d-DLB and I-DLB biodistribution assays (raw data may be 
found in appendix sections Al and A2). 
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Figure 3.20 Mouse biodistribution of d-DLB over 24 hours 
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Figure 3.21 Mouse biodistribution of I-DLB over 24 hours 
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The results of d-DLB and I-DLB two-hours post-injection showed low overall organ 
uptake, with bone being the highest of the tissues. Uptake in all other organs was less 
than 2% of the injected dose (i. d) per gram indicating a favourable distribution. Blood 
clearance was rapid and this is probably the reason for the low retention by all organs, 
which is the desired effect for protection from tissue-toxicity and reduced systemic 
dose. Low blood, muscle, liver, gut and spleen radioactivity values were observed, 
whilst bone had the highest uptake. d-DLB had a lower bone uptake and the standard 
deviation was smaller than the I-DLB value. 
At six hours with both isomers, clearance had increased further and most tissues 
showed lower 90Y-DLB retention than at two hours. In both isomers kidney radioactivity 
remained unchanged at a little under 2 %. While radioactivity values of the spleen 
remained the same with I-DLB, radioactivity values for d-DLB fell by a third. Bone 
radioactivity decreased with both isomers by 34 % and 35 % respectively, though 
I- 
DLB values remained higher. Blood radioactivity with both Isomers was reduced, with I- 
DLB having a greater reduction (26 %) than d-DLB (11 %). 
At twenty-four hours the trend of tissue clearance continued. d-DLB and I-DLB showed 
kidney radioactivity values fall by 29 % and 34 % respectively, each having similar 
values. Blood, muscle and especially liver and gut radioactivity levels were all very low. 
Muscle radioactivity in the I-DLB study decreases the most over the twenty-two hour 
time period, by 46 % and both isomers had a low «0.7 % i. d by twenty-four hours. 
The spleen and kidney radioactivity levels were reduced only slightly In the d-DLB assay 
over twenty-four hours and an unchanged uptake in the I-DLB compared to the six- 
hour figure. Bone radioactivity levels of d-DLB were reduced by 29 % and 60 % in the 
case of I-DLB, where bone radioactivity values were comparable to kidneys levels. 
As bone uptake was relatively high compared to the other tissues, concern grew over 
DLB and its viability as a radiopharmaceutical. The most obvious cause of bone uptake 
of yttrium-90 is due to the presence of yttrium chloride, which Is known to bind 
strongly to bone mineral. However, if this was the cause for this phenomenon then 
uptake would be expected to increase with time rather than decrease, as Is the case 
here. Since the femur contains bone marrow which is a well vascularised tissue, it is 
possible that this accounts for a proportion of the bone uptake. However, since the 
blood levels themselves are low this cannot be a large proportion. Another possibility is 
that the chelated yttrium-90 could still interact with the bone mineral and that any 90Y- 
labelled DLB would accrete into the bone mineral. As a result of this, the 
bremsstrahlung emissions that were emitted and used to count the amount of 
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radioactivity in each sample may be attenuated by the bone mineral itself. To resolve 
this question the bone samples were dissolved in hydrochloric acid and made up to a5 
ml volume with scintilant. The samples were first counted in the gamma counter and 
subsequently in the beta counter. No difference in the final data was observed 
indicating that the great majority of yttrium-90 bremsstrahlung emissions were 
accounted for. 
A second problem was that, since the levels of radioactivity injected were low, to keep 
radiation doses to a minimum, the number of counts in the samples were relatively low. 
Therefore inaccuracies could be the result and the high standard deviations observed in 
the biodistribution results support this fact. 
To investigate this further, both DLB isomers were labelled with "In3+ and similar 
biodistribution studies were performed. Indium chloride is not taken up by bone 
mineral, so if it were released from the chelate, it would not show the same pattern of 
uptake. If bone uptake were observed with "In-DLB, therefore, it would suggest 
another mechanism of uptake. 
Another change in the protocol was that the activity was increased five-fold to improve 
sample counting statistics so that between twelve mice 5.5 MBq of "'In-DLB was 
administered. The protocol was the same for both isomers and importantly the same 
concentration of DLB was used. Below are the results of the repeat biodistribution assay 
(raw data may be found in appendix sections A3 and A4). 
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Figure 3.22 Mouse biodistribution analysis of "1In-d-DLB 
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Figure 3.23 Mouse biodistribution analysis of "In-l-DLB 
There was no apparent differences between the biodistribution of the two isomers, 
however all tissues except kidneys appear to have a reduced tissue uptake when 
compared to the yttrium-90 study. To see if this difference was statistically significant, a 
two-tailed t-test, comparing the uptake of the 90Y-d-DLB and "In-d-DLB was 
performed (90Y-d-DLB and "'In-DLB biodistribution raw data can be found in appendix 
sections A3 and A4 respectively). The Null hypothesis was that there was no difference 
in the two populations of data. P-values less than 0.05 (i. e. less than 5%) indicated that 
this hypothesis should be rejected and that there were therefore differences in these 
tissues. 
Table 3.3 P values comparing the two d-isomer biodistribution studies 
P Values 2 Hours 6 Hours 24 Hours 
BLOOD 0.0102 0.0006 0.0001 
MUSCLE 0.3769 0.3229 0.0012 
BONE 0.0481 0.2053 0.0618 
KIDNEY 0.4589 0.6460 0.6894 
LIVER 0.2762 0.48440 0.2422 
GUT 0.6499 0.0557 0.4585 
SPLEEN 0.2453 0.6164 0.0048 
Statistically significant results have been highlighted in grey in table 3.3 to facilitate 
easy interpretation. The t-test results reveal that only blood shows a statistically 
significant difference between the "'In- and 90Y-DLB study at all three time points. 
Although the bone uptake at two hours has been reduced at the two hour time point, 
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neither of the latter time points were shown to be statistically different. All other tissues 
sampled were found to be statistically similar. 
The repeat biodistribution assay and subsequent statistical analysis was performed in 
order to determine whether free yttrium-90 might be produced in-vivo as a result of 
instability and thus leach into the bone mineral thus helping to explain the higher than 
expected bone uptake values. Indium-111 does not localise to bones and was thus an 
obvious choice of isotope to help determine whether yttrium-90 was being released 
from its chelate. Because two out of three of the three time points were shown not to 
be statistically different, this would suggest that release of free yttrium-90 is not the 
cause of the relatively high bone uptake. This is especially true at the later time-points 
because it would be expected that if this was happening radiation values would be 
expected to increase rather than decrease over time. However in both assays radiation 
levels in the bone reduce at a similar rate to each other. 
The biodistribution data has mixed consequences for the application of pretargeting 
since clearance rates of the effector molecules are high, but kidney and bone retention 
are much higher than the other tissues sampled. The high bone uptake in particular 
brings about a level of concern if therapeutic doses were to be used for pretargeting as 
it would quickly become the dose-limiting organ. The design of the pretargeting 
approach is such that tumour radiation doses can be maximised to the amount of 
radiation that the avidinylated tumour can take up while maintaining a low normal 
tissue dose. Thus high bone and kidney uptake of radiolabelled DLB will reduce to a 
potentially large extent the efficacy of such a pretargeting regimen. 
3.11 Discussion and conclusions 
The aim of the work in this chapter was to evaluate the synthesis of d- and I-DLB, and 
explore its possible use as an effector molecule in a pre-targeting context. All assays 
were performed with the view to the use of the compounds in both animal and human 
studies. 
Both DLB isomers were simple to synthesise once the correct conditions were 
discovered. After purification, both compounds produced clean, sharp peaks on analysis 
by RP-HPLC when run on a shallow water/acetonitrile gradient. Both isomers labelled 
well with three different radio-metals. Labelling was reproducible and a labelling yield in 
excess of 99 % was obtained consistently when analysed by RP-HPLC. 
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Radiolabelling reaction times were shown to be not critical and high labelling yields 
were obtained when incubated in boiling water from 30 minutes to one hour. Thirty 
minute reaction times were deemed to be optimal though the compounds stability and 
labelling efficiencies were not greatly affected if incubations for up to twice as long 
were used. 
Mass spectrometry results demonstrated clearly that both isomers had been 
synthesised correctly by the corresponding molecular masses found on the 
spectrographs. The analysis did not reveal the sample purity because the number of 
species obtained is related to fragmentation pattern rather than sample purity. 
Contamination of the 111InCI3 and 90YC13 radiometal solutions was successfully localised 
to the pipette tips. Following the pre-washing of the tips in acid, the labelling efficiency 
remained high and successful labelling was achievable over a week period. 
Specific binding to streptavidin was demonstrated clearly when the d-DLB isomer was 
incubated in the presence of streptavidin whereas the I-DLB Isomer was found not to 
bind to streptavidin at all. The results gave initial signs that the d-isomer would be able 
to bind to a pre-targeted streptavidin. 
The DLB binding kinetics were rapid, binding to nearly 92 % in 2 minutes, suggesting 
that d-DLB is an efficient pre-targeting effector molecule. Rapid binding kinetics of d- 
DLB are essential to bind to tumour localised streptavidin when rapid in-vivo clearance 
of DLB takes place as shown in the mouse biodistribution study. 
The ratios of d-DLB to streptavidin binding were shown to bind in a ratio of 
approximately 4: 1 indicating that DLB binds to streptavidin with the same ratio as 
biotin. To this end therapy is made more effective by increasing the stoichiometry of d- 
DLB moieties to streptavidin-conjugated MAb localised to the tumour and thus the 
relative increase in tumour dose that would ensue. 
Serum incubation studies show that both isomers are biotinidase resistant for at least 
three days. This was an important aspect in the design of the effector molecule, as its 
half-life must exceed that of the Isotope it chelates. This in turn maximises the 
potential tumour dose by retaining the DOTA-radiometal complex at the tumour. 
Protein binding studies performed in human serum showed that 5% of d-DLB 
remained bound to serum proteins indicating a low but significant percentage that may 
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become ineffective at binding to protein. Although size exclusion HPLC was not able to 
accurately demonstrate the amount of serum protein association of DLB, the gel- 
filtration columns proved fast, accurate and reproducible in determining results. 
The stability of the radiolabelled compound under strongly acidic conditions was shown 
to be very high and no difference in stability between the un-conjugated DOTA and 
DLB could be appreciated. Importantly 111Ina+, 9°Y3+ and 17Lu3+ were all shown to have 
excellent stability at all pH values down to pH 0.5. Such high stabilities indicated the 
potential use for both accurate imaging and therapy with apparently no difference in 
stability for each of the radiometals used. Even when one of the normally chelating 
carboxyl groups is used for conjugation, it appeared that the stability under the 
conditions tested remained equal to the unconjugated DOTA complex. DOTA and its 
derivatives were shown to have a far superior stability over DTPA and its derivatives as 
demonstrated in the pH stability assay. This evidence shows a strong reason for using 
DOTA over DTPA for chelating radio-lanthanides, especially in a therapeutic setting 
where chelates may be resident at the tumour site for a long time and the potential 
loss of radiometal could result in considerable normal tissue toxicity. 
A solution with a final concentration of 20 pg/ml of ascorbic acid was shown to 
abrogate the effect of radiolysis when yttrium-90 was used to label DLB, with no sign of 
radiolysis even two days after labelling. Radiolysis of 90Y-d-DLB was however shown to 
be rapid in a solution without ascorbic acid. Thus the results indicate that post-labelling 
addition of ascorbic acid is essential to maintain the integrity of the 
radiopharmaceutical pre-administration. 
Both biodistribution studies illustrated the efficiency with which both isomers of the 
pharmaceutical were cleared from the murine models. Increasing the amount of activity 
used to label DLB with improved the statistical accuracy of the data and reduced the 
standard deviations of the results. Thus in most tissues DLB has a very rapid clearance 
and does not produce a radiation risk to those organs. However DLB uptake In the 
kidney is concerning, and although clearance is gradual such a situation could produce 
potential renal toxicity in a RAIT context. Behr found that with a radiolabelled anti-CFA 
F(Ab)2 fragment kidney doses were reduced five fold by giving a pre-administration 
dose of cold d-lysine 257. Renal tissue radio-sensitivity is quite low and Is therefore not 
as dose limiting as other organs. This method should almost certainly be explored if 
such a molecule was to be used for therapeutic pretargeting. Because the first 
biodistribution assay was performed with 90Y-labelled DLB and higher than expected 
bone uptake was observed, a repeat assay was performed using "'In-DLB with a five- 
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fold increase in activity to reduce standard deviation. The measurements of all organs 
over the three time-points of both the indium-111 and yttrium-90 labelled DLB studies 
were statistically compared in order to determine whether there was a real difference in 
the bone uptake between the two complexes and thus determine whether free yttrium- 
90 was being produced as a result of in-vivo instability. Yttrium-90 localises to bone 
and would be a source of bone marrow toxicity in a therapeutic context. A t-test 
showed that the two sets of data were not statistically different and suggests that any 
DLB-bone localisation is a property of the radioligand as a whole rather than the 
radionuclide with which it is radiolabelled. This is an undesirable characteristic of DLB 
and would reduce the potential maximum dose of yttrium-90 used for therapy and 
could cause increased complexity in patient management. 
Using the d-DLB effector molecule as a ligand to streptavidin, we propose to use 
streptavidin bound MAbs as a two-step pre-targeting system. To use the I-isomer, a 
novel bispecific MAb or F(Ab)2 would need to be derived in order to localise the 
radioactive effector molecule to a tumour target in a two-step strategy. 
In a clinical setting all of the experiments go some way to demonstrating the viability of 
such an effector molecule for pretargeted therapy. Both isomers showed a 
biodistribution with low overall tissue uptake but relatively high kidney and moderate 
bone retention. Though initial bone radioactivity uptake was higher than other tissues, 
it was later demonstrated that in the repeat biodistribution study to be significantly less 
than first thought. 
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Chapter 4 Synthesis and evaluation of 
DOTA-bis-lysine-biotin 
4.1 Introduction 
Due to the many desirable characteristics of DLB a second effector molecule was 
designed with the view to increasing the binding to pretargeted streptavidin and 
reducing the need for a clearing agent after pretargeting a tumour. The molecular 
design used the same design strategy as with DLB however a second lysine-biotin 
conjugate was bonded to the first lysine-DOTA derivative. The bivalent molecule 
produced, may show increased uptake and retention at sites of high concentrations of 
streptavidin (for example at the tumour) as opposed to sites of low concentration (such 
as that circulating in the blood), in a manner analogous to that seen with Bispecific 
antibody targeting. 
It was hypothesised that a bivalent effector molecule may bind to two pretargeted 
MAbs at the cell surface simultaneously, a phenomenon known as affinity enhancement 
199. Affinity enhancement was noted to improve the tumour radiation-dose in murine 
pretargeting models 180, iss. Improved effector molecule kinetics and retention to 
pretargeted tumour cells in-vitro was demonstrated with bivalent effector molecules by 
Le Doussal et al 258-260 . Goodwin et al in a murine model also improved tumour uptake 
using pretargeted bispecific antibodies (BsAbs) with a bivalent DOTA construct named 
Janus-DOTA 261. This could in turn raise the potential tumour radiation dose by the 
localisation of more effector molecules to the tumour. Below is the molecule designed 
(DBB) the formula of which is C48H80N12014S2, 
HO 
ON 
N 
oNND oS 
HO OH 
N 
H 
Figure 4.1 Chemical structure of Bio-Lys [Bio-Lys (DOTA)]-OH 
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4.2 Synthesis of DOTA bis biotin (DBB) 
The synthesis of DOTA bis biotin (DBB) uses a lysine-bound pre-loaded resin in a very 
similar way to that of DLB (section 2.3.7) as shown by the scheme in figure 4.1. 
Removal of the Fmoc blocking group facilitated the first biotinylation. The first MTT 
blocking group was then removed and the free lysine was modified by the addition of a 
second Fmoc-Lys (MTT)-OH group. The second Fmoc group was removed and the 
compound biotinylated with d-biotin. The second MTT blocking group was removed and 
tris-butyl DOTA was conjugated to the free amine group. After washing off the 
reagents, the molecule was deprotected and cleaved from the resin with 95 % TFA and 
precipitated with ether. The compounds were washed and dried before being dissolved 
in ultra-high purified water. Below is the chemical reaction scheme of the DBB 
compound synthesised. 
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Figure 4.2 DOTA bis biotin reaction scheme 
The reaction was a nine-step process with the same basic conditions as DLB except that 
a further lysine residue was added to the complex and biotinylation was performed at 
two separate steps. The yield of the product was between 70 and 80 %. 
4.3 DOTA bis biotin analysis by RP-HPLC 
The synthesis product obtained was purified by semi-prep HPLC (section 2.3.3 and 
2.3.7) and analysed by RP-HPLC (section 2.3.5). UV-RP-HPLC was used to determine 
the quality of the purification and whether a single species had been isolated from any 
reagents and reaction intermediates. 
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The mobile phases used were water/TFA and acetonitrile/TFA and run on a changing 
gradient method (section 2.3.6). Below is the UV-chromatogram obtained from the RP- 
HPLC analysis. 
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Figure 4.3 RP-HPLC analysis of DOTA bis biotin showing the purified 
product eluting at 24 minutes (measured at 220nm) 
The UV-chromatogram shows a single defined peak with a very small degree of 
shouldering and near baseline resolution apart from a small concentration of 
contaminants. Small amounts of other contaminants are seen at various time points but 
these are no more than 5% of the total area under the curve for all peaks above the 
baseline. 
The purity of the compound is relatively high and due to the lack of alternative peaks 
was hoped to radiolabel well. Nevertheless the first operation was to analyse a small 
sample of the purification product for the correct molecular mass. 
4.4 Mass spectrometry of DBB 
The synthesised product was first analysed by matrix-assisted laser 
desorption/ionisation time of flight (MALDI-TOF) mass spectrometry to verify the 
correct molecular mass of 1113 amu. Although the technique was not the most suitable 
for determining the mass of a small molecular weight compound, the technique proved 
more than adequate in section 3.3.2 when DLB was also analysed by mass 
spectrometry. 
104 
0 10 20 30 40 
Time (m Ins) 
A single peak seen at 1113 amu with relatively few alternative peaks would indicate a 
well purified compound. Below is the analysis of the double lysine biotin conjugated 
DOTA. 
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Figure 4.4 Mass spectrometry analysis of the purified DBB product 
Although other species were present, an excellent signal is given from the peak at 
1113.854 amu atomic mass units). The predicted RMM was 1113.37 amu, indicating 
that our desired compound was successfully synthesised. The discrepancy between the 
two figures exists due to naturally occurring isotopes within the compound. The 
compounds seen in the sample with a RMM lower than 1113 may correspond to 
molecules which have broken up by the mass spectrometric method of ionising the 
molecules. The molecules with a RMM greater than 1113 may correspond to DBB 
derivative metal complexes such as sodium (molecular weight of 23 amu). 
Combining the mass spectrometry data with the data from the post-synthesis UV- 
chromatogram, there was strong evidence that the predicted molecule had been 
synthesised. Impurities amounted to only a small percentage when analysed by RP- 
HPLC and so further characterisation was pursued. 
4.5 Radiolabelling of DBB 
To characterise the compound further, a radiolabelling with both y- and ß-emitting 
radioisotopes was carried out. Analysis by RP-HPLC should indicate the degree of purity 
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of the compound of interest as any different species would have a different retention 
time and be distinguished by alternative peaks of which the percentage area could be 
determined. 
To determine the radiochemical purities, the products were radiolabelled with 111In3+ 
and 90Y3+ using the procedure described in section 2.3.1. Analysis was carried out in the 
form of RP-HPLC and the two overlaid chromatograms can be seen below. 
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Figure 4.5 DBB radio-chromatograms combined to demonstrate the 
labelling patterns with different radio-metals 
A single large peak characterised the radiochromatogram consisting of 98 % with only 
minimal quantities of impurities totalling the remaining 2 %. No other radiolabelled 
peaks resulted from labelling, and only a small amount (less than 1% of total activity) 
of111In-EDTA or 90Y-EDTA remained at the solvent front. The single labelled peaks were 
sharp and without shoulders indicating a single labelled product when analysed on a 
shallow gradient. 
It is noteworthy to mention that DBB radiolabelled with both radioisotopes had a similar 
retention time, whereas DLB labelled with yttrium-90 had a different retention time to 
that of "'In-DLB. This is most probably because DBB is a larger molecule and the 
increase in the molecular weight better counters the effect of adding a highly charged 
radiometal to the compound. 
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4.6 Binding of DBB to streptavidin in solution 
Streptavidin binding was used to gain a better understanding of how well DBB would 
bind to a streptavidin-derivatised MAb and also provide an additional indication as to 
the purity of the effector molecule preparation. An indication of DBB interaction with 
streptavidin was sought to establish whether DBB would be an efficient effector 
molecule in-vivo. 
In order to determine the level of streptavidin binding, an in-vitro assay was set up to 
determine the maximal level of binding of DBB to excess free streptavidin dissolved in 
PBS. A ten fold molar excess of streptavidin was used and allowed to bind to d-DLB 
over a 24-hour period. At set time-points, samples were taken and analysed by spin 
column separation of high molecular weight species from low molecular weight 
compounds (section 2.5.4 (11)). The measurements were taken and converted into 
percentage-bound values and plotted in the graph below. 
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Figure 4.6 Binding of 111In-DBB to streptavidin in PBS solution 
Approximately 92 % of "'In-DBB bound to the free streptavidin in 30 minutes. The 
percentage of DBB binding to streptavidin increased up to a maximum at twenty-four 
hours with a value of 96.2 %. The maximum amount of DBB binding was lower than 
was expected, especially since a ten-fold excess of streptavidin was used though with 
less than 4% of the activity remaining unbound it was clear that DBB was excellent at 
binding to streptavidin. 
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The reason for at least 4% of DBB remaining unbound from the streptavidin was 
unclear though it suggests that a degree of heterogeneity within the DBB sample, 
streptavidin sample or both may have existed and that sample purity may not have 
been as high as originally presumed. 
4.7 DBB stability in human serum 
It is important to determine the stability of an effector molecule in serum as the 
amount of DBB that will be able to reach the tumour along with its chelated radiometal 
will define the efficacy of the treatment. Biotinidase resistance was known from 
previous published studies to be an important factor in any biotin based effector 
molecule (see section 3.11). 
As the same covalent structural configuration of biotin and lysine was used in DBB, 
it would be logical to presume it will have the same resistance. Nevertheless, an 
"'In-labelled sample was analysed by RP-HPLC after being incubated in human serum 
for 72 hours using the same protocol that was used with DLB (section 3.6). No 
degradation was observed indicating that DOTA-bis-biotin was indeed biotinidase 
resistant. 
Although the molecular conformation of the biotin covalent linkers was slightly 
different, the electronegative oxygen groups were hoped to provide biotinidase 
resistance. This turned out to be the case ensuring that DBB remained a viable 
pretargeting effector molecule. 
4.8 pH stability of DBB 
The radiometal stability in the chelate of the effector molecule was established for DLB 
in section 3.8 by competing the radiometal with hydronium ions. Therefore as a 
potential effector molecule, DBB was tested In the same way and plotted against 
previous data. A similar result to that obtained with DLB was expected as the molecular 
configuration of the molecule, especially the DOTA conjugation method, was very 
similar however it was not known whether any other molecular interactions would be 
influential. 
The stability of the DOTA-biotin complex was tested for chelation stability by competing 
the radiometal with hydronium ions for the DOTA chelate (section 2.5.1). A range of 
glycine buffers with different pH values was used to incubate "'In-DBB In for a 30- 
minute period (section 2.5.1). Below is a graph showing the results. 
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Figure 4.7 pH stability of indium-111 DBB 
At pH 0.5, DBB stability is very high with an average value of 97.8 % of "'In remaining 
in the chelate. As the concentration of hydronium ions decreases with an increase in 
pH, the percentage of111In-chelate increases gradually to 98.9 % at pH 5. This graph is 
very similar to that obtained with the DLB molecule (section 3.14) and indicates good 
stability under the conditions tested. 
The conclusion from this assay is that the DOTA complex is very stable and as stable as 
DLB with little susceptibility to hydronium attack over the half-hour period of the assay. 
DBB has far superior pH stability characteristics to DTPA and DTPA a, w-bis 
biocytinamide, as shown by incubations at the lower pH values. 
4.9 DBB-serum protein binding analysis by G50 microspin column 
Serum proteins may be non-specifically bound by pharmaceuticals in serum, especially 
if the compounds have a more lipophillic nature. This interaction renders the bound 
fraction inactive and removes the pharmaceutical from its site of action. It will then be 
destined for liver clearance at a later time, meanwhile systemic radiation is increased. 
To determine how much DBB was binding to serum proteins, 1µg of "'In-DBB was 
incubated in a total volume of 500 . tl of fresh human serum (Section 2.6.7). After an 
incubation of 24 hours, two 25 µl samples were placed on two G50 Spin columns, 
separating high molecular weight serum proteins and bound compounds from low 
molecular weight compounds. 
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On average serum protein binding of "'In-DBB was 6%±0.3 %. Results from this 
assay were reproducible and consistent. 
The performance of DBB in terms of not binding to serum protein was similar to that 
expected in the light of the experience gained from DLB (section 3.7.2). However the 
result is higher than would be preferable and a degree of systemic radiation dose will 
ensue if the labelled pharmaceutical is used in-vivo. 
4.10 Biodistribution of ""Lln -labelled DBB 
The biodistribution of the effector molecule as discussed in chapter 3 is extremely 
important in deriving good tumour targeting. This is seen most clearly in studies where 
despite three-step targeting a single organ has unexpectedly high radiopharmaceutical 
uptake. A recent pretargeting study 210 using a 64Cu radiolabelled DOTA-biotin which 
has been used in other studies 214,262,263 was demonstrated to have a considerably high 
liver and kidney uptake. A large degree of radioactive uptake in any organ is highly 
undesirable, but especially in radiosensitive organs, as complications will ensue with 
cytotoxic therapy doses. 
Preparation of the sample for injection was performed in exactly the same way as DLB 
(section 2.5.8). Below is the data detailing the biodistribution of "'In-DOTA bis biotin 
(raw data may be found in appendix section A 5). 
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Figure 4.8 Mouse biodistribution of'11In-DBB over 24 hours 
The most noteworthy observation is that "'In-DBB tissue-uptake is low in all tissues 
sampled. Except for the spleen, all tissue levels decreased with time to varying degrees. 
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suggesting that counter measures (e. g. d-lysine) may be required to counteract kidney 
retention should such a pharmaceutical be used in the clinic. 
4.11 Conclusions 
The DBB synthesis involved four more reaction steps than the DLB synthesis protocol. 
However, the increased complexity does not seem to produce a compound with a lower 
degree of purity than DLB once purified. A 95 % chemical purity was seen by RP-HPLC 
and radiochemical purity was 98 %. 
In excess streptavidin solution "'In-DBB bound to a maximum of 87 % after two 
minutes. After 24-hours 96.2 % of "'In-DBB remained bound to the free streptavidin, 
indicating that the high binding affinity of streptavidin-biotin will facilitate therapeutic 
studies. This data supports the RP-HPLC analysis data indicating that the purity of the 
compound is very high. 
Serum stability of the DBB construct was expected to be the same as with the DLB 
construct. This hypothesis proved correct showing as with DLB, complete stability up to 
3 days of incubation in human serum. 
Serum-protein binding was low and again comparable to that of the DLB construct 
being just 6% of the total radiolabelled construct. Although not as low as hoped for, 
nevertheless 6% is low enough not to significantly increase systemic radiotoxicity. 
Just as with DLB, we can conclude that three DOTA carboxyl groups are sufficient to 
form a stable complex. The pH stability study was only conducted with "'In-DBB as an 
yttrium-90 source was not available at the time of experimentation. However such a 
study should be completed if the effector molecule should be further characterised in 
order to provide a clearer picture of 90Y-DBB stability. Although four carboxyl groups 
may provide greater long-term stability, it does not seem a prerequisite for the use of 
medium length half-life isotopes such as indium-111 and yttrium-90. 
Biodistribution results are promising as normal tissue-uptake values of "In-DLB across 
the tissue samples selected are low. The biodistribution pattern obtained Is extremely 
similar to that of DLB. All tissues have "'In-DBB uptake of less than or approximately 
equal to 2%I. D/g and all values had fallen significantly by 24-hours. Nonetheless 
bone, kidney and gut retention levels were seen as higher than optimal. 
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In summary DBB has been shown to be a viable candidate effector molecule having 
very similar properties to DLB but with the additional biotin moiety. This feature may or 
may not prove to be useful or advantageous though further experimentation in this 
area is detailed in section 8.7. Further studies must be undertaken to elucidate whether 
DBB is actually superior in pretargeting applications over DLB however there is little to 
distinguish between them after the initial characterisation studies. 
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Chapter 5 Synthesis and evaluation of a 
trastuzumab-streptavidin conjugate 
5.1 Introduction 
The HERZ (c-erbB2) proto-oncogene encodes a trans-membrane receptor protein of 
185 kDa, which is structurally related to the epidermal growth factor receptor (EGFR). 
HER2/neu protein over-expression is observed in 20% - 25% of primary breast cancers 
264 and has been mapped to chromosome 17g21265. HERZ protein over-expression can 
be determined using an immunohistochemistry-based assessment of fixed tumour 
blocks. 
The receptor is also expressed at low levels in a wide variety of normal tissues such as 
breast epithelia, endometrium, lung, gastrointestinal tract, kidney and central nervous 
system 266.267. HER2/neu's physiological role in normal tissues is not fully understood; 
however it is considered to be important in actively signalling for proliferation and 
differentiation. However, In breast tumours up to 100 c-erb62 gene copies exist per cell 
instead of just 2 268-270 . The c-erbB2 gene amplification of p18511ER2/"eu results in over- 
expression at both the mRNA and protein level. As a result, instead of approximately 2 
x 10 5 to 5x 10 5 HER2/neu molecules per cell there may be up to 2x 106 molecules 
per cell in malignant tissue. At this high level of expression, the kinase becomes 
constitutively activated probably due to auto-activation of p185"E`2""e1 within the cell 
membrane 271. This in turn produces mitogenic cell signalling which increases cell 
proliferation. The potential sensitivity of using ligands to upregulated HERZ receptors of 
this magnitude could be dramatic as target to background ratios of 50: 1 are unheard of 
in conventional RAID or RAIT. Thus the potential therapeutic efficacy using HERZ 
receptor specific ligands would facilitate very large doses of MAb to target HER2 
expressing tumours. 
Aberrant receptor activation resulting from gene amplification and over-expression has 
been correlated with reduced survival and reduced time to relapse in breast cancer 
patients, HER2 was identified as a potential drug target 269,272. The humanised 
monoclonal anti-HER2 trastuzumab was the first genomic-research-based targeted anti- 
cancer therapeutic, being approved by the FDA in 1998. 
The trastuzumab IgG1 immunoglobulin (anti-HER2) has been shown, In both in vitro 
assays and in animals, to inhibit the proliferation of human tumour cells that over 
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express HERZ 273. Trastuzumab is also a mediator of antibody-dependent cellular 
cytotoxicity (ADCC) 274 by inducing an immune response 275. In-vitro, trastuzumab- 
mediated ADCC has been shown to be preferentially exerted on HER2 over-expressing 
cancer cells compared with cancer cells that do not over-express HERZ 276-278. 
Several research groups have used streptavidin conjugated MAbs as part of the 
streptavidin/biotin pretargeting strategy as reviewed by Goodwin and Meares 279. Many 
have shown significant benefit over current RAIT techniques, though tumour-type, MAb 
specificity and stability in-vivo seem to be the determining factors to a successful 
treatment. 
Trastuzumab has been demonstrated as one of the few humanised MAbs that has 
clinical value and potential 250. Pretargeting using trastuzumab would be a novel 
technique and one that is believed to yield improved therapeutic benefit. Trastuzumab 
pretargeting would combine the ADCC activity with a therapeutic radiation dose to 
tumours or metastases. Trastuzumab has been reported not to internalise and thus 
proves a suitable vehicle for pretargeting neoplasms 281. For the reasons detailed above 
it was decided to pursue a therapeutic trastuzumab-pretargeted RAIT development 
regimen. 
5.1.1 Trastuzumab-streptavidin 
As trastuzumab is one of the most effective MAbs in current clinical use, a natural 
progression is to use trastuzumab in a pretargeting context. The streptavidin/ biotin 
method was chosen due to the greatest tumour to background ratios obtained 
by pretargeting methods 227. This chapter describes the synthesis of streptavidin- 
trastuzumab and some evaluative work supporting its role for pretargeting. Below is a 
schematic diagram summarising the synthesis steps in forming the heteroconjugate. 
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Figure 5.1 A schematic diagram highlighting the reactions involved in 
trastuzumab-streptavidin conjugation 
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The MAb solution is UV-irradiated in the presence of stannous ions in order to reduce 
the sulphydryl groups. Streptavidin is derivatised via the lysine residues with SMCC, a 
cross-linking agent with two different reactive groups. The un-reacted end of SMCC is 
then reacted with the reduced MAb solution to form a heteroconjugate. The products at 
stage 2 and stage 3 can be frozen quickly and used when required, ensuring that each 
step does not have to be performed in controlled and time managed steps in order for 
combination at the correct times. 
5.1.2 Bio-conjugation 
The most common schemes for forming a heteroconjugate involve the indirect coupling 
of an amine group on one biomolecule to a sulphydryl group of a second biomolecule, 
usually by a two- or three-step reaction sequence 282. The high reactivity of sulphydryl 
groups and, with the exception of a few proteins such as p-galactosidase, their relative 
rarity in most biomolecules, make sulphydryl groups ideal targets for controlled 
chemical cross-linking 283. If neither molecule contains a sulphydryl group, then one or 
more can be introduced using one of several sulphydryl-producing methods. 
Bio-conjugation cross-linking agents use a wide variety of functionalities and reactivities 
and have been extensively reviewed 254286. Hetero-bifunctional reagents, especially 
maleimide active ester linkers, are particularly attractive for conjugations. This is 
because they may be reacted chemoselectively with amines on the first molecule and 
then conjugated to a second molecule via a sulphydryl group in a highly controlled way 
at pH 6-8. Maleimide active ester linkers are more selective than lodoacetyl groups as 
they do not react with histidine and methionine or thionucleotides 287,288. 
Previous approaches of chemically cross-linking MAbs to proteins have Involved 
introducing sulphydryl groups to the MAb. A number of disulphide group reducing 
methods exist where free sulphydryl groups are produced by chemical methods 289 or 
by UV light 239. Disulphide bridges within the antibody molecule are cleaved by the use 
of a compatible reducing agent such as 2-mercaptoethanol 289 or stannous ions 239. 
Streptavidin activated with a cross-linking agent presenting a free maleimide group for 
sulphydryl reaction will complete the cross-linking reaction with the reduced sulphydryl 
groups. 
5.1.3 Bifunctional cross-linking agent (sulpho-SMCC) 
The use of Sulpho-SMCC (Sulpho-succinimidyl 4-(N-maleimidomethyl) -cyclohexane-1- 
carboxylic acid) for the conjugation of two proteins is a well established technique and 
has been used to conjugate a variety of proteins and MAbs 189,190,290Sulpho-SMCC 
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reacts with a lysine of the biomolecule at one end, resulting in hydrolysis of the sulpho- 
succinimidyl group as the carboxylate group bonds to the amine group of lysine 191. At 
the other end of sulpho-SMCC, a maleimide group is present which reacts selectively 
with sulphydryl groups of the second biomolecule 283. 
Sulpho-SMCC is water soluble,. non cleavable and membrane-impermeable 291. The 
cyclohexane bridge gives extra stability to the maleimide reactive group 291. The 
reactive maleimide groups are stable for 64 hours at 4°C according to the supplier. 
Reaction conditions must be regulated quite tightly when using SMCC. Maleimide 
reactions are specific for sulphydryls in the pH range 6.5 - 7.5. According to the 
manufacturers literature, at pH 7 the cross-linking reaction of the maleimide with 
sulphydryl proceeds at a rate 1000 times greater than its reaction with amines. At 
higher pH values, some cross reactivity takes place. Below is an overview of the 
reaction scheme proposed. 
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Figure 5.2 Reaction scheme of the reaction intermediates of the 
streptavidin-trastuzumab conjugation 
The reaction is a simple two-step procedure, which should ensure high yields. The 
bonds formed between the two biomolecules and the SMCC cross-linking agents are 
covalent and stable ensuring a long-lasting product is formed. 
5.2 Production of free MAb sulphydryl groups 
The conjugation of biomolecules can be an inconvenient, time consuming, multi-step 
and low yielding material-consuming process. Hnatowitch made a comment suggesting 
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that some reducing reagents produce variable results 292. The most widely used 
reductants are mercaptoethanol 293 and tin 294 but all such methods require removal of 
the reductant before further steps in the reaction. However, Mather et al published a 
reduction technique facilitated by UV irradiation 239 to directly radiolabel the PR1A3 MAb 
with 99mTc that lacks the negative points mentioned above. The MAb is irradiated in a 
nitrogen-filled sealed vial for a few minutes in the presence of stannous ions to reduce 
some of the disulphide bridges that stabilise the IgG molecule. Varying the irradiation 
time allows the concentration of free sulphydryls to be controlled, which is useful for 
optimising the conjugation stoichiometry. The preparation may subsequently be 
conjugated with sulphydryl-reactive probes such as maleimide derivatives, where the 
sulphydryl group is open to nucleophilic attack of maleimide 295. There is no need for 
purification or concentration prior to conjugation 239. The reduction and conjugation 
process results in a fully functional IgG conjugate that can be used for a variety of 
biochemical applications. The technique is simple, safe, efficient and rapid and has the 
potential to enable various MAb-conjugates to be synthesised in a controlled manner. 
The photoactivation method also has the advantage of using non-toxic reducing agents 
which may be safely administered to patients 296. 
5.2.1 Photoactivation of trastuzumab 
The UV-irradiation reactor is a cylindrical drum with a restricted round opening at the 
top with mirrored internal walls. Eight UV lamps are spaced equally around the inside 
walls of the reactor leaving a central open section to place the reaction vessel. The 
choice of glass vial is important to facilitate maximum transmission of UV photons, thus 
a high-quality nitrogen-filled borosilicate vial was used for each reaction. The 
radiopharmaceutical kit normally used for bone-scanning, medronate II, was used as a 
high concentration stannous ion source to provide a reducing environment. 
The UV-irradiation instrumentation set-up was organised so that a glass vial could be 
reproducibly placed in the same position in the centre of the reactor at equal distance 
from all of the eight lamps. This ensured that each vial received the same radiation 
dose during each irradiation procedure. For each preparation a fresh sealed vial of MDP 
II (Section 2.7) was reconstituted with 2 ml of PBS. The solution was mixed and 2 ml 
was added to an identical volume of 10 mg/ml trastuzumab in PBS rendering the 
solution a5 mg/ml MAb concentration. The reaction solution was briefly mixed and 
placed in the reactor with all eight lamps switched on. After designated incubation 
periods the vial was removed and used for experimentation or further reaction. Initially 
a ten-minute incubation was performed and a resulting SE-HPLC analysis was 
performed as seen below. 
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Figure 5.3 Photo-activated trastuzumab in the presence of stannous ions 
A small hump exists prior to the main peak which is a small amount of MAb aggregate 
which is formed over time even when stored at 4 °C. On comparing the chromatogram 
of the irradiated MAb with a non-irradiated sample it is clear that a small degree of 
aggregation ensues as part of the photoactivation process. This was thought to be the 
result of either cross-linking between reduced sulphydryl groups or the effect of the 
increased temperature in the reactor during the photoactivation period. To try and 
overcome this problem the air temperature in the reactor was reduced by blowing cool 
air into the reactor. No aggregation was seen when this precaution was taken as shown 
in the sample chromatogram above. A slight discrepancy in the retention times of the 
native MAb and the irradiated MAb are seen in the comparative data sets above 
however this highlights a degree of variability which is evident between each HPLC 
analysis. Factors that affect this may be the amount of protein loaded onto the column, 
the sample volume or the length of time that the column was equilibrated. 
This analysis indicates that UV-irradiation of the MAb for ten minutes does not cause 
the molecule to break down and that with sufficient cooling no aggregate is formed 
either. This data is supported by the results from Stalteri et al who also produced a 
single clean peak after UV irradiation for twenty minutes with the PR1A3 IgGi 239. 
5.2.2 Determining the number of reduced MAb sulphydryl groups 
Measurement of the number of free suiphydryl groups formed is important in 
determining the optimal time of MAb irradiation using UV-light. From this information, it 
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is possible to more readily determine the number of sulphydryl groups that need to be 
produced to derive optimal stoichiometry. Several methods have been used to quantify 
the concentration of sulphydryl groups in solution; some use absorption spectra, while 
others use fluorescence spectra. Although other assays probably exist, both seem to be 
standard and reproducible albeit flexible. 
5.2.3 The Ellman's test 
The standard quantitative sulphydryl test is the Ellman's test 240-243 (see section 
2.7.4.1). Ellman's reagent (DTNB) is a highly sensitive method of suiphydryl 
quantification with sub-nanomolar concentrations able to be quantified accurately 297. 
Ellman's test is a colourimetric method whereby DTNB binds to free sulphydryl groups 
and the solution becomes yellow on reaction. The concentration of sulphydryls can be 
accurately measured by performing the reaction in excess DTNB and the increase in 
colour is directly proportional to the concentration of free sulphydryl groups. A standard 
curve is constructed using known amounts of cysteine in excess DTNB, plotted against 
absorbance. A blank is made with the same concentration of DTNB in the absence of 
cysteine. A UV-spectrophotometer is required for analysis of DTNB, though these are 
inexpensive and available in most laboratories. Muddukrishna et al 2 published a graph 
detailing the absorption spectrum of DTNB reacted species as seen below. 
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Figure 5.4 Absorption spectra of DTNB reacted species relative to air 2 
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The maximum absorption wavelength as read from this graph and supported with other 
data 241 is 412 nm, thus all DTNB absorbance readings were performed at 412 nm. This 
wavelength has the advantage of not conflicting with absorbencies of other species 
such as proteins. Below is the molecular structure of Ellman's reagent. 
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Figure 5.5 Ellman's Reagent (5,5'-Dithio-bis(2-Nitrobenzoic Acid) 
One major disadvantage with Ellman's reagent is that a high background is observed in 
the presence of stannous ions 239. However, Eliman's reagent is undoubtedly the most 
commonly used sulphydryl quantification method employed since it was first discovered 
in 1958 242. For standard Ellman's assay reaction conditions used in this chapter refer to 
section 2.7.4. 
5.2.4 Fluorescent labelling 
Fluorescent labelling is widely used in histochemistry, cell sorting and 
spectrophotometric markers of substances for identification. Fluorescent labels are 
among the most sensitive for these applications and overcome many of the problems 
associated with radiochemical labelling 298. Fluoresceins are a set of molecules, which 
absorb energy from light at a wavelength energy of 490 nm and emit a wavelength of 
530 nm. These absorption and emission characteristics ensure that most compounds 
will not interfere with fluorescence detection. However the nature and intensity of the 
fluorescence is variable and influenced by many factors such as temperature, solvent, 
ionic composition, pH, the degree of labelling and the properties of the substance being 
studied 299. Iodoacetamide compounds are relatively specific to sulphydryl groups and 
because of their small size are well suited to molecular quantification techniques. The 
compound we chose to use was 5-IAF (5-iodoacetamidofluorescein), the molecular 
structure of which can be seen below. 
Figure 5.6 5-IAF (5-iodoacetamidofluorescein) 
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5-IAF is a relatively unstable compound and degrades in light over time. It is thus 
important to work under low light conditions and maintain the standards in the same 
environment as the samples to be measured. The major disadvantage of this technique 
is that an expensive fluorimeter is required to produce an excitation wavelength and to 
measure an emission wavelength. For standard 5-IAF fluorescence quantification 
methodology conditions used in this chapter refer to section 2.7.4.2. 
5.2.5 Quantification of MAb suiphydryl groups with 5-IAF 
One method of quantification of sulphydryl groups is to analyse the molecular species 
of interest by SE-HPLC after complexation with 5-IAF as recommended by 
Muddukrishna et al 2. The reaction mixture can be analysed by SE-HPLC to measure the 
areas under the peaks of the MAb-5-IAF complex and free 5-IAF. This allows us to 
determine the amount of 5-IAF complexed and that remaining unbound and thus the 
concentration of complexed 5-IAF and hence the number of sulphydryl groups can be 
ascertained. The irradiated MAb was therefore Incubated with excess 5-IAF until fully 
reacted and analysed by SE-HPLC using UV detection at 491 nm. By measuring the UV 
absorption of 5-IAF and its complexes at 491 nm 2, only 5-IAF compounds would be 
detected. 
A1 ml sample of trastuzumab was irradiated for 10 minutes in the presence of a 1: 1 
vol/vol ratio of MDP reconstituted in PBS. Immediately afterwards a 100 pI sample of a 
1 mg/ml 5-IAF solution was added to the MAb/MDP vial and placed in a light-proof 
container to prevent photo-degradation of 5-IAF. The solution was incubated at 37 °C 
for an hour to ensure complete reaction between the two species before SE-HPLC 
analysis. The mobile-phase used was a 0.1 M sodium phosphate solution at pH 7.2 with 
a flow rate of 1 ml per minute. The column was equilibrated for an hour prior to use 
and a 10 pl sample volume was injected onto the column. 
When this experiment was performed however, no peaks were observed on the 
chromatogram at 491 nm indicating that 5-IAF had not reached the UV detector. As the 
HPLC system had a diode array detector giving readings from 190 nm to 600 nm, 
chromatograms at other wavelengths were also checked. At both 220 nm and 280 nm 
no signal or peaks were observed further confirming that the molecules of interest were 
not traversing the column matrix. By injecting a small volume of unlabelled 
trastuzumab onto the column a normal retention time was observed confirming that 
only the 5-IAF bound compounds were remaining stuck to the column. 
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As 5-IAF compounds were not observed when analysed by SE-HPLC as described above 
a comparison of the differences between the reported system and the system used for 
this work was performed. 
5.2.6 Investigation of the problems encountered using fluorescent labelling 
with SE-HPLC 
One of the problems experienced during the use of 5-IAF was based upon 
Muddukrishna et al's claim that a SE- HPLC technique could be used 2. A very similar 
set-up was used to Muddukrishna et al but we found without exception that such a 
technique could not be used. Neither 5-IAF alone nor MAb-5-IAF complexes were 
detected on a diode array detector when analysed on a SE-column so a set of logical 
changes to the system were made to determine if the technique could in-fact be used. 
Time was not a factor in eluting 5-IAF as the compound was not eluted during 3 hour 
analysis periods. Different analysis periods were used and flow rates of up to 1.25 ml 
per minute were used to determine whether the compounds would elute at all under 
the conditions used. 
Comparing the column used with that of the publication it seemed apparent that the 
columns were almost identical. The column we used for SE-HPLC analysis was a 
hydrophilic, silica-based Phenomenex Bio-SEP-S 3000,300 x 7.80 mm l. d column 
whereas Muddukrishna et al used a hydrophilic, silica-based Toso Haas G3000SWXL 
column and TSK SWXL guard column. These columns are very similar In their ability to 
separate proteins and peptides with hydrophilically bonded rigid spherical silica gel 
which has a low adsorption and high sample recoveries. 
Removal of the pre-column filter did not result in any increase in signal, however when 
the SE-HPLC column was bypassed, 5-IAF was strongly detected Indicating that the 
compound was being retained by the SE-HPLC column. The labelling compound is 
seemingly rather hydrophobic due to the four aromatic rings of 5-IAF suggesting that 
the mobile phase cannot stop 5-IAF from irreversibly adhering to the column surface. 
The only difference between the set-up used and Muddukrishna et al's set-up was that 
they used a 0.1 M sodium phosphate and 0.1 M sodium sulphate mobile phase whereas 
we used a 0.1 M sodium phosphate mobile phase. Therefore the alternative mobile 
phase was used and a large sample of 5-IAF in PBS was analysed again. This time 
some signal was observed however, it was very low. 
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It appears that at least in part, the increased salt concentration of the mobile phase 
used kept a small proportion of 5-IAF in solution but that without it the compound 
rapidly adheres to the silica matrix of the column. What is not known is whether 5-IAF- 
labelled compounds were retained with different proportions to free 5-IAF. For this 
reason the technique was not pursued any further and a different technique was 
sought to quantify free sulphydryl group production by UV-irradiation. 
5.2.7 An alternative approach to sulphydryl group analysis 
Since SE-HPLC was found to be an unreliable method of analysis, we decided to use a 
simple open-column gel-filtration method for separation of bound from free 5-IAF. To 
enhance the reliability of the data and expose any major differences in quantification 
that may exist, two methods (fluorimetry and spectrophotometry) of quantification 
were used. 
The first technique used was the Eliman's assay whereby a known concentration of UV- 
irradiated MAb was incubated with a 100 fold excess concentration of DTNB for an hour 
at 37 °C. Once reacted, the MAb was purified on a PD10 sephadex column and 500 NI 
fractions of eluate were collected. These samples were diluted to 2 ml and two 1 ml 
aliquots were analysed by UV-spectrophotometry. The readings were compared to 
those obtained from a standard curve constructed from known concentrations of 
cysteine in excess DTNB and the concentration of sulphydryl groups in the reduced 
MAb was established. 
When fluorimetry was used for sulphydryl concentration quantification, samples of 
irradiated MAb were incubated with 5-IAF for an hour at 37 °C to ensure that maximal 
reaction occurred. The 5-IAF labelled reduced-MAb was separated from the free 5-IAF 
by a PD10 sephadex column and 500 NI fractions were collected. The fractions were 
aliquoted in triplicate into 96-well white plates for fluorimetry reading. A white plate 
was used to reduce the detection of scattered and reflected light by the fluorimeter. 
Alongside the samples a range of known 5-IAF concentrations were measured to 
produce a standard curve. The fluorescence of all of the fractions was measured 
enabling the concentration of 5-IAF to be calculated. The fluorimeter readings were 
then compared to the standard curve and the sulphydryl concentrations extrapolated. 
At all times the stock solution of 5-IAF and the measured samples were kept In the 
same, low light conditions, in order to reduce the loss of signal over time and ensure 
that concentrations were proportional to the standard curve measurements. 
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The total number of sulphydryls present per IgG-1 (immunoglobulin subtype to which 
trastuzumab belongs) is thirty-two. MAb with and without added stannous ions were 
irradiated as described in section 2.7.1 and the number of suiphydryl groups 
determined as described above. Measurements were also performed on the same 
solutions without irradiation. Results are shown below. 
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Figure 5.7 Graph indicating the number of sulphydryl groups per MAb 
produced under different times of UV irradiation 
The results confirm that stannous ions are needed to reduce the disulphide bonds in 
the MAb molecule as twenty minutes of UV irradiation in the absence of stannous ions 
does not cause an increase in the number of sulphydryls per MAb. Also the presence of 
stannous ions alone without UV irradiation does not reduce the MAb. In the presence of 
tin, the number of sulphydryl groups produced increases with an increase in UV 
irradiation time. A slight discrepancy of results exists between the fluorimeter-based 
readings and the spectrophotometric-based readings though these are marginal. As a 
molar ratio, at five minutes the difference is ± 0.5 sulphydryls per MAb, at ten minutes 
the difference is ± 1.1 sulphydryls per MAb and at twenty minutes the difference in the 
two methods is ± 1.7 sulphydryls per MAb. This demonstrates a high level of 
agreement between the two systems and hence reliability and accuracy can be 
expected from both methods over all the time points used. Thus, on averaging the two 
methods of measurements at 0 minutes UV there are no sulphydryls per MAb, at 5 
minutes UV 0.6 sulphydryls per MAb, at 10 minutes UV 6.9 sulphydryls per MAb and at 
20 minutes UV 28.8 sulphydryls per MAb. From this data it is possible to determine an 
optimal length of time of MAb UV irradiation. 
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From the data it was decided that 10 minutes would produce the desired concentration 
of sulphydryls per MAb. Taking into account slow re-oxidising of the sulphydryls and 
degrading performance of the UV-lamps with time, six sulphydryls per MAb should 
suffice to facilitate a 1: 1 stoichiometric conjugation reaction. Even though in theory 
only one or two sulphydryls per MAb are required to facilitate a conjugation reaction, 
by using a standard ten minute irradiation protocol a degree of variability is allowed for, 
without jeopardising a future conjugation reaction and wasting costly reagents. 
Importantly a ten minute UV-irradiation method does not disrupt the integrity of 
trastuzumab which remained intact upon SE-HPLC analysis as seen in figure 5.3. 
5.3 Forming the streptavidin-trastuzumab conjugate 
From a literature search two papers were identified as reporting possible methods for 
developing a MAb-streptavidin conjugate 191,290. Both methods were very similar, but 
the main differences related to the method used for sulphydryl production which 
probably gave rise to the differences in synthesis product yield. The main details of the 
two studies are shown in the table below. 
Table 5.1 Table detailing the conditions used for MAb-streptavidin 
conjugation by two independent investigators 
Reference pH PBS pH PBS Ratio of Sulphydyl Percentage 
SMCC MAb: MAb: production yield 
reaction streptavidin streptavidin 
Hylarides 8.0 unknown 1: 1.3 DTT 37 % 
290 
Karacay' 1 7.3 7.3 1: 1 MEA, 21T 20 - 25 % 
From the outset of this work it was considered that a homogeneous preparation of a 
trastuzumab-streptavidin heteroconjugate was the desired synthesis product. Since the 
reported yields in these papers were low and the samples heterogeneous, it seemed 
clear that a degree of wastage was inevitable. It was also apparent from the reports 
that a higher proportion of MAb to streptavidin would yield a more homogeneous 
preparation. 
It was decided that as Karacay et al's MAb-streptavidin conjugate preparation was 
more homogeneous than Hylarides et al's, and that by Increasing the molar ratio of 
MAb to streptavidin (2: 1), a potentially greater amount of homogeneous conjugate 
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would be formed. The reaction was scaled down to 1/250 of the published amounts and 
SE-HPLC analysis was then performed to determine the outcome. The mechanism used 
to generate free suiphydryl groups was to UV-irradiate the MAb for 10 minutes as 
described in section 5.2.7. Simultaneously SMCC was added to streptavidin and 
incubated for ten minutes. The streptavidin reaction mixture was then added to the 
MAb reaction solution drop-wise over a one-minute period. The assay was repeated 
several times and a typical attempted conjugation reaction mixture analysed by SE- 
HPLC can be seen below. 
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Figure 5.8 UV Chromatogram of trastuzumab, streptavidin and MDP mix 
in an attempted conjugation analysed by SE-HPLC 
No discernible conjugation product was formed as no new peaks were observed. The 
assay was repeated several times; however upon reanalysis, still no apparent 
conjugation product had been formed. Trastuzumab (185 kDa) is the first component 
to elute from the column and passes through the UV detector at 15.8 minutes. 
Streptavidin (50 kDa) is the next protein to elute from the column at 19.2 minutes. The 
large peak shown at 24 minutes is composed of salts and other low molecular weight 
compounds. The trastuzumab-streptavidin conjugate has a predicted molecular mass of 
235 kDa and would be expected to elute prior to the MAb peak. 
No obvious reason was evident for the lack of product except for possible scaling down 
complications or the incorrect concentration of reagents in each sample. Nevertheless it 
was essential to the success of the work to find out why no conjugation product had 
been formed. 
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5.3.1 Determining where the encumbrance to forming the streptavidin- 
trastuzumab conjugation is in the reaction chain 
The conjugation procedure consists of three reactions that must each function correctly 
in order to derive the Herceptin-streptavidin conjugate. The lack of product could be 
due to the failure of one or more steps in this reaction. We therefore studied each 
reaction separately to ascertain which was or wasn't working and why. Below is a 
diagram of the reaction process, with each process numbered for easy reference in the 
following text. 
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Stannous Ions > Trastuzumab-SH 
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Trastuzumab-SMCC-Streptavidin 
Streptavidin SMCC Streptavidin-SMCC 
derivatisation 
Figure 5.9 Reaction strategy diagram prior to defining why no 
conjugation product was being formed 
By analysing each reaction in some detail not only qualitative information would be 
provided but also quantitative information. This information would then be useful in 
further enhancing or optimising reaction and method conditions. 
5.3.2 Determining whether the suiphydryl groups were oxidising prior to 
reaction 
To study Step 1, a line of investigation was undertaken to determine whether the free 
sulphydryl groups are In fact produced in the MAb and remain reduced long enough to 
take part in the reaction. If free suiphydryl groups were not available for reaction then 
conjugation could not occur. If slow re-oxidisation of sulphydryl groups occurred it 
would be Important to know how long and what concentration of sulphydryl groups 
remained available for reaction over the time of a conjugation. By performing the 
Eliman's assay on the UV-irradiated MAb solution after different periods of delay it 
would be possible to observe whether the concentration of sulphydryl groups remains 
the same or declines over time. 
Trastuzumab samples (100 pl of stock reaction mixture) were irradiated as described in 
section 5.2.1 and kept at room temperatures for different periods of time prior to 
analysis by Ellman's assay as described in section 5.2.3. Room temperature Incubations 
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were performed for 0,5,10 and 20 minutes before excess DTNB was incubated with 
the reduced MAb. Incubation of the DTNB-MAb solution was performed at 37 °C for an 
hour to ensure complete reaction. The samples were then measured in a UV- 
spectrophotometer and the readings compared to the cysteine-DTNB standard curve 
constructed previously. 
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Figure 5.10 Graph displaying the number of sulphydryls per MAb over time 
prior to an Ellman's assay to help determine whether low yields could be 
partly due to a low concentration of free sulphydryl groups. 
The graph demonstrates that at all time points up to twenty minutes the after antibody 
reduction have free sulphydryls available for reaction with SMCC. The control groups 
show that non-irradiated MAb samples have no free suiphydryls, either in PBS or more 
significantly in a reducing environment (Sn2+ containing MDP). The ratios of sulphydryl 
groups per MAb show some variation but approximately ten sulphydryls per MAb were 
available for reaction at all times. 
Because a sufficient number of suiphydryl groups were available for reaction it seems 
likely that the first reaction in the process was working as expected. Therefore the 
problem in the reaction was thought to be at reaction steps two or three in the 
procedure. 
5.3.3 Assay of functional maleimide groups on streptavidin 
The next step of the reaction (step 2) to be studied was the conjugation of SMCC to 
streptavidin. SMCC has two different reactive groups - the succinimide group, which 
binds to lysine residues on the streptavidin and the maleimide group, which binds to 
the reduced sulphydryl groups on the antibody. It would be possible to assay either of 
these groups. We could, for example, measure the number of lysine residues on the 
streptavidin (with a ninhydrin assay) before and after reaction with SMCC. Alternatively, 
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we could measure the number of maleimide groups present on the streptavidin before 
and after the reaction. This second approach would have the advantage that it would 
determine if the maleimide groups were still functional after the reaction. If they were 
hydrolysed or themselves reacted with lysine residues, they would no longer be able to 
bind to the reduced Herceptin. The number of functional maleimide groups bound to 
the streptavidin were therefore assayed by their ability to react with cysteine as follows: 
The streptavidin was reacted with the SMCC, and free, unbound SMCC removed with a 
gel-filtration spin-column. A molar excess of cysteine was then added and an Ellmans 
assay performed on the reaction mixture to measure the concentration of free 
sulphydryls remaining in solution. Subtraction of this concentration from the starting 
cysteine concentration gave the concentration of functional maleimide groups bound to 
the streptavidin. 
A number of controls were also assayed as follows: 
1. as described above but no SMCC added 
2. as described but no streptavidin added 
3. as described but no cysteine added 
4. as described but no SMCC or cysteine added 
5. as described but no streptavidin or cysteine added. 
The results are summarised in Figure 5.11, 
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Figure 5.11 Chart displaying the concentration of cysteine available in 
different stages of the reaction in order to determine whether SMCC was 
binding to free sulphydryl groups (Cys) and lysine (streptavidin) 
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As expected Controls 1 and 2 show no consumption of cysteine since no conjugation of 
SMCC to the streptavidin occurs in either case. Controls 3-5 show the presence of no 
suiphydryls, since no cysteine was added and indicate that none of the other reagents 
interfere with the assay. 
However the full test reaction shows a reduction in the cysteine content from a starting 
concentration of 132 pM to 50 NM, indicating the presence of approximately 70 pM 
functional maleimide groups conjugated to the streptavidin. 
The assay was also repeated every 10 minutes for up to 30 minutes after the 
streptavidin-SMCC reaction to check the stability of the maleimide groups over this 
period of time. The results are shown in figure 5.12 and (although somewhat variable) 
indicate no loss of maleimide groups over the time period studied. 
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Figure 5.12 Graph showing the ability of SMCC derivitised streptavidin to 
bind to cysteine over different time periods in solution 
These results therefore show the presence of significant concentrations of functional 
maleimide groups In the reaction mixture up to 30 minutes after mixing, indicating that 
step 2 of the reaction is proceeding correctly and is not likely to be the source of the 
problem in the overall conjugation scheme. 
The results so far indicate that all of the preliminary steps in the reaction appear to be 
working correctly. Only the final conjugation step wasn't functioning. Re-examination of 
figure 5.8 gave a clue as to the possible cause of the problem. A comparison of the 
peak heights of the trastuzumab and streptavidin peaks shows that the streptavidin 
peak is much smaller, even though it is supposedly present in a two-fold molar excess 
and the extinction coefficient of streptavidin is higher than that of the MAb. 
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5.3.4 Determining the protein concentrations of trastuzumab and 
streptavidin by SE-HPLC 
We therefore decided to check the concentrations of the MAb and streptavidin solutions 
since if one of the protein concentrations was too low then the amount of conjugation 
product may be too small to observe. 
Ranges of streptavidin and trastuzumab amounts from 0 to 50 pg in a 20 pl volume 
were analysed by SE-HPLC (automatic integration of the areas under the curves of the 
protein peaks of interest measured at 280 nm gave a relative protein amount). The 
area under the curves were plotted against the apparent mass of analyte which is 
proportional to the amount of protein in the sample as seen below. The relative protein 
concentration analysis results of trastuzumab and of streptavidin are seen below in the 
graph. 
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Figure 5.13 Graph comparing HPLC integrated area of the peaks of 
trastuzumab and streptavidin 
The results show that trastuzumab has a 7.5 fold greater area under the curve than the 
Sigma streptavidin (not taking into account the differences in the absorbance extinction 
coefficients) indicating that the streptavidin concentration was very much lower than 
that of the MAb. The extinction coefficient of streptavidin (E) is 32 000 M-' cm -1 read at 
280 nm 300. This is considerably higher than that used for MAbs which is generally 14 
000 M-' cm-' read at 280 nm 300. This graph indicates the low concentration of the 
streptavidin sourced from Sigma though further characterisations were completed to 
confirm the findings. 
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The findings described above led us to obtain streptavidin from a different supplier in 
order to compare the quality of the protein sources. On receiving the protein, a set of 
SE-HPLC analyses were performed to determine the area under the curve in the same 
way as the Sigma sample was analysed. Samples from ICN were injected in 10 pg, 20 
pg and 50 pg amounts onto the column and the integrated areas were plotted along 
with the Sigma streptavidin data for comparison as seen below. 
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Figure 5.14 Graph comparing HPLC integrated peaks of streptavidin from 
different sources to proportionate the amounts of protein 
The streptavidin from ICN has a 10 fold greater area under the curve than the 
streptavidin from Sigma. Both data sets provided consistent and linear data with a very 
low degree of error in each series. As both samples contain only streptavidin, E is the 
same for each sample and the difference in protein concentration is directly 
proportional to the differences in absorbance. 
Since the results produced indicate only relative concentrations of each protein species, 
further analysis was needed to quantify and support the data by other methods. 
However based on this experiment it appears that the concentration of the Sigma 
streptavidin is so much lower than the ICN streptavidin that this may explain the lack of 
conjugation product achieved. 
5.3.5 Determining the protein concentrations of streptavidin from two 
different sources by UV spectrophotometry 
To support the SE-HPLC protein concentration data a UV-spectrophotometric analysis of 
protein concentration was performed. This is the normal and rapid method of 
determining protein concentration in a laboratory. The absorbance of proteins at a 
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specific wavelength is directly proportional to the concentration of protein in solution, 
though the extinction coefficient (E) is specific to each protein. For MAbs E is 1.4 and 
for streptavidin E is 3.2 for a1 mg/ml solution. 
The absorbance of a5% dilution of streptavidin solution (nominal 20 mg/ml stock 
solution) in PBS was measured at 280 nm on a general purpose UV/Vis 
spectrophotometer in a 1000 pl volume and a 1250 pl micro-cuvette. Blanks were 
performed with PBS solution and readings were repeated three times. The absorbance 
readings were then multiplied by the dilution factor (D. F) and divided by the extinction 
coefficient. The spectrophotometric readings can then be used to produce an estimate 
of protein concentration. Below is a table of the raw measurements produced from UV- 
spectrophotometric analysis. 
Table 5.2 Differences in UV absorption of two sources of streptavidin 
Sigma SA AU Measurement I Avg 0.0265 ± 0.0015 
ICN SA AU Measurement I Avg 0.290 ±0 
Therefore the concentrations of the streptavidin solutions are: 
Sigma Streptavidin 
0.0265x200 Dilution Factor (D. F) T 3.2 (E) = 1.656 mg/ml (f 10%) 
ICN Streptavidin 
0.290x200 Dilution Factor (D. F) + 3.2 (E) =18.125 mg/m/ (t 10%) 
The ICN streptavidin thus has a 10.95 fold greater protein concentration than the 
Sigma sample. Following communication with the Sigma Company it transpired that the 
amount of protein was determined by weight of dry product and not concentration of 
protein. The protein concentration of streptavidin (Sigma) is so much lower than the 
ICN source that it is easy to reason why very low yields were seen in the conjugation 
reactions. 
5.3.6 SDS PAGE analysis of streptavidin from Sigma and ICN 
The last method of characterising the two species of streptavidin was to analyse them 
on an SDS PAGE gel. This was to visually distinguish the differences in streptavidin 
concentrations from the two sources. SDS PAGE separates proteins by size and ionic 
charge so that large proteins take longer to pass though the gel matrix whereas smaller 
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proteins move through the gel at a more rapid rate and thus the species with different 
molecular masses separate. The proteins are initially boiled in the presence of SDS 
which unfolds and denatures the proteins ensuring that the molecules run according to 
their molecular masses and not their morphology. One feature of boiling proteins is that 
proteins with non-covalently bound subunits are usually broken up into their 
constitutive subunit elements. 
The analysis was performed as described in section 2.6.6.4 on a 20 % (a high 
concentration of polyacrylamide) polyacrylamide gel to resolve the low molecular 
species to a maximum. Two separate expected concentrations of streptavidin were 
used at 10 pg and 20 pg quantities. A5 pg native trastuzumab sample was used as a 
control and molecular weight standards used to check the molecular mass of the 
protein bands. After electrophoresis was completed, the gel was stained with 
Coomassie Blue to identify the position of the protein bands. Below is a scanned image 
of the PAGE gel showing trastuzumab and streptavidin from the two different suppliers. 
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Figure 5.15 SDS PAGE analysis of streptavidin from ICN and Sigma 
The streptavidin samples migrate with a molecular weight of approximately 10 kDa. 
This agrees with the -12.5 kDa molecular mass of the streptavidin subunit 301,302. The 
gel shows that all of the protein solutions are very pure since the only a single band is 
present; however the difference in protein concentration visualised between the two 
sources is striking. The 10 pg sample from Sigma is barely visible and the 20 jig sample 
is very faint. Comparing ICN samples with Sigma samples the difference in protein 
concentration is very clear. 
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A report describing the analysis of the ICN and Sigma sources of streptavidin was made 
and sent to Sigma. They too eventually confirmed that the streptavidin concentration 
was only 10 % of the expected protein concentration. 
5.3.7 Reattempting the conjugation experiment with streptavidin (ICN) 
With a new incentive to attempt a conjugation reaction in the knowledge that all stages 
of the reaction worked and protein concentrations were as expected, the conjugation 
reaction was repeated using streptavidin from ICN rather than Sigma. 
Using the same method as used in section 5.3 the reaction was performed, incubated 
for two hours and then analysed by SE-HPLC as seen below in the UV-chromatogram 
produced. 
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Figure 5.16 Conjugation attempt in PBS using ICN streptavidin 
The chromatogram shows the presence of a new molecular species with a retention 
time of 14.6 minutes eluting before the MAb peak. The streptavidin peak previously 
present at 19 minutes is now absent. The yield of the new species however, 
ascertained by automatic software integration and dividing the area for the MAb over 
the area for the new peak, was only 8.4 %. 
Clearly reaction yields were not high and much improvement was hoped for, however it 
seemed that trastuzumab-streptavidin may have been synthesised for the first time. 
Nevertheless a means of improving yields was thought to be necessary as large 
amounts of waste would otherwise result. 
5.4 A new buffer system, TSMZ, and a new product 
From personal communication with a collaborator (Peter Harrison, KS Biomedix) we 
learned that that he had also experienced low yields of conjugation product from a 
streptavidin-MAb heteroconjugation experiment using PBS and that a new buffer had 
been developed for the purpose of improving yields. 
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The buffer consisted of triethanolamine, sodium chloride, magnesium chloride and zinc 
chloride and was denoted TSMZ (section 2.1.4). To transfer the MAb in PBS into the 
TSMZ buffer a dialysis cassette was filled with 30 mg of a 10 mg/ml solution of the 
trastuzumab solution and dialysed in a two litre volume of TSMZ at 4 °C over a 
weekend. Once dialysed, UV-irradiation and conjugation with streptavidin was 
performed as described previously in section 5.3 using the same proportion of reagents 
i. e. 2: 1 ratio of streptavidin to trastuzumab as the original conjugation. After a two- 
hour reaction incubation the mixture was analysed by SE-HPLC and the chromatogram 
can be seen below. 
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Figure 5.17 SE-HPLC analysis of the trastuzumab and streptavidin-SMCC 
conjugation reaction 
The chromatogram shows a new peak with a retention time of 14.6 minutes eluting 
prior to the MAb peak at 15.8 minutes. The new peak which was presumed to be the 
conjugate and confirmed by analysis described later in this chapter, is shouldered by 
larger molecular weight compounds which were presumably aggregates and MAbs 
derivatised with several streptavidin molecules. 
The overall yield of conjugate (including oligomers) was approximately 40 %. Much 
higher than that obtained using PBS as the buffer. However, the presence of the earlier 
eluting impurities means that this conjugate would not be suitable for pretargeting and 
would require purification to obtain 1: 1 antibody: streptavidin conjugate which was 
considered the optimal objective in the synthesis. 
In order to try and improve the purity of the conjugate formed, a conjugation was 
undertaken using a 1: 2 ratio of streptavidin to MAb. After two hours the reaction was 
analysed by SE-HPLC and gave the chromatogram shown below. 
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Figure 5.18 UV-SE-HPLC analysis of a 1: 2 streptavidin: antibody reaction 
It can be seen that the yield is considerably lower than that obtained with the 2: 1 
conjugation (20 %), but the purity is much greater with only a small shoulder eluting 
ahead of the conjugate peak at 14.6 minutes. 
It is apparent that a conflict exists between the desire to obtain a high yield and a high 
purity of product. High yields are economically important and make the best use of 
scarce resources, but if the resultant product is suboptimal, then no advantage is 
gained. 
The desired product was a 1: 1 stoichiometry of MAb to Streptavidin conjugate in order 
to obtain a product with a molecular mass that was as close to trastuzumab as 
possible in order to improve binding kinetics. Very large molecular mass compounds 
may be quickly cleared from the blood by the liver so keeping the molecular mass lower 
may Increase the half-life of the immunoconjugate in the blood. High molecular mass 
compounds also have slower clearance kinetics, reducing the potential amount of MAb- 
conjugate that would reach the tumour and increasing circulating blood levels. 
5.4.1 Oxidation of sulphydryl groups not Involved in conjugation 
Several papers have reported on the use of different methods for re-oxidising the un- 
reacted suiphydryl groups that were not used In conjugation 214,29o. Although these 
papers used chemical methods to reduce their MAb samples, the same methods should 
be applicable to UV-irradiated MAb samples. The re-oxidisation of free suiphydryl 
groups of reduced antibodies may be more important than those Introduced by 
chemical conjugation since the stability of the IgG may be reduced by the reduction. 
Most research groups used sodium tetrathionate to oxidise free sulphydryls, however 
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iodoacetamide has also been used to block free suiphydryls. It was decided to use 
sodium tetrathionate as the possibility of recreating disulphide bridges to restore 
molecular integrity seemed preferable to simply blocking each suiphydryl individually. 
Thus disulphide bridges which were previously broken due to reduction from stannous 
ions and UV photons may be reconstructed potentially preserving the conformation and 
biological efficacy of the molecule. 
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Figure 5.19 The sodium tetrathionate ion along its two-fold axis 
Re-oxidising the suiphydryl groups with tetrathionate was performed by adding a5 mM 
final concentration of sodium tetrathionate to the reacted MAb solution (section 2.6.8). 
It is noteworthy to mention that due to the instability of the compound, either solid or 
immediately dissolved sodium tetrathionate must be used on completion of the 
conjugation reaction. 
An Ellman's assay was performed to determine whether the free sulphydryl groups had 
been re-oxidised by the addition of sodium tetrathionate. This was performed by taking 
a completed reaction mixture and splitting the solution into twelve equal volumes. A 
blank was made using PBS and DTNB at the same concentration as the reaction 
mixtures. Incubation times were varied to monitor any possible changes in absorbance 
over time and the absorbencies measured by UV-spectrometer as seen below. 
Table 5.3 UV (412 nm) absorbance from UV-spectrophotometric analysis 
of the immunoconjugate reacted with and without sodium tetrathionate 
Conjugate Incubation time (mins) 
reaction 5 15 30 
With tetrathionate 0.001 0.002 -0.001 
Without tetrathionate 0.0370 0.0354 0.0361 
The data in table 5.1 clearly demonstrated that DTNB did not react with any of the 
tetrathionate-treated conjugate whereas a significant absorbance was seen with the 
un-reacted sample had reacted strongly. Any free sulphydryl groups had been 
completely re-oxidised by tetrathionate after 5 minutes whereas the untreated samples 
still retained free sulphydryl groups over the thirty minute incubation time. 
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No publication was found investigating the relative performance and stability of re- 
oxidised versus non-re-oxidised conjugate in-vivo. It is likely that the disulphide bridges 
will, in any event, slowly re-oxidise with time in the absence of an added oxidant, but it 
is also possible that the reduced MAb may form adducts with other reactive species 
circulating in the blood and re-oxidation was therefore considered to be a wise 
precaution. Though no detailed stability checks of the conjugate were made, the 
integrity of the molecule in solution remained unchanged when stored in PBS at 4 °C 
for up to six months when analysed by SE-HPLC. 
5.4.2 Scaling up of conjugate preparation 
Since optimal stoichiometry was considered more important than high yields, a large 
scale reaction was set up using a 1: 2 streptavidin: antibody ratio. Thus 30 mg of 
trastuzumab (185 kDa) and 4.5 mg of streptavidin (RMM 50 kDa) were combined to 
produce enough conjugate for further experimentation. The reaction mixture for this 
conjugation was purified on a semi-preparative SE-HPLC column as described in section 
2.3.4 producing the chromatogram shown below. 
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Figure 5.20 Analysis of the pre-purification conjugation reaction solution 
The semi-preparative column has a larger mobile phase capacity and an increased 
length, thus greater amounts of protein can be purified on the column. This produces a 
slightly different chromatogram from analytical SE-HPLC with an increased height of 
each peak due to larger amounts of protein and longer run times. Due to these longer 
run times and low flow-rates a good resolution is observed with the semi-preparative 
column. A total volume of 180 ml of mobile phase was passed through the column 
during the run and 1 ml fractions were taken and analysed by SE-HPLC to identify 
those that contained the purest compound. As an example, the analysis of the 55th 
fraction is shown below. 
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The fractions between 50 and 55 minutes were then combined to form a5 ml solution 
of purified conjugation product. This conjugation fraction was then concentrated using 
a Centriprep concentrator to a more concentrated stock solution of 1 mg/ml. 
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Figure 5.21 Size exclusion UV-Chromatogram of the purified trastuzumab- 
streptavidin conjugate product 
The trastuzumab-streptavidin peak has the expected retention time of 14.6 minutes 
and appears to be a single species as no shouldering is apparent. The small group of 
compounds at twenty-five minutes represent small molecules and ions that are present 
in the mobile phase (PBS) of the purification set up that are not in the analytical SE- 
HPLC mobile phase (sodium phosphate/EDTA). 
5.4.3 Iminobiotin purification of the trastuzumab-streptavidin conjugate 
Iminobiotin is the guanadino analogue of biotin which has a lower dissociation constant 
to that of biotin. The dissociation constant of the streptavidin-iminobiotin complex is pH 
dependent and at pH 9.5 - 11.0, the complex will associate very strongly, whereas at 
pH 4, the streptavidin-iminobiotin complex will dissociate 303-305. An immobilised 
iminobiotin gel support was purchased to bind to streptavidin conjugates and purify it 
from streptavidin-free species. Because no denaturing agents such as guanidine 
hydrochloride or urea are used in the purification, trastuzumab-streptavidin has a better 
chance of maintaining its biological activity during purification. Also formation of 
aggregates is minimised and any change in conformation or loss of receptor-binding 
ability is minimised. 
The iminobiotin resin was placed in a syringe body that had been plugged with sterile 
gauze to act as a filter. The manufacturers instructions suggest that 1 ml of iminobiotin 
resin will bind 1 mg of streptavidin however 100 % excess was used to ensure 
complete binding could occur. Since streptavidin comprises approximately 25 % of the 
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mass of the conjugate, it was possible to purify 4 mg of conjugate on the column using 
just 2 ml of support. The conjugate was loaded onto the column in a pH 11 ammonium 
carbonate buffer. The column was then washed using the same pH 11 buffer to 
elute any unbound protein from the column. The specifically bound streptavidin- 
containing proteins were then eluted using a pH 4 ammonium acetate buffer. The 
conjugate was then quickly brought back up to physiological pH using an ammonium 
carbonate pH 9 buffer before being dialysed into pH 7.3 PBS. The details of this 
methodology are described in section 2.6.5. Below is the graph produced after SE-HPLC 
analysis of an iminobiotin-purified trastuzumab-streptavidin heteroconjugate. 
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Figure 5.22 Iminobiotin purified streptavidin derivitised trastuzumab 
The chromatogram displays a clean, un-shouldered peak with no impurities. The 
retention time (14.6 minutes) remains the same and comparing trastuzumab with the 
conjugate indicates that all of the MAb in the purified sample has been removed. No 
aggregation or degradation products can be seen in the purified sample demonstrating 
that even though the immunoconjugate was exposed to extreme pH conditions the 
molecule appears to remain unchanged. However since this procedure requires 
exposure of the conjugate to pH's ranging from 4 to 11, it is possible that some 
molecular damage will occur. 
Because the semi-preparative SE-HPLC was able to produce purity comparable to that 
of the iminobiotin column using less harsh conditions, this method was used for 
purification of material required for further characterisation. 
The only evidence that the desired product had been synthesised thus far was that the 
molecular weight of the product was greater than that of native trastuzumab when 
analysed by SE-HPLC. Also a range of species had been formed with higher molecular 
weight suggesting that a reaction had taken place with multiple streptavidin 
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derivatisations occurring. Further characterisation of the conjugate was needed to 
accurately determine whether the isolated product was indeed the desired product and 
whether it had been correctly synthesised. 
5.4.4 Defining the extinction coefficient (E) for trastuzumab-streptavidin 
In order to take advantage of UV spectrophotometry it needs an accurate measure of 
the protein of interest's extinction coefficient (molar absorption coefficient). Assays that 
have been used include dry weight calculations, spectral methods, and colourimetric 
techniques (Bradford and Lowry assays). These methods work well but require a fairly 
large amount of protein, yet modern protein sequencing methods allow us to use 
sequence data to determine extinction coefficients. Several assumptions are made, 
where the primary assumption is the spectral contributions of the tyrosine, tryptophan 
and cysteine at 280 nm do not differ significantly in the native form of the protein, 
relative to the denatured form. The calculation is based on the Edlehoch model 306 in 
which proteins are examined in a6M guanidinium hydrochloride denaturing solution 
which allowed for matching of native to denatured forms. Another assumption is that 
the protein contains no other chromophores (thus those proteins containing prosthetic 
groups absorbing UV and visible portions of the spectrum can't be measured using this 
calculation). There are freely available software programs found on the internet to 
derive an estimated E of different proteins calculated by sequence. 
The extinction coefficient (1 % at 280 nm) for streptavidin is 32, and that of 
trastuzumab 14. Thus the extinction coefficient of the conjugate must be different from 
either trastuzumab or streptavidin. Unfortunately the amino acid sequence of 
trastuzumab could not be found in order to determine the extinction coefficient from 
the internet based ExPASy Protparam program. However the sequence of another IgGi 
PR1A3 was obtained and, together with streptavidin's sequence, was used to derive the 
molar extinction coefficients (1 and 2) of the two molecules. A combined sequence was 
then constructed (3) and analysed using Protparam to derive the molar extinction 
coefficient (M"1 cm-') of the Immunoconjugate and thus the 0.1 % extinction coefficient. 
Below are the simple formulas used to determine the 0.1 % extinction coefficient 
necessary to determine protein concentration from a protein solution. 
(1) IGG10.1 % extinction coefficient @ 280 nm = 
(222960) 
_ 1.51 147800 
(2) streptavidin 0.1 % extinction coefficient @ 280 nm = 
(150780) 
= 3.14 48014.7 
(3) Conjugate 0.1 % extinction coefficient @ 280 nm = 
373740 
= 1.93 194146.9 
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The calculated 0.1 % extinction coefficient of the conjugate was used to calculate the 
concentration of protein in the later analyses. 
5.4.5 Determining the molecular weights of compounds by SE-HPLC 
In order to provide a more complete characterisation of the conjugate, the molecular 
mass was determined by SE-HPLC (section 2.6.6.1). By the very nature of SE-HPLC, 
compounds of different molecular weights are separated by the length of time that the 
compounds remain in the matrix of pores. The smaller the molecule, the more time it 
remains within the large pores of the size-exclusion column, while conversely high 
molecular weight compounds spend less time in the pores and therefore elute more 
rapidly. 
Molecular weight standards were obtained (BioRad, Hercules, CA) and analysed using 
the same method as used for the conjugates. The standards comprised of four proteins 
with molecular weights ranging from 17 kDa to 670 kDa providing a range of points 
from which analysed proteins can be calibrated in terms of RMM according to the 
retention time produced. A standard curve was constructed by plotting retention time 
against the log of the RMM. From this graph the retention times of various species 
could be equated to a specific molecular weight. Below is the chromatogram produced 
of the molecular weight standards analysed by SE-HPLC. 
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Figure 5.23 SE-HPLC molecular weight standards 
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The retention times (R. t) of the molecular weight standards were plotted against the 
loglo molecular weight values to produce the plot seen below. It can be seen that the 
plot is linear in the region corresponding to molecular weights ranging from 44 to 670 
kDa. A linear correlation was performed to this portion of the curve to obtain the 
parameters A, B displayed in the figure. 
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Figure 5.24 Scatter graph forming the calibration curve for SE-HPLC 
molecular mass determination 
From these parameters, the molecular weights (Mwt) corresponding to HPLC retention 
times were determined by using the formula seen below. 
LogMwt=R. t -A 
B 
The calculated figures were then compared with the known molecular weight values for 
each of the molecular species as shown below. 
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Figure 5.25 Bar graph showing the known molecular weights of various 
species compared to the molecular weights as determined by SE-HPLC 
The observed values are encouraging due to their relative proximity to the known 
values. Values are 101 %, 88 % and 56 % of their expected molecular weight values. 
This method of analysis produces only an estimate of molecular weight since factors 
other than molecular weight may have a direct influence over the retention time of the 
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analyte. Such factors include the tertiary configuration (morphology) of the protein and 
its lipophilicty which influences the interactivity of the protein with the HPLC column 
substrate. 
5.4.6 Mass determination by SDS PAGE 
In order to further characterise the conjugate, SDS-PAGE was performed to determine 
the molecular weight of the proteins. SDS-PAGE operates by separating molecules by 
molecular weight and overall charge by passing a current across the gel causing 
migration of the molecules through the gel at different rates. Molecular weight markers 
are run concurrently to calibrate the molecular weight of the proteins of interest. In 
order to determine the molecular masses of proteins it is usual to denature the proteins 
in order to reduce any influence of differing protein conformations. As proteins are 
denatured, they are often broken down into their respective subunits. As some protein 
subunits are more stably associated with each other than others it is common that a 
range of molecular species are produced which may elucidate protein structures and 
conjugations. 
Six 4 pl protein samples consisting of the conjugation product, trastuzumab and 
streptavidin (all at 1 mg/ml) in duplicate plus molecular weight markers were loaded 
onto a 7.5 % polyacrylamide gel using a Phastpage mini SDS PAGE system. After the 
protein separation had taken place, the gel was stained with Coomassie Blue and then 
destained. For further methodology please refer to sections 5.3.7 and 2.6.8.4. Below is 
an image of the gel produced from the analysis described. 
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Figure 5.26 SDS gel of trastuzumab-streptavidin 
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The conjugate shows many bands with molecular weights corresponding to the 
different antibody subunits and their streptavidin adducts larger than 200 kDa and a 
band corresponding to streptavidin. An attempt was made to identify the bands as 
shown in the figure legend. The large species with a molecular mass greater than 200 
kDa is most probably the MAb conjugated with at least one subunit of streptavidin. The 
bands seen in both the trastuzumab and streptavidin lanes are also seen in the 
conjugate lanes. However the bands which have no corresponding species are those 
which have been introduced by streptavidin conjugation. It is important to remember 
that just as streptavidin has been split into its four constituent subunits, the same 
occured with the conjugate. Thus a conjugated sub-species will have an increased 
mass of 12.5 kDa. Trastuzumab Is predominantly observed between 150 kDa and 185 
kDa though smaller species are seen corresponding to various combinations of heavy 
chains and light chains. Streptavidin is found predominantly at 12.5 kDa which is due to 
it separating into its four equal weight subunits though a faint band is observed at 25 
kDa which corresponds to a two-subunit species. These results confirm the formation 
of the conjugate and support the SE-HPLC mass data. A band with a molecular mass of 
approximately the expected weight of 235 kDa is seen on the gel indicating that the 
correct species has (probably) been synthesised although the separating properties of 
the gel are not Ideal for a protein of this size. It is interesting that despite re-oxidation 
of the thiols with sodium tetrathionate, the antibody is still dissociated by the SDS 
treatment into its constituent chains whereas little dissociation takes place with the 
MAb control. Although a band is seen corresponding to light chain and streptavidin (B 
and F) no band is seen corresponding to heavy chain and streptavidin (N 60 kDa). This 
suggests that the conjugation is occurring at either the antra-chain disulphide bond on 
the light chain or else the L-H disulphides, rather than the H-H hinge sulphydryls. 
Although such data is relatively qualitative and specific stoichiometric characterisation 
of the heteroconjugate may not be very accurate, Importantly the data showed that 
new species had been created by the conjugation product and the Increases in 
molecular mass were by the mass of one quarter of a streptavidin tetramer providing 
evidence that the conjugate had been formed. 
5.4.7 Mass spectrometry of the collected fraction 
In order to further determine that the correct species had both been synthesised and 
collected upon purification a sample was analysed by mass spectrometry. The process 
involved the isolation of the native protein band on a polyacrylamide gel. A mass 
spectrometry device which could accurately analyse large macromolecules was not 
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available to the group at the time of conjugate synthesis. Instead the molecule was 
trypsinised and analysed. 
The analysis identified the presence of streptavidin conjugated plus unconjugated Fab 
fragments and heavy chains derived from trastuzumab. Although this confirmed that 
the sample consisted of a trastuzumab-streptavidin conjugate, the stoichiometry of 
both species in the conjugate could not be determined from such an analysis. 
5.4.8 Radiolabelling of the immunoconjugate with 1251 
In order to study the protein binding of the conjugate, it was considered necessary to 
radiolabel it. Radioiodination was chosen as the method of choice since both 1251 and 
1311 have the advantage of low cost and wide-spread availability. Electrophilic 
substitution is by far the most common practice used in radiolabelling with iodine 3. The 
oxidation of the iodide ion to the positively charged iodous ion facilitates the 
electrophilic substitution of the iodine for a hydrogen of the phenolic ring of tyrosine in 
the ortho- and para-positions as seen below 3. 
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Figure 5.27 Reaction mechanism of the radio-iodination of tyrosine by 
electrophillic substitution3 
The Iodogen method 137 is the most popular oxidising protocol for clinical and 
laboratory preparations. A solution of chloroamide, 1,3,4,6-tetrachloro-3a, 6a- 
diphenyiglycoluril in dichloromethane (DCM) is placed into a sterile glass or 
polypropylene tube and the DCM is evaporated off using a very slow flow of nitrogen 
gas. The tubes are covered and stored in the freezer or refrigerator. Immunoconjugate 
or MAb labelling methods involve the use of a small final volume of reaction mixture. 
Typically 20 pg of protein was incubated in a 100 pl final volume with 3 MBq of Na125I 
for ten minutes and then the protein was isolated from free iodine-125 by PD10 
sephadex column purification as described in section 2.2.2. 
A labelling yield of around 85 % was obtained and the purified labelled conjugate had a 
radiochemical purity of greater than 99 % as assessed by SE-HPLC. When labelling 
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MAbs for in-vitro or in-vivo targeting it is essential that the immunoreactivity of the MAb 
is not impaired 3. In the case of most MAbs the Iodogen method will preserve the 
antigen binding capabilities though other methods exist should such a situation arise 
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5.4.9 Conjugate-serum protein interaction analysis by SE-HPLC 
In order to determine whether the conjugate develops non-specific binding interactions 
with serum proteins over time an assay was performed. Such interactions would reduce 
the binding of trastuzumab-streptavidin to the tumour and would be highly undesirable. 
The assay involved incubating a sample of 125I-radiolabelled conjugate in fresh human 
serum for 24 hours at 37 °C. After the incubation period a sample was analysed by SE- 
HPLC and the eluant was collected in 1 ml fractions by a fraction collector for analysis 
by y-counter. Any protein interactions would cause complexes to be formed with the 
conjugate thus increasing the combined molecular mass and shorten the SE-HPLC 
retention time (prior to 14.6 minutes). Below is a bar chart indicating the radioactivity 
found in each fraction. 
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Figure 5.28 Bar graph of fractions collected from SE-HPLC of 1251-Labelled 
conjugate after incubation with human serum 
The major peak of the serum incubated iodine-125 labelled conjugate consists of 87 % 
(± 0.8 %) of the total activity injected at the time expected of an intact non- 
aggregated MAb. The PBS incubated sample has a radioactive peak equal to 88 % (± 
0.4 %) at a retention time between 14 and 15 minutes. In both samples, the rest of the 
activity is found after the main peak and tails off slowly indicating that the efficiency of 
the column is less than perfect. From this result we can conclude that the conjugation 
product does not form complexes with serum protein and remains a viable tool for 
pretargeting tumours. 
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5.4.10 Size-exclusion analysis of 1111n-DLB and TSA incubation reaction 
The next characterisation process was to determine whether the conjugate was able to 
bind to the effector molecule synthesised in Chapter 3 or not. 
UV-chrom atogram 
Radio-chrom atog ram 
DLB control radiochrom atogram 
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This was done by incubating 10 pg of the purified product with 200 ng of "In-DLB on 
a rotating mixer for thirty minutes at 37 °C. The reaction mixture was then analysed by 
SE-HPLC (as a control I-DLB was incubated in parallel). Below is an overlaid 
chromatogram showing both radio- and UV-detection. For comparison a second 
chromatograms displayed of the SE-HPLC analysis of "'In-DLB alone. 
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Figure 5.29 SE-HPLC analysis of "'In-DLB and TSA incubation reaction 
A large radioactive peak is observed at the same retention time as the protein peak in 
the UV chromatogram indicating that "'In-DLB was associated with the trastuzumab- 
streptavidin conjugate. Approximately 83 % of the radioactivity is associated with the 
conjugate indicating that the species is able to bind the effector molecule. Small ions 
are evident after 25 minutes of the run time seen in the UV as is "In-d-DLB indicating 
that not all of the effector molecule fraction was conjugate-bound. This is supported by 
comparing the retention time of the smaller radioactive peak (figure 5.28) with the 
"'In-DLB peak in the same chromatogram. 
5.4.11 Stability of "In-DLB bound to the streptavidin-trastuzumab complex 
To identify any potential instability in the DLB-immunoconjugate complex it was 
decided to study its stability in human serum. Any instability which did arise would 
prove detrimental to a potential therapeutic regime and would need to be addressed 
before further testing proceeded. The stability of trastuzumab in serum was not under 
question as it was approved as a licensed drug by the MCA and FDA and the serum 
1 cn 
stability of DLB was demonstrated over four days in section 3.6. However to ascertain 
whether any other interactions such as biotin competition or enzymatic processes 
occurred with the combined complex, the two components were studied together. 
The association of DLB to streptavidin in the conjugate must be as stable as possible in 
order to derive the best chance of therapeutic success. Because the KA of DLB- 
streptavidin binding is higher than that of streptavidin-HER2 binding (1015 opposed to 
109 respectively) it is likely that the pretargeted conjugate will dissociate from the 
tumour cells before the effector molecule will uncouple from trastuzumab-streptavidin. 
However if after the period of the assay the effector molecule had decoupled then 
exploring other solutions may have been necessary. If on the other hand the complex 
is very stable both as a complex and as a tumour targeted radiopharmaceutical then 
radioisotopes with longer half-lives may be employed to good effect. 
A 50 ng sample of "'In-labelled d-DLB was incubated with 20 pg of trastuzumab- 
streptavidin conjugate (1: 1 molar ratio) in fresh human serum at 37 °C for up to four 
days to determine if d-DLB would remain stably bound over time. A SE-HPLC analysis 
was performed each day for four days to determine the rate of dissociation of DLB or 
enzymatic catabolism of the complex if any. The four day analysis can be seen below in 
the radiochromatogram. 
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Figure 5.30 SE-HPLC chromatogram after a four day stability analysis of d- 
DLB binding with trastuzumab-streptavidin in PBS 
At each time-point the radioactivity associated with the immunoconjugate was greater 
than 99 %. The vast majority of the radioactivity is concentrated in a single peak just 
before 15 minutes. This indicated that the conjugate-DLB complex was very stable and 
showed no sign of degradation or d-DLB dissociation over the four day period. The 
151 
vv iv 15 20 25 30 
Time (m ins) 
signal intensity is low as only a small volume was injected onto the column. This is 
because serum proteins can be very large and with a high concentration may remain 
adherent to the column which would rapidly degrade the column performance. The 
radio-chromatogram conjugate peak has a slightly longer retention time than the UV 
chromatogram analyses due to the physical distance of separation of the UV detector 
from the sodium-iodide detector. 
The trastuzumab-streptavidin-DLB association has been shown to be stable in human 
serum when incubated for four days at 37 °C. This association is imperative if a 
successful therapy is to be achieved thus maintaining the possible tumour radiation- 
dose. 
5.4.12 Determining the stoichiometry of binding of trastuzumab- 
streptavidin to 1111n-d-DLB. 
In the same way that the stoichiometry of "'In-DLB-streptavidin binding was 
determined in section 3.5.4, it was possible to determine the maximum stoichiometry of 
the binding of trastuzumab-streptavidin conjugate to d-DLB (section 2.5.4). 
A range of concentrations of immunoconjugate (1 pg to 1 Ng) were incubated with 10 
ng of "'In-d-DLB for two hours to facilitate maximum binding between the reactants. 
After the incubation period the high molecular weight compounds were separated from 
the low molecular weight compounds by G50 sephadex spin column. Any free 11'In-d- 
DLB was retained in the sephadex resin and the conjugate bound 1 'In-d-DLB was 
found in the filtrate. Below is the graph constructed from the data points obtained in 
exactly the same way as d-DLB-Streptavidin binding was measured (section 3.5.4). 
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The binding curve formed is sigmoidal and levels of binding ranged from 3% to 98 % 
of "'In-DLB bound to trastuzumab-streptavidin. 
Binding saturation is reached at a conjugate: DLB ratio of around 1: 4 which is the 
expected value for binding of streptavidin to biotin. This suggests that the conjugate is 
fully functional in terms of its ability to bind the effector molecule and is also supporting 
evidence that the stoichiometry of the conjugate is 1: 1. 
5.5 Conclusions 
The aim of the work described in this chapter was to synthesise and evaluate a 
trastuzumab-streptavidin conjugate for pretargeting of HER2 receptor positive tumours. 
The conjugation required the cross-linking of trastuzumab and streptavidin using an 
SMCC cross-linker. The conjugation reaction was novel because trastuzumab was UV- 
irradiated in the presence of stannous ions to produce free sulphydryl groups which 
were then reacted with SMCC-derivatised streptavidin. Below are detailed a summary of 
the findings obtained in the study. 
The UV-irradiation process was chosen because none of the reaction products were 
required to be removed after the synthesis. This results in a simpler, faster process 
with greater yields. The initial irradiation of a solution of trastuzumab to which 
Medronate II had been added was initially performed for fifteen minutes and the MAb 
was subsequently analysed by SE-HPLC. After determining that any aggregation during 
the irradiation process could be averted by air-cooling the reactor during incubation, 
the SE-HPLC analysis indicated that the MAb had not been degraded in the process. 
To determine the number of free suiphydryls generated from the reduction process, a 
quantification study of the number of groups produced per unit time was performed. 
Both irradiated and non-irradiated trastuzumab were analysed with and without 
stannous ions with and without UV-irradiation. Two methods of quantification were 
used to provide more reliable data and to compare the ability of both systems to 
accurately define the number of sulphydryls produced per MAb. Fluorimetry was 
performed with 5-IAF and UV-spectrophotometry was performed with Ellman's reagent. 
From this study an Irradiation time of 10 minutes was identified as sufficient to produce 
a conjugation product from the six moles of sulphydryls per mole of trastuzumab 
produced. 
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A conjugation reaction was performed using a 2: 1 molar ratio of SMCC-derivatised 
streptavidin to trastuzumab. However, upon SE-HPLC analysis, no synthesis product 
was observed, indicated by the lack of new peak formation. 
Due to the lack of synthesis product obtained from the conjugation reaction, it became 
necessary to investigate at which point in the reaction the hindrance to a successful 
synthesis lay. An Ellman's assay was used to demonstrate that a significant number of 
sulphydryls per MAb remained available for reaction over a twenty minute period, thus 
ensuring that a small delay before combining the reactants would not be a reason for 
the lack of reaction. The next step again involved an Ellman's assay to reveal that the 
maleimide groups of SMCC, with which streptavidin was derivatised, remained 
functional. The last aspect of the reaction to be studied was to check the 
concentrations of streptavidin used in the reaction. By comparing streptavidin from two 
separate sources, it was shown by SE-HPLC analysis that the concentration of the 
Sigma streptavidin was ten times lower than the ICN protein. UV-spectrophotometry 
was used to verify these results and produced a result indicating almost 11 times lower 
concentration of Sigma streptavidin relative to ICN. 
A new conjugation reaction (2: 1 streptavidin: MAb molar ratio) was performed using 
ICN streptavidin, and a new peak amounting to about 8% of the total area under the 
curve was produced. The yield was lower than those seen in published data, so a new 
buffer system, TSMZ, was used in the hope of improving reaction yields. SE-HPLC 
analysis of the synthesis gave yields of approximately 40 %. The resulting synthesis 
product however appeared to be very heterogeneous, and since a singly streptavidin 
derivatised trastuzumab was desired, the molar ratios of the reactants were modified In 
an attempt to reduce heterogeneity. Although only a 20 % yield was obtained from the 
modified reaction, the new product showed much greater heterogeneity. 
Since previous studies had re-oxidised the un-reacted sulphydryl groups with sodium 
tetrathionate, to reduce the possibility for the conjugate to form adducts with other 
species, we used the same method and showed that it was effective In reducing the 
number of free sulphydryls to zero. 
A larger scale reaction was performed in order to obtain sufficient material for further 
characterisation. Fractions from a semi-preparative HPLC purification were pooled to 
obtain a larger amount of TSA which was then concentrated for future experimentation. 
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The use of iminobiotin purification was studied to obtain a pure TSA sample by 
removing any un-conjugated antibody. The sample collected from the purification had a 
similar purity to that obtained from the semi-preparative purification. However due to 
the harsh conditions that the immunoconjugate was subjected to and because a 
similar purity could be obtained from HPLC purification the technique was not used for 
large scale purification. 
Since the extinction coefficients for trastuzumab and streptavidin are markedly 
different, this presents a problem for defining the concentration of such a solution of 
the conjugate. As a result the extinction coefficients of both species were combined 
and an average of both was taken on the basis that other experimentation pointed 
towards the conjugate being in a 1: 1 ratio of streptavidin and MAb. 
In order to characterise the purified conjugate, mass determination by SE-HPLC was 
performed. After the analysis of molecular weight markers was performed, the 
retention times were plotted against their known molecular weights to produce a 
standard curve. From this standard curve it could be calculated that the compound had 
approximately the same molecular mass as would be expected from the 
immunoconguate. 
SDS-PAGE analysis was performed to determine the molecular mass of the collected 
compound and whether any new species had been created. Bands greater than 200 
kDa were observed though specific mass data was not obtainable. New species with 
mass increases equal to the mass of streptavidin subunits were seen though these 
were seen principally associated with antibody light chains indicating that conjugation 
had occurred with intra-chain disulphide bonds of the light chains or light-heavy chain 
disulphide bonds. 
Mass spectrometry was performed on trypsinised samples of the immunoconjugate with 
the view to identifying any conjugated species. Streptavidin-MAb conjugates were 
identified by subsequent sequence analysis confirming that a successful conjugation 
had occurred. 
Analysis of serum-protein binding by the conjugate was performed by SE-HPLC and the 
fractions collected by a fraction collector for gamma counting. No apparent serum- 
protein-TSA complexes were observed indicating that the conjugate would be viable for 
use as an in-vivo pretargeting agent. 
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By incubating indium-111 labelled DLB with TSA, it was possible to characterise the 
synthesised product further. The majority of "'In-DLB associated with the complex 
upon SE-HPLC analysis indicating that the conjugate was functioning correctly. 
To gain an idea of the potential stability of the "In-DLB-TSA complex in-vivo, the 
complex was incubated in human serum for the four days. Aliquots were taken at 
regular time points and upon SE-HPLC showed no sign of dissociation from each other 
for the entire length of the study. 
A more detailed study was performed in order to determine the stoichiometry with 
which DLB bound to TSA. Using a known concentration of DLB, a range of TSA 
concentrations were incubated with the "'In-labelled DLB. The percentage of'11In-DLB 
that was found to be bound to streptavidin was plotted against the molar concentration 
of TSA. From these results it was possible to approximate that the molar ratio of DLB- 
TSA binding was in the order of 4: 1. 
From the data in this chapter the formation of a trastuzumab-streptavidin conjugate 
was shown to be possible using a UV-irradiation technique to produce free sulphydryl 
groups necessary for conjugation. The buffer, TSMZ, was shown to produce higher 
synthesis yields than obtained with PBS buffered reactions. The conjugate was shown 
to be the correct compound by SE-HPLC, SDS-PAGE, mass spectrometry and binding 
techniques. The conjugate is stable in solution for a long time and a complex formed 
with d-DLB remained in-tact for up to four days without any indication of dissociation. 
By producing a binding curve with increasing concentrations of conjugate, it was 
possible to estimate that DLB binds to trastuzumab-streptavidin in a 4: 1 relation, 
further suggesting that the immunoconjugate was formed with a 1: 1 stoichiometry. 
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Chapter 6 Cell-binding studies on the 
trastuzumab - streptavidin conjugate 
6.1 Introduction 
The successful synthesis of trastuzumab-streptavidin (TSA) detailed in chapter 5 
enabled its further characterisation as a potential pretargeting precursor 
pharmaceutical. All the preliminary studies showed that TSA had been synthesised 
correctly and performed as well as could be hoped for. This chapter describes in 
greater detail the performance of a series of in-vitro tumour cell-binding studies. 
The streptavidin/biotin pretargeting system would typically use a clearing agent to 
remove excess immunoconjugate from the blood. Since, in the absence of such an 
agent the tumour to background ratio of the streptavidin/biotin system will be no 
different to conventional RAIT. Such a drug would however significantly increase the 
duration and complexity of the multi-drug development. A very good clearing agent 
was developed by Theodore and Axworthy 308 and would complement a 
streptavidin/biotin pretargeting study such as this. 
The human breast tumour cell line SKBR3 is known to represent HER2-overexpressing 
breast cancers and respond in a cytostatic manner in-vitro in the presence of 
trastuzumab. Trastuzumab was designed with the purpose of targeting HER2 receptors 
and as SKBR3 cells over-express HERZ receptors, adhere easily to well-plates and have 
been extensively studied 309-311, the cell line was an obvious choice. Thus for all cell- 
based studies detailed in this chapter, SKBR3 cells were used for tumour model 
purposes. Apart from the Lindmo assay, all of the cell based studies were performed in 
well plates to greater simulate an adherent cell population such as that found in-vivo. 
The effector molecules DLB and DBB have both been shown to have suitable in-vitro 
binding characteristics when incubated with streptavidin as demonstrated in chapter 3 
and with TSA in chapter 5. Though the effector molecules are known to bind to 
streptavidin well, TSA itself has not yet been shown to target cells. Consequently 
pretargeting has not yet been demonstrated with the two components of the 
streptavidin/biotin system and the demonstration of this in-vitro, is the aim of this 
chapter. 
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The reciprocal intercept value (1.39) for 125I-trastuzumab indicates a 72 % 
immunoreactivity and (1.323) 75.6 % with 125I-labelled TSA. The gradient of the plot is 
a function of binding affinity, therefore because the gradient of both plots is very 
similar, and the immunoreactive fraction the same, the binding affinity of each species 
is essentially identical. Non-specific binding was less than 0.1% of the total activity 
indicating that all binding was specific to the receptors. 
This demonstrates that the conjugation process does not significantly affect the overall 
receptor binding in-vitro. As a comparison the MAb huA33 was reported to have an 
immunoreactivity of 78 % 170 indicating a similar result to that seen above. 
6.3 Conjugate cell-binding study 
Cell-binding studies produce important information relevant to how different ligands will 
perform in-vitro and in-vivo. The most rapid localisation time at the tumour possible is 
desired. Countering the rate of ligand binding and thus membrane-presentation are 
factors such as dissociation, internalisation and ligand clearance. For in-vitro studies, 
binding kinetics must be determined to gauge incubation times and establish the 
concentration at the cells of the pretargeted complex to enable the conjugate to be 
radio-targeted with the correct amount of effector molecule. 
In order to determine how the kinetics of conjugate-receptor binding compared to that 
of trastuzumab, an in-vitro cell-binding assay was performed (section 2.7.2). Six-well 
plates were seeded the night before with SKBR3 cells and on the morning of the 
experiment the media replaced to remove any non-adherent cells. A 330 ng amount of 
125I-TSA or 125I-trastuzumab was added into each well and the plates were Incubated 
for up to six hours at either 37 °C or 4 °C. At designated time-points the media 
supernatant was removed, the cells washed and the cells removed from the plates 
using strong alkali. Each fraction was collected separately and the radioactivity in each 
sample quantified in a gamma counter in order to determine the level of ligand-cell 
binding. Three data sets were produced in order to the kinetics of receptor binding. By 
using both 37 °C and 4 °C incubation temperatures the effect of temperature on the 
binding kinetics could be determined. The un-conjugated native MAb was assayed to 
allow us to determine how the conjugation of streptavidin affected binding kinetics. 
Below is the graph of the data collected from this study. 
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Figure 6.2 Cell-binding study comparing the kinetics of 1251 radiolabelled 
trastuzumab-streptavidin with 1251-trastuzumab 
The un-conjugated MAb at 37 °C has the most rapid rate of binding of the ligands 
studied, which was expected due to its lower molecular mass. TSA had a slightly 
decreased rate of binding compared to native trastuzumab, though not greatly so. By 
three hours 67 % of the labelled conjugate has been associated with the cell receptors, 
while the un-conjugated trastuzumab reached a total of 71 % bound to the cells after 
three hours. The binding at six hours is about the same, showing that equilibrium 
binding was reached by six hours. The 4 °C assay demonstrated that, as expected, 
binding was much slower at this temperature, and equilibrium had still not been 
reached by six hours. 
Figure 6.2 provides the data necessary for future TSA binding studies where the 
concentration of TSA at the cells must be known. The binding study at 4 °C provides a 
relative comparison of different kinetic rates of binding but no more than that. 
6.4 Monoclonal antibody internalisation 
MAb internalisation into the cell is required for many targeted therapeutics such as 
immunotoxins 313 and antibody-drug conjugates 314. This can be accomplished if the 
receptor, upon ligand binding, is activated by homo- or hetero-dimerisation either 
directly with a bivalent ligand or by causing a conformational change in the case of a 
mono-valent ligand. This may cause, depending upon the receptor, the complex to 
become internalised via endocytosis and deliver the payload into the cell. Below is a 
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figure adapted from both Hendriks et al 4 and Burke et al 5 which illustrates the 
internalisation process and the fate of internalised receptors and ligands. 
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Figure 6.3 Schematic generalised receptor trafficking model 4,5 
In the late endosome the ligand is removed from the receptor and the receptor is 
signalled either for recycling or destruction. Receptor internalisation and its ultimate 
destruction in lysosomes results in receptor down-regulation and thus moderation of 
the signal produced from an activated receptor 315. It is important to note that 
internalised MAbs are always degraded to prevent repeated or constitutively active 
signalling. 
In the case of pretargeting, it is imperative that TSA remains presented upon the 
exterior of the cell membrane. This is required so that once TSA is tumour localised, 
the effector molecules which are administered up to two days later can successfully 
bind the immunoconjugate. Whether TSA internalises or not is especially important as 
only a small proportion of the injected pretargeting conjugate actually localises to the 
tumour before the clearance phase. 
Interestingly Wells et al 316 and Huang et al 317 have demonstrated that a low rate of 
internalisation is correlated with cell transformation. What is not known and not 
established by these studies is whether receptors are stabilised against endocytosis or 
whether the recycling of the receptors makes it more difficult to determine the degree 
of internalisation 5. Section 6.4 will consider whether TSA internalises or not and thus 
the viability of TSA as a pretargeting pharmaceutical. 
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6.4.1 Determining whether the immunoconjugate internalises 
An internalisation assay (section 2.7.3) was performed to determine where radiolabelled 
TSA resides once receptor-bound at different time-points as indicated in figure 6.3. The 
assay functions by separating the unbound, membrane bound and internalised 
radiolabelled ligand fractions. 
One of the most extensively used methods to date has involved the use of low (2.8) pH 
salt-balanced glycine-HCI buffer for the dissociation of antigen-MAb bonds 318-326. The 
general outline of this method includes the following steps. 1) Incubation of 125I-TSA 
with the HERZ presenting cells (SKBR3) for various time-points to allow internalisation. 
2) Measurement of the amount of surface-bound '25I-TSA employing different 
techniques, at each time point. 3) Application of the glycine-HCI buffer to the sample in 
order to dissociate surface bound antigen-1251-TSA complexes. 4) Estimation of the 
amount of 125I-TSA remaining in the target cell assuming that all surface bound 
complexes have been dissociated. This assay was performed as described in section 
2.7.3. Each time point was assayed in triplicate and the data plotted as a function of 
total counts added in the graph seen below. 
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Figue 6.4 Internalisation assay to determine the amount of conjugate 
that is internalised over a two-hour period. Pre-bound excess competitive 
inhibitor was also used to determine the degree of non-specific binding 
Internalisation of TSA appeared to be greater than half of the cell-associated 
radiolabelled conjugate with a value of 63 %, whereas the membrane-bound fraction 
accounted for the other 36 % of the total conjugate both at two hours. The non- 
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specific binding of TSA is on average less than 1% of the total activity. This was 
demonstrated by pre-incubating the cells with a 500 fold excess (150 pg per well) of 
the competitive inhibitor (trastuzumab). 
From these results it is apparent that the degree of internalisation is greater than the 
remaining TSA found on the outer-membrane of the SKBR3 cells. To investigate this 
effect further, a more detailed picture can be obtained by performing an externalisation 
assay which would provide more information as to the degree of recycling of the 
radiolabelled ligand. 
6.4.2 Externalisation assay 
Externalisation of an internalised MAb is a phenomenon that takes place after the 
endocytosed ligand returns to the plasmalemma surface in the form of catabolised 
products for ejection from the cell (see figure 6.3). Thus by removing the supernatant 
and monitoring for any increase in radioactivity, the radiolabelled ligand that has been 
degraded and externalised can be detected. 
For the externalisation assay, an internalisation assay was first repeated and at a 
designated time-point of two hours post ligand-addition, the cell media was replaced 
with fresh media thus removing any unbound ligand. Any increase in activity found in 
the media thereafter is then caused by externalised 125I-TSA. Below is the graph 
produced from time zero until two hours which represents the internalisation phase and 
at two hours the media was changed to observe externalisation over a further four- 
hour period. 
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Figure 6.5 Externalisation assay of125I-labelled trastuzumab-streptavidin 
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After two hours the amount of immunoconjugate bound to the cells (43 %) is almost 
the same as the percentage seen in figure 6.5. At the two hour time-point, once the 
media has been replaced, the level of the internalised fraction remains the same and 
shows no sign of changing over the duration of the assay. However no further 
internalisation was seen to occur as the remaining membrane-bound fraction remained 
the same during the externalisation phase as the initial internalisation phase after two 
hours. 
6.4.3 Internalisation of trastuzumab brought into question 
It was considered surprising that no further internalisation or externalisation of 
radioactivity occurred after the two-hour time-point. Since significant membrane bound 
levels of the conjugate remained at this time, one would expect these to be internalised 
unless by some unexplained mechanism, the internalisation capacity had been reached 
at this time (though this seems unlikely). It is also surprising that no externalisation of 
radioactivity took place. Iodine-labelled MAbs are known to be catabolised within the 
, lysosomes and small molecular weight catabolites released from the cell with time 
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but this did not occur in this experiment. 
A number of published studies have investigated the internalisation of HERZ receptors 
upon ligand binding, though the HERZ receptor internalisation is far from being 
completely understood. Burke et al demonstrated that EGFR and HER2 heterodimerise 
before internalising 5. Burke et al had previously showed that the two cell-lines studied, 
HB2 and 184A1, had essentially identical trafficking 328. The group discovered that 
internalised EGFR molecules were hyperphosphorylated relative to surface receptors 329, 
331 by a two-fold amount. A slow accumulation of internal EGFR-HER2 complexes after 
twenty to thirty minutes was observed, approximately when EGFR left the early 
endosomes. Burke et al concluded that HERZ complexes Initially form at the cell 
surface, but can accumulate in later compartments in the endocytic pathway, which 
was consistent with results of previous studies 331. EGF addition to the exterior of the 
cells resulted in the loss of EGF-HER2 complexes from the cell-surface, concomitantly 
with the loss of surface EGFR. Burke et al demonstrated that the half life of EGF-HER2 
internalisation was about five minutes with HMEC cells, but at least twenty minutes was 
required to transit to the early endosomes 5. Therefore he surmises that at least a four- 
fold greater concentration of EGF will be seen inside the cell at a steady state. 
A study performed by Borchardt et al using the same protocol as used in section 6.5.1 
showed that 50 % of actinium-225 labelled trastuzumab internalised after a two-hour 
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time period 332. This is a similar rate of internalisation to the one we found for the 
streptavidin conjugate. 
Hommelgaard et al however report that "HERZ is preferentially and stably associated 
with plasma membrane protrusions and that trastuzumab does not change this 
localisation or stimulate internalisation of HERZ 281. It is only by substantial cross-linking 
of HERZ that it was possible to drive HERZ away from the protrusions and thereby 
make it internalisable" 281. Hommelgaard et al used confocal microscopy, immunogold 
labelling electron microscopy and biochemical techniques with SKBR3 cells to evaluate 
how the receptors were internalised. These techniques are not quantitative and as such 
the results do not provide conclusive evidence that the amount of internalisation is the 
same as Hommelgaard's et al's prediction. However as a piece of research it contests 
the view that HERZ is very rapidly internalised, once ligand bound. 
It may be that both reports are not mutually exclusive or individually incorrect in their 
conclusions, rather that under different conditions both situations may exist. However a 
deeper analysis of the practical techniques as well as an improved knowledge of HERZ 
activation and internalisation is required to provide more conclusive answers. 
6.4.4 Iodine metabolism assay altering the internalisation/externalisation 
assay results 
Because of the possibility of metabolism of internalised 1251 -labelled proteins the 
internalisation/externalisation assay may be misinterpreted by assuming that the 
supernatant radioactivity is immunoprotein bound when in fact the activity may be due 
to free iodide in solution. 
To discriminate between these two possibilities, an internalisation assay was performed 
over a twenty-four hour period. To one group of cell-seeded well plates an excess of 
native trastuzumab was used to block the HERZ receptors, the second group remained 
competitor free. The results from the receptor-blocked data set provided a negative 
control by ensuring that no conjugate would be internalised in those fractions. The 
supernatants were collected as described above and trichioroacetic acid (TCA) was 
added to each sample fraction to form a final solution of 10 % TCA so as to precipitate 
the protein in solution. After centrifuging the protein into a pellet, the supernatant was 
removed and both fractions were counted using the y-counter. Both the supernatant 
fraction and the acid wash fraction were analysed. Below is a graph showing the results 
of the supernatant fraction analysis which are displayed as a percentage of the total 
counts of supernatant and pellet samples. 
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Figure 6.6 Graph displaying the amount of protein-bound radioactivity 
over the duration of a twenty-four hour externalisation assay 
At time zero, there was no difference in the percentage of un-precipitated iodide-125 
between the two data sets. However a gradual increase in the amount of non-protein- 
bound radioactivity was observed where at six hours 5% more activity was found in 
the supernatant than the control rising to 6% after 24 hours. The amount of non- 
precipitated activity increased steadily but appeared to taper off after six-hours 
indicating that the process by which the free iodide was being created was slowing 
down or reaching equilibrium. 
The data suggests that at least a small amount of metabolism has occurred as the 
amount of activity which is not protein-bound does increase. Nevertheless this amount 
of radioactivity is low in relation to the degree of apparent internalisation of 125I-TSA 
and would not confound interpretation of the results. 
6.4.5 Analysing different pH washing buffers with the aim of removing more 
of the potential receptor-bound TSA 
If the degree of the internalised fraction is to be disputed after the arguments 
discussed in section 6.4, then the first line of investigation is the reliability of the results 
of the assay. The single most important feature of the assay which required further 
analysis was the effectiveness of the acid-wash buffer used in the internalisation assay. 
The acid-wash step facilitates the dissociation by causing the amino acids at the 
receptor recognition site of the MAb to change their ionic charge and thus reduce or 
nullify the electrostatic interactions. Therefore by lowering the pH of the acid-wash 
Iii 
buffer further, a greater degree of ionisation should occur increasing the likelihood that 
the '251-labelled TSA is displaced from the receptors. Thus starting with the pH 2.8 acid- 
wash buffer, two more buffers were made in the same way but being either a half or 
one pH value lower than the original buffer. 
A sample of 125I-TSA was incubated with adherent cells for two hours and afterwards 
the cell media was replaced to remove any unbound conjugate as described in section 
6.4.2. The cells were then incubated with the acid wash solutions for designated times 
at which point the separation and analysis of the different fractions took place (see 
section 6.4.2). Below is the graph created from the data-set using the pH 2.8 acid-wash 
buffer to remove membrane-bound 125I-TSA. 
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Figure 6.7 pH 2.8 acid wash buffer externalisation assay 
The pH 2.8 buffer used in the above assay produced very similar results to earlier 
studies with regard to both the internalised and membrane-bound fractions. The 
internalised fraction remained steady and unchanged with an average of 31 %±1.8 % 
of the total activity over the six-hour period. The membrane bound fraction had a very 
similar pattern giving an average 29 %±1.3 % of '25I-labelled TSA associated with it. 
Thus from the cell-associated activity, 52 % was indicated as being intemalised. Non- 
specific binding was relatively low always below 4% of total activity, though not as low 
as previously observed. 
The same externalisation assay was then repeated except that the pH 2.8 acid-wash 
buffer was replaced with a pH 2.3 acid wash buffer of the same salt concentration. 
Below is the graph representing the data set obtained. 
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Figure 6.8 pH 2.3 acid wash buffer externalisation assay 
The average total cell-associated radioactivity is very similar to that of the assay above 
indicating that ligand binding was comparable in terms of proportion bound. However 
the membrane-bound TSA fraction represents by far the greatest fraction being 49 %± 
1.8 %. The internalised fraction only constituted 8%±1.9 % which was a decrease of 
23 % from the pH 2.8 acid wash assay. An average internalisation value of 20 % of 
total cell-associated radioactivity was allocated as internalised. Non-specific binding was 
similar to that of the previous assay. 
The assay was then repeated with an acid wash buffer at pH 1.8 in order to determine 
whether further dissociation of the radiolabelled TSA occurred. The results produced 
from this assay can be seen in the graph below. 
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Figure 6.9 pH 1.8 acid wash buffer externalisation assay 
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Very similar results were obtained from this and the previous assay. The membrane- 
bound fraction now consisted of 57 %±2% and the internalised fraction represented 
10 %±3%. Of the total cell-associated radioactivity, 15 % was attributed to 
internalised 125I-labelled TSA demonstrating that there was no further dissociation of 
TSA from the cells between the pH 2.3 and pH 1.8 acid washes. 
From these results, it appears that a pH of 2.8 is not sufficient to fully dissociate the 
MAb from the cell membrane and that some of that proportion of TSA assumed to be 
internalised, was, in fact still membrane bound. The amount of conjugate remaining 
after the pH 2.3/1.8 acid washes is approximately 15 % of the cell-associated MAb and 
thus may be a more accurate estimation of the proportion of internalised TSA. 
However, it may also be the case that even these conditions are insufficient to 
dissociate the entire membrane-bound antibody. It may also be that the very harsh 
acidic conditions used to strip the cells may actually damage them and provide 
artefactual results and was considered to require further investigation. 
6.4.6 Cellular response to low pH conditions 
By reducing the pH of the acid-wash buffer, it has been shown that more 
immunoconjugate can be released from the cells into the supernatant. However the 
assay does not elucidate whether the reduction in pH changes the cellular structure and 
membrane integrity. Indeed pH tolerances of human cells are very limited, so a 
microscopy study was performed on the acid-treated cells to simulate the conditions 
under which the cells were treated in the internalisation/externalisation assays (section 
2.7.6). 
SKBR3 cells were harvested from a culture flask and aliquoted into four tubes which 
were subsequently centrifuged and the media removed. The cells were then washed in 
PBS before being centrifuged again. To three of the tubes, the supernatant was 
removed and the three different pH acid wash buffers were applied. The cells were 
mixed and incubated for 20 minutes at 37 °C to recreate the environment of the 
internalisation assay. Immediately at the end of the incubation period, Trypan blue was 
added as a marker to determine cell death, whereby cells that took up the dye after a 
five-minute incubation were deemed dead. Cells which did not take up the dye were 
considered alive. Below are some images acquired from a digital Imaging microscope of 
cell populations under the different acid wash conditions. 
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Figure 6.10 Images of the cells treated with different acid-wash buffers 
As the pH of the buffer is reduced, the number of viable cells decreases. Interestingly 
however, most of the cells appear in-tact and rotund in the pH 2.8 study, and a 
significant number in the pH 2.3 study. This is the case even though an increasing 
number of dead cells occur at the lower pH wash. Conversely, in the pH 1.8 acid wash 
study all the cells appear to be lysed and amorphous. 
As the number of dead cells increased the possibility of the cell contents being released 
into the media environment increased. This is almost certain at pH 1.8 where all of the 
cell membranes appear to be indefinable. However at pH 2.8 and to some degree pH 
2.3, the cells were not seen to be blebbing, flaccid or fragmented suggesting that the 
inner contents of the cells had not been released into the supernatant during the acid- 
wash step. However, using the pH1.8 acid washer buffer clearly lyses the cells 
indicating that the use of such a harsh environment is not a viable option in attempting 
to remove all of the membrane-bound ligand for quantification. 
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6.4.8 Displacement of the immunoconjugate with cold trastuzumab 
In a further attempt to explain the results or indeed contest the results of the 
externalisation assay, under more physiologically acceptable conditions, a displacement 
assay was performed. Since antibody binding to its epitope is reversible, by adding a 
large excess of cold antibody to the cells, it was hoped to displace any membrane- 
bound radiolabelled TSA by competitive binding, while internalised '25I-TSA would be 
unaffected. Thus any displaced 125I-immunoconjugate conjugate may be related to the 
amount of conjugate bound to HER2 receptors at the cell surface, whereas any 
internalised 125I-immunoconjugate would not be displaced from the cell. The counts in 
the supernatant at the end of the displacement period represent the amount of 125I- 
conjugate that was displaced from the external HERZ receptors and the cell-associated 
radioactivity represents the fraction of internalised 125I-immunoconjuagate. A 1500 fold 
molar excess (0.5 mg/well) of cold native trastuzumab was therefore added to the 
supernatant of immunoconjugate pre-bound cells, in the hope that the 330 ng of 125J_ 
labelled TSA per well would be displaced. Non-specific interactions of 125I-TSA were 
previously demonstrated to be less than 1% (section 6.2) which is important as any 
cell-associated activity is assumed to be internalised if it cannot be competed off the 
cell-surface. Specificity of both the cold competitor and the radiolabelled 125I-TSA are 
imperative so that both ligands are competing for the same site and thus displacement 
of the 125I-immunoconjugate is directly related to its competition with cold trastuzumab. 
The SKBR3 cells were incubated with the 125I-TSA for two hours and at that time-point 
the media was replaced with fresh media prior to the addition of the competitive 
inhibitor. The assay was continued for two days in an attempt to compete out all of the 
membrane-bound '25I-TSA. The cells were kept under normal growth conditions during 
the incubation period of the experiment. Below is the graph displaying the results. 
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Figure 6.11 Graph displaying the percentage of 125I-TSA found on the cells 
over time and then with the excess competitive inhibitor trastuzumab 
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The '25I-labelled TSA is displaced from the cells rapidly by the competitor. After only 
two hours 50 % of TSA had been removed from the cell-surface and by twenty-four 
hours 92 % of the TSA was found in the solution. Without the competitive inhibitor, 
125I-TSA does dissociate from the cells to the supernatant, albeit at a much reduced 
rate. Indeed for the first three hours, greater than 90 % of 125I-TSA remained cell- 
bound and 85 % at six hours although 50 % had dissociated by twenty-four hours and 
75 % by forty-eight hours. Non-specific binding of TSA was 1 %. 
It is clear that the great majority of 125I-TSA can be displaced from the cells by excess 
cold competitive inhibitor (native trastuzumab). This suggests that the majority of 125I- 
TSA is in fact membrane-bound and not internalised over the time-spans of the studies 
conducted although it is possible that internalisation may occur over a longer period of 
time. Interestingly, the 8% of activity that remains cell-associated remains associated 
for up to forty-eight hours. The dissociation seen in the non-competed series is most 
probably due to equilibrium being established after the removal of 125I-TSA from the 
supernatant. However it may also have been the case that the binding of ligand to the 
receptors caused modulation of the receptors and increased the rate of ligand 
recycling. 
To investigate this further, a repeat study was performed with some variations. (i) The 
1251-TSA was allowed to bind for six rather than two hours. (ii) The unbound 125I-TSA 
was not removed after the initial incubation period and (iii) and the percentage of 
iodine-125 that remained protein bound at each time was measured using a TCA 
precipitation assay (section 6.4.4) to determine the extent of ligand recycling. 
In this study, a cell-binding assay was performed with 0.33 pg of 125I-TSA per well- 
plate for six hours to obtain maximum binding. After the six-hour incubation period, 
point measurements of the amount of cell-associated activity were determined for a 
total of twenty-four hours. Importantly the supernatant was not replaced after the 
initial six-hour incubation allowing for a greater proportion of the MAb to remain bound 
to the cells without dissociating by allowing for a greater degree of binding equilibrium 
at the cell-surface. A parallel study was undertaken to determine the degree of 
dissociation by using the same 1500 fold excess of cold native trastuzumab as in the 
previous study was determined in order to provide an Improved estimate of the degree 
of ligand internalisation. After the fractions were counted in a y-counter, the 
percentage of radioactivity remaining cell-bound was calculated and plotted in the 
graph below. 
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Figure 6.12 125I-TSA binding and displacement assays over thirty-six hours 
The amount of TSA bound to SKBR3 after a six-hour incubation period was 49 %. In 
the absence of competition this figure remained relatively constant over a twenty-four 
hour period indicating that the maximum level of binding of TSA is about 99 % and 
that the amount bound remains stably associated for at least a twenty-four hour 
period. This corresponds very closely with the immunoreactivity assay seen in section 
6.2. The degree of conjugate dissociation from the cell-surface in this assay is reduced 
compared with the previous study. When the '25I-TSA bound HERZ receptors are 
competed for by excess cold trastuzumab, the labelled TSA quickly dissociates from an 
initial 99 % bound to 49 % after six-hours and 18 % after twenty-four hours. 
In order to determine if the radioactivity in the supernatant was in fact dissociated 
'25I-TSA from the cell-surface or low molecular weight catabolites released from the cell 
following internalisation, the extent of protein bound iodine in the solutions was 
determined. 
The supernatants of both the competed and non-competed series were treated with a 
20 % TCA solution in a 1: 1 ratio to produce a final TCA solution of 10 %. The 
precipitated protein was then collected in a pellet by high-speed centrifugation and the 
supernatant and cell fractions were separated and analysed in a y-counter. Below are 
the results detailing the amount of 125I-labelled protein in each of the supernatant 
fraction samples. 
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Figure 6.13 Graph to determine the degree of recycled products 
(internalisation) with and without competitive inhibition after cell-binding 
The amount of labelled protein in both series starts at 99 % and decreases steadily 
over the twenty-four-hour period to 91 % in the absence of competition and 83 % in 
the presence of cold trastuzumab. 
Taken together, these assays suggest that a relatively small but significant proportion 
of the labelled TSA is being internalised by the SKBR3 cells. Approximately 18 % of the 
125I-TSA cannot be displaced from the cells by co-incubation with unlabelled 
trastuzumab, and thus corresponds well with the amount of 125I-TSA that cannot be 
stripped from the cells by the pH 2.3/1.8 acid wash. The presence in the supernatant of 
non-protein bound radioiodine suggests in addition that around 8% of the'25I-TSA has 
been internalised and recycled. In total, therefore, the results indicate that a maximum 
of about a quarter of the bound '25I-TSA is internalised over a twenty-four hour period. 
6.5 Pretargeting adherent cells with li'In-radiolabelled DLB 
After it was established that internalisation did not appear to be a large feature of 125I- 
TSA-HER2 binding a pretargeting assay was carried out. The effect of a clearing agent 
was imitated by replacing the media containing unbound TSA by fresh media after 
pretargeting the cells. Using different concentrations of effector molecule both at lower 
molar concentrations to TSA and greater it was possible to define the level of effector 
molecule binding and the concentration at the cell-surface. 
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After the SKBR3 cells had adhered to the well plates the media was replaced, the cells 
were pretargeted with 0.33 pg of cold TSA for two hours and then the media was 
replaced to remove the unbound TSA. Using the data from the kinetics study graph in 
figure 8.5, the concentration of TSA bound to the cell surface at this time was 
calculated to be approximately 50 % of total TSA added. Different concentrations of 
effector molecules (DLB or DBB) were then added to each well. These concentrations 
were a multiple of the bound TSA concentration being five-fold less, five-fold greater 
and ten-fold greater than TSA. By using a smaller amount of effector molecule, 
maximum binding could be determined. By using an excess of effector molecule relative 
to TSA, the concentration of available TSA conjugates at the cell-surface could be 
determined and related to an expected amount of effector molecule bound. Below is 
the graph constructed from the six data sets showing the time after effector molecule 
addition. 
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Figure 6.14 Graph displaying the percentage binding of a fixed 
concentration of effector molecules d-DLB and DBB to two different 
concentrations of Immunoconjugate pretargeted on adherent SKBR3 cells 
The study containing a five-fold lower molar ratio of "'In-DLB to TSA produced cell 
binding of 90 %±1.7 % and 111 In-DBB bound with 86 %±1.5 % of the total activity. 
When a five-fold greater molar ratio was used, DLB was found to bind with 68 %±2 
% and DBB bound with 70 %±4% of the total activity. With a ten-fold molar excess 
of TSA binding to DLB and DBB was 38.6 %±0.7 % and 39 %±0.8 %. The table 
below compares the levels of binding seen with those that would be expected 
(assuming that four molecules of DLB or DBB are able to bond to each molecule of TSA. 
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(assuming that four molecules of DLB or DBB are able to bond to each molecule of 
TSA. 
Table 6.1 Table comparing expected over observed pretargeted effector 
molecule concentrations 
Moles to TSA % Observed Bound 
DLB DBB 
% Expected 
DLB DBB 
5x Less 90 86 100 100 
5x More 68 70 80 80 
10x More 36 33 40 40 
The results show firstly that there is very little difference between the binding of the 
mono-valent DLB-effector molecule and the bivalent DBB. They also show that the 
levels of binding achieved in practice are very close to the maximal levels of binding 
that could be achieved assuming a 4: 1 biotin: streptavidin binding stoichiometry. 
6.6 Cross-linking study 
An assay was performed to investigate whether the double biotin substituted effector 
molecule was able to cross-link cell bound TSA in order to differentiate between cell- 
bound and circulating streptavidin. As a clearing agent had not been developed it was 
hoped that such a mechanism could provide a way of increasing the amount of 
radiolabelled DBB at the tumour and amplify the tumour dose. 
A pretargeting binding study of TSA was performed with SKBR3 cells for two hours and 
the excess trastuzumab was then removed. The concentration of cell bound cold TSA 
was assumed to be 50 % of the total added. Additional concentrations of TSA relative 
to that bound were then added to the fresh media covered cells to simulate different 
levels of "circulating" conjugate. These concentrations of cold TSA in the media were 1, 
2,4 and 8 times the concentration of cell-bound TSA. Immediately following the TSA 
addition a 1: 1 molar ratio of DLB or DBB to bound TSA was added to each well. Over a 
three hour period at 20,40,60,120 and 180 minute time-points the radioactive 
supernatant was removed for analysis, the cells washed and the remaining cell-bound 
radioactivity quantified. Below is the graph indicating the percentage of "'In-labelled 
effector molecule remaining bound to cell-bound TSA relative to the concentration of 
cold TSA in solution after the three hours incubation. 
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Figure 6.15 Graph comparing the cross-linking abilities of DLB with DBB 
The binding curve loosely follows a first order decay curve whereby each doubling of 
the concentration of TSA in the supernatant halves the amount of cell binding. Thus a 
1: 1 ratio of cell localised to cell media suspended TSA produces a 48 % and 47 % 
binding of radiolabelled DLB and DBB molecule respectively. With a 2: 1 ratio, 23 % and 
24 % of radioactivity is cell bound and with a 4: 1 ratio, 13 % and 12 % of "'In-d-DLB 
and DBB respectively had localised to the cells. The eight fold excess of TSA in the 
supernatant reduced the amount of radiolabelled effector molecule found at the cell- 
surface to only 2% with DLB and 6.5 % with DBB. 
When comparing the data for DLB and DBB it is clear that there is no discernible 
difference in performance between the two effector molecules found at the pretargeted 
cell surface. This remains true for all concentrations of excess TSA and at all time-points 
across the three hour assay. If cross-linking was occurring, a greater proportion of the 
radiolabelled bivalent effector molecule would be expected to localise to the adherent 
pretargeted cells than with DLB. The results suggest that no cross-linking occurs when 
using DBB at least under the experimental conditions employed. 
6.7 Conclusions 
In this chapter it has been shown that TSA has an unaltered immunoreactivity (75.6 %) 
when compared to that of native trastuzumab (72 %). Non-specific binding was very 
low demonstrating that interactions were specific. The cell-binding rates of TSA were 
not very different to that of trastuzumab though they were slightly slower probably due 
to the increased molecular mass of the conjugate species. 
It is a requirement of the pretargeting approach that the pretargeted conjugate 
remains on the surface of the tumour cells until the effector molecule is administered 
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and is not either shed or internalised by the cells. Published studies on the 
internalisation had been inconclusive. While some 5' 332 suggested that internalisation 
did occur, another 281 suggested that it did not. We therefore considered it important to 
investigate the extent of internalisation of our trastuzumab-streptavidin conjugate. 
First experiments using published methodologies indicated that internalisation accounts 
for two thirds of the total cell-associated activity after a two-hour incubation. From a 
pretargeting viewpoint this would suggest that HERZ may not be a viable pretargeting 
receptor. However, following the analysis of the externalisation assay demonstrating 
that no externalisation had taken place over a four hour period it was considered 
necessary to further investigate whether internalisation results were reliable. 
When radioiodinated antibodies are internalised by cells they are catabolised in the 
lysosomes and low molecular weight fragments including free iodine are secreted by 
the cells. We found only 5% of non-TCA precipitable radioiodine in the cell culture 
supernatant and this suggests that only a small degree of internalisation was in fact 
taking place. We therefore studied more closely the conditions employed in the 
internalisation assay. This assay depends entirely on the proviso that a buffer at pH 2.8 
is able to strip receptor-bound antibody from the surface of the cells but leaves the 
internalised antibody unaffected. 
However the acid-wash buffer with a pH of 2.8 clearly was not able to remove all the 
cell membrane-bound 125I-TSA as harsher conditions brought about greater radioactive 
wash fractions. Buffers at pH 2.3 and 1.8 proved equally successful at removing the 
external 125I-TSA from the cells thus demonstrating the lower effective pH limit 
necessary for removal by a wash method. As 10 % of the activity remained cell-bound 
after the pH 1.8 and pH 2.3 wash, the data suggests that either all of the membrane- 
bound 125I-TSA has been removed by the wash or there was an intrinsic limit in the 
assay. 
Upon microscopic analysis it was observed that the cells tested under a range of pH 
acid-wash buffers had varying degrees of cell-death and lysis proportional to the 
hydronium ion concentration. When using the pH 1.8 wash all the cells were lysed, 
whereas at pH 2.8 and 2.3 treated cells appeared to maintain their cellular integrity 
even though a greater number of cells took up Trypan Blue. This raises the possibility 
of Internalised cell contents leaking out of the cells and confounding the results of the 
internalisation assay. Therefore it seems that the pH wash-buffers were not suitable for 
both removing surface-bound TSA at the same time as maintaining cell viability. 
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One of the most conclusive analyses of determining the level of internalisation is the 
displacement of 125I-TSA with cold trastuzumab. Only external radiolabelled species 
would be able to be dissociated from their receptors. A large degree of displacement of 
the ligand occurred showing that by 24 hours 80 - 90 % of 125I-TSA had been 
uncoupled from HERZ. Only low levels of radiolabelled antibody catabolites were found 
in the cell supernatant. These results therefore suggest that in total only about 20 % of 
the bound TSA would be internalised by the cells and that the majority would therefore 
still be available for pretargeting by the effector molecule. 
In-vitro pretargeting studies showed that the labelled effector molecules were able to 
effectively target the TSA conjugate pre-bound to the cells. This process was very 
efficient and approached the maximum levels that would be expected if four molecules 
of the labelled biotin analogues were able to bind to each of the pretargeted 
streptavidin molecules. The discrepancy can be explained either by errors in estimating 
the levels of surface-bound conjugate, by internalisation, or steric hindrance to binding 
on the cell surface but it certainly suggests that, at least within the two-hour period 
studied, internalisation is unlikely to be a problem. 
When unbound conjugate was added in controlled amounts to the supernatant of the 
cells, the degree of pretargeting was, as expected, reduced in proportion to the 
concentration of free conjugate. This mimics the situation in-vivo when, unless a 
clearing agent is used, circulating levels of conjugate in the blood compete with 
tumour-bound conjugate for the injected effector molecule. We had hoped to, at least 
in part, overcome this problem by the use of a bivalent effector molecule (DBB) in a 
manner analogous to that seen with the bispecific antibody pretargeting approach. It 
was hoped that the DBB would bind more efficiently to the high concentrations of 
conjugate found on the cell surface than to the lower concentrations of conjugate 
found in the supernatant. However, we found no difference between the cell uptake of 
the monovalent (DLB) and bivalent (DBB) effector molecules. 
There are several possible explanations for this. Below is a streptavidin-biotin complex 
showing two subunits of the tetrameric protein with a single biotin per subunit. From 
the diagram below it is possible to see how biotin lies in the binding pocket which 
appears to lie flat to the circumference of the molecule. This may provide a reason why 
in fact DBB does not appear to cross-link to two or more immunoconjugates together. 
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Figure 6.16 Streptavidin-homobiotin complex obtained from molecular 
modelling data from RCSB Protein Data Bank and reconstructed in Rasmol 
v2.7. The primary data was obtained by X-ray diffraction of streptavidin 
avidinii at a resolution of 2.2 A. The Blue and green molecules are a and ß 
subunits of streptavidin and the red molecules are d-biotin. 
Restrictions in the binding of DBB to two streptavidin molecules simultaneously may be 
due to several factors. The spacer length between the two biotins may not be able to 
span the gap required to link the macromolecules together. This may be emphasised by 
the fact that the binding pocket may to a large extent bury the biotin group. 
Electrostatic interactions around the binding-pockets may be unsuited to being in close 
proximity to that of another binding pocket and repulsive forces may be stronger than 
attractive forces. The shape of DBB may be a point of study in that this may affect both 
the lie and the reach of DBB for a second streptavidin. Upon streptavidin binding, the 
polarity of the DBB molecule may shift and reduce both the affinity and capacity of 
binding. 
It is also possible that the relative concentrations of pretargeted conjugate, circulating 
conjugate and effector molecule may not provide the best opportunity for cross-linking. 
This simple in-vitro model may not adequately simulate the conditions in-vivo and other 
combinations should be explored before this concept is discarded as being ineffective. 
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Ease of preparation 
DOTA forms very stable chelation complexes when incubated at boiling temperatures 
with lanthanides as demonstrated by labelling yields approaching 100 %. Other 
chemical interactions that reduce labelling yields may form as a result of appended 
molecular species which are required to be radiolabelled. The adjoining molecular 
species must be thermostable at the labelling temperatures required to achieve 
maximal binding. Incubation times for radiolabelling reactions were varied to determine 
the optimal length of time required to obtain maximum labelling yields. A fifteen minute 
radiolabelling produced a 96 % yield whereas incubations from thirty minutes to one 
hour produced labelling yields greater than 98 % with no indication of instability and no 
purification step required. This compares well to other DOTA-biotin compounds where 
for example Cremonesi et al report labelling yields of 97 % in a very similar structured 
compound 227. 
High specific activity 
High specific activities were not fully explored with either DLB or DBB, though activities 
of up to 40 MBq of yttrium-90 were used to label 5 pg amounts of effector molecule 
with no sign of a reduction in labelling yield. Similar DOTA-biotin compounds have been 
radiolabelled with a specific activity of up to approximately 2.5 GBq/mg of effector 
molecule where 2 mg was administered and labelled with a patient specific dose 221 . 
The specific activity achievable will depend upon the quality of the radioisotope source 
and its age since production, but these studies suggest that therapeutic doses can be 
achieved when using only very small amounts of either DLB or DBB. The specific 
activity obtained in this work is as high as that obtained by other authors 227 though if 
DLB or DBB were to be radiolabelled with therapeutic levels of radioactivity counter 
measures must be put in place to ensure that rapid radiolysis of the 
radiopharmaceutical does not take place. These measures could be provided In the 
form of either ascorbic acid as mentioned in Chapter 3 or human serum albumin 256. 
High stability in-vitro and in-vivo (especially with respect to biotinidase) 
Determining the stability of DLB and DBB was an important aspect of their 
characterisation and potential use as pretargeting effector molecules. Previous attempts 
to derive radiolabelled biotin analogues have been susceptible to biotinidase 
degradation 208 after only a few hours. Several successful attempts have been made at 
synthesising biotinidase resistant compounds and this was seen as Imperative to 
producing a useful effector molecule 252,333,334, In our studies when DTPA- 
biocytinamide was incubated in serum the compound had completely broken down 
after three days whereas DLB and DBB showed no sign of degradation over the same 
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time period indicating a successful compound design. The need for a stable compound 
is supported by the data from an in-vivo 99mTc-MAG3-biocytin conjugate pretargeting 
study in which the compound was rapidly degraded and proved unsuitable for 
pretargeting applications 335. Wilbur et al have published several papers detailing the 
requirements of biotinidase resistant pretargeting effector molecules and possible 
solutions 
252,333,334 
Stimmel et at first published a chelate stability challenge assay analysing different 
chelate stabilities with yttrium-90 237. Though DLB did not have the optimal four 
carboxylates per conjugated DOTA residue available for radiometal chelation, the 
radiolabelled compound was shown to be stable under strongly acidic conditions and 
showed very little instability under the time tested. As a comparison DTPA's stability 
was tested under the same conditions and was demonstrated to have far lower affinity 
for the Indium-111 and yttrium-90 than DOTA. This result confirmed Stimmel et al's 
findings but our study did not go so far as to determine the differences between 
unconjugated DOTA and DLB with either four or three carboxylates respectively 
available for chelation. Stimmel et al's study was different to ours in that the 
radiolabelled complexes were incubated in a pH 2 glycine buffer for up to 15 days 
whereas our we varied the pH down to pH 0.5 and incubated the complexes for half an 
hour. Even though our study was altered from Stimmel et al's, both studies show that 
DLB and DOTA in our study and DOTA in Stimme) et al's study has a considerable 
stability in the form of the yttrium-90 radiometal complex and were shown to have no 
difference under the conditions studied. Thus DOTA and its resultant derivatives were 
an obvious choice as a chelate to deliver radiation to a pretargeted tumour. 
The stability in solution of yttrium-90 labelled DLB with a measured activity of 40 MBq 
per 500 pl was determined by RP-HPLC analysis at designated time points. The 
compound had completely broken down after six hours, whereas on addition of 
ascorbate, no apparent degradation was observed over a forty-eight hour period. 
Radiolysis associated with antibody molecular destruction was described by Mather et at 
336 and Salako et al 256. Chakrabarti et al published a paper detailing the use of 
ascorbate to prevent molecular destruction of proteins los. 
Low protein binding 
Non-specific protein binding in serum of a pharmaceutical is a phenomenon that occurs 
if the compound possesses a degree of lipophilicty. Ideally a pharmaceutical will 
demonstrate no protein binding as the portion that does binds to protein is rendered 
unavailable for specific interactions. "In-DLB and "'In-DBB were found to bind serum 
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protein with 5% and 6% respectively after a day period. With a pretargeting strategy 
whereby tumour to background levels are sought to be maximised, serum protein 
binding is an undesirable characteristic that should be reduced to a minimum. No 
comparative data was found detailing serum-protein binding levels with alternative 
DOTA-biotin constructs. The results observed with DLB and DBB are significant though 
this would not preclude the use of these effector molecules in a therapeutic regime. 
Nevertheless the degree of systemic radiotoxicity would be increased and tumour to 
background ratios decreased to some degree indicating a less than favourable effector 
molecule characteristic. 
High avidity for streptavidin 
In order to observe the association of the indium-111 radiolabelled biotin analogues, 
binding studies were performed with DLB and DBB in the presence of excess 
streptavidin producing binding yields of 98 % and 96 % respectively. For comparison, 
Wilbur et al synthesised a pretargeting effector molecule which bound to excess avidin 
with a yield of 90.4 % 252 though few new effector molecules have been published and 
even fewer extensively evaluated. The high chemical and radiochemical purity of the 
indium-111 labelled DLB and DBB obtained as a result of a pure synthesis product 
facilitated the high streptavidin-binding yields observed with both compounds. DLB and 
DBB streptavidin binding results compare favourably with the compounds described by 
Wilbur et al and indicate that the effector molecules chemical purity and simple 
molecular design facilitate an unimpeded high proportion of binding to streptavidin. 
Rapid localisation to the avidiny/ated tumour cells 
A high binding affinity for streptavidin was demonstrated when "In-DLB and "'In-DBB 
were both incubated with a ten-fold excess of streptavidin in solution. High binding 
yields of 97 % and 96 % respectively were obtained when incubated for twenty-four 
hours and 96 % and 92 % respectively after thirty minutes of incubation. Such rapid 
and long-lasting binding of the effector molecules indicates that their binding 
characteristics suit their application in pretargeting nuclear medicine therapy. 
High clearance rate through the urinary tract and low tissue retention in all tissues 
The clearance of the effector molecules through the urinary tract was very rapid. 
Although the actual rate was not determined, the amount of residual activity in all 
tissues sampled for in the animal biodistribution studies using both indium-111 and 
yttrium-90 radiolabelled DLB and DBB effector molecules was low. However although 
some of the Injected activity was retained in several tissues, the percentage of the 
injected dose per gram was low and reduced gradually over the twenty-four hour time 
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period studied. The highest uptake was seen in the kidney though as published by Behr 
et al lysine ions can significantly reduce kidney retention by administration prior to the 
administration of radiopharmaceutical 257. Kidney and bone retention were higher than 
optimal with both 90Y-DLB and 90Y-DBB molecules so a repeat study was performed 
using greater activity which revealed much lower standard deviations. However a t-test 
revealed that the two data sets were not statistically different and therefore ruled out 
the possibility of free yttrium leaching into the bone. High bone uptake was seen by 
Chinol et al when 90Y-DTPA-biotin was used as a pretargeting effector molecule in a 
murine tumour model 337 though this highlights the relative instability of DTPA-yttrium 
compared to that of DOTA-yttrium. A recent pretargeting study by Lewis et al 210 using 
a 'Cu radiolabelled DOTA-biotin which has been used in other studies 214,262,263 was 
demonstrated to have a considerably high liver and kidney uptake. Overall the 
biodistribution of both molecules was less than perfect, and any future effector 
molecules developed should be designed with a view to reducing bone and kidney 
uptake without sacrificing uptake in other tissues. 
Summary 
Both DLB and DBB were shown to have very similar chemical properties and as such 
will be easy to evaluate comparatively in an in-vivo pretargeting context which is 
planned for future experiments. Both compounds were shown to be stable in the 
presence of biotinidase and labelled with very high radiochemical yields. Nearly all of 
the radiolabelled DLB and DBB bound to excess streptavidin very rapidly demonstrating 
the suitability of the effector molecules for in-vivo targeting of avidinylated tumours. 
Although many of the characteristics of DLB and DBB were favourable, several features 
were suboptimal for in-vivo use. Serum protein binding was higher than hoped for and 
will reduce to some extent the benefit of the pretargeting regime over RAIT. The other 
drawback with these molecules was the relatively high kidney uptake and moderate 
bone retention seen with the animal biodistribution studies. Although counter measures 
can be used to reduce kidney toxicity, bone toxicity may be the limiting factor if large 
levels of activity are used to label these effector molecules. 
Use of alternative radioisotopes 
Different radioisotopes were used to radiolabel the effector molecules in order to 
perform various assays and evaluations. Indium-111, lutetium-177 and yttrium-90 were 
all used to label the effector molecules and produced very similar radiochemical yields 
upon labelling. When ascorbate was used to abrogate radiolysis, 90Y- and "'In-labelled 
DLB both showed similar stabilities. Cobalt-57 was also used to label DLB with a similar 
radiochemical yield to the other isotopes and although cobalt-57 does not have the 
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physical properties necessary for in-vivo imaging; it proved useful for accurately 
determining the concentration of DLB synthesis product. DOTA has been shown to 
stably chelate a range of radioisotopes 338 as our data confirms and thus the application 
of DLB and DBB for imaging and therapeutic nuclear medicine applications 338. 
A clearing agent was not designed and synthesised though several have been 
synthesised 189,337. A clearing agent was designed by Theodore and Axworthy which 
339 appears to have a very successful design 34ý" 
After two effector molecules had been synthesised the next step was to develop a 
streptavidin-antibody immunoconjugate with which a tumour could be pretargeted. A 
successful pretargeting MAb-streptavidin conjugate must possess the following 
essential properties: 
  high degree of purity 
  specific to the tumour associated antigen (TAA) 
  high affinity for the TAA 
  high affinity for effector molecule 
" does not internalise 
" able to be cleared to the liver rapidly with the use of a clearing agent 
  able to bind with multiple instances of effector molecule 
High degree of purity 
Trastuzumab-streptavidin (TSA) was produced using a novel conjugation method 
whereby the sulphydryls of trastuzumab were reduced in the presence of stannous ions 
and UV irradiation. Streptavidin lysine residues were derivatised with SMCC, as used by 
many groups 190,191,290, which then enabled the conjugate to form. The conjugation 
reaction was initially carried out in PBS to produce an 8% yield. This result compared 
poorly with a streptavidin-antibody conjugation reaction performed by Hylarides et at 
290 who reported a 37 % yield also using PBS as a buffer. Hylarides also claimed to 
have a purified product with 90 % of the product being of a 1: 1 and 1: 2 ratio of MAb to 
streptavidin 29°. An alternative MAb buffer (TSMZ) was used in an attempt to increase 
synthesis yields which subsequently was calculated to be closer to 40 % using the 
same reaction ratios as Hylarides et al. It was our goal to obtain a pure 
immunoconjugate with a 1: 1 ratio of MAb to streptavidin, so the ratio of reactants was 
altered to a 2: 1 MAb to streptavidin ratio in order to reduce the heterogeneity of the 
synthesis product. This reaction produced yields of approximately 20 % and the 
synthesis mixture was purified using a semi-preparative HPLC system to produce a 
clean un-shouldered peak. From mass determination assays and radiolabelled biotin 
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binding studies it was ascertained that the peak consisted of a heteroconjugate with a 
1: 1 ratio of MAb and streptavidin components. Therefore although the degree of 
reagent wastage increased, the purity of our purified sample was far more homogenous 
than previously published data. This suited our design criteria best as the greater the 
molecular weight, the greater the potential degree of clearance from the blood. Thus 
minimising the potential rate of blood clearance to obtain a high pretargeted tumour- 
TSA concentration and maximising the available biotin binding sites for radiotargeting is 
the balance that was sought. 
Specific to the tumour associated antigen (TAA) and high affinity for the TAA 
Previously published conjugation techniques used chemical reduction methods 239,289 
and the addition of sulphydryl groups to the MAb 191,342 Stalteri et al showed that a 
99mTc labelled photo-irradiated MAb (PR1A3) localised in the same way as 99niTc labelled 
mercaptoethanol reduced PR1A3. However with the additional complexity of a 50 kDa 
conjugated protein, it was unclear whether the immunoreactivity of the 
immunoconjugate would be lower than native trastuzumab. A Lindmo assay 244 
indicated that the immunoreactive fraction was very similar with both species (73.5 % 
± 1.5 % on average). From a literature search it appeared that TSA had not been 
synthesised previously for any type of application, thus comparative binding data was 
not available. In the same way the conjugation method used in the formation of the 
TSA conjugate had not been published on previously. TSA does not show any signs of 
possessing a reduced immunoreactivity compared with trastuzumab and appears to 
remain bound to cells well after twenty-four hours demonstrating a high affinity for the 
HERZ TAA. 
High affinity for effector molecule 
DLB was able to bind to TSA, remaining completely bound in serum over a four day 
period indicating that the effector molecule-TSA complex association is strong and 
suitable for therapeutic applications. DBB was also shown to remain completely bound 
to excess streptavidin for a minimum of twenty-four hours though longer time-points 
were not assayed for. In the same way as DLB was used to derive the stoichiometry of 
its binding to streptavidin in chapter 3, TSA was demonstrated to posses an 
approximate 1: 4 molar ratio of binding. Pretargeting with different concentrations of 
DLB and DBB were both successful and the degrees of binding were close to the 
expected values reaching a total of 90 % and 86 % of total bound respectively. This 
was close to that seen in the original streptavidin binding studies in chapters 3 and 4 
though inaccuracies introduced with the greater number of variables in the in-vitro 
studies may be the cause for the lower degrees of binding observed. The effector 
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molecule DBB was designed with the view to improving tumour radiation doses by 
sequestering more TSA molecules to a cell bound TSA-effector molecule complex. 
Although the assay featured in section 6.6 detailing an attempted cross-linking study 
was unsuccessful at localising more TSA to the adherent cell population, further studies 
are required in order to determine whether greater concentrations of DBB will prove 
more successful at cross-linking the TSA molecules than previously. Published data 
relating to binding studies performed with effector molecules and streptavidin 
conjugated MAbs was not found and only the binding studies mentioned above 
pertaining to free streptavidin reactions were seen. Most publications pass over this 
aspect and introduce the pretargeting of tumour-bearing mice at such a point 340,343. 
Although in-vivo pretargeting studies were not performed in this study, in-vitro binding 
and pretargeting studies demonstrated a very rapid association of the indium-111 
labelled effector molecule to streptavidin and the streptavidin-conjugated trastuzumab. 
In-vitro studies where "'In-DLB or "'In-DBB was incubated with excess streptavidin 
showed association rates of greater than 90 % after two just minutes though 
comparative published data could not be found. Rates of binding of radiolabelled biotin 
to the trastuzumab-streptavidin conjugate were also rapid and suggest a high binding 
rate in a RAID or RAIT context. 
Does not internalise 
Using a standard internalisation method which uses a low pH glycine buffer to 
dissociate MAbs from their receptors, internalisation was determined to be 60 % of the 
total cell-associated activity. However on reducing the pH of the acid-wash buffer by 
half a pH value the degree of internalisation was determined to be In the order of 12 % 
of total activity or 15 % of the cell-associated activity. The problem with the assay used 
lay in the assumption that any activity that remained associated with the cells was the 
internalised fraction of 125I-TSA. However, when competing out the bound'25I-TSA with 
excess cold trastuzumab, 92 % of the activity was removed from the cells. Further 
analysis of the amount of free Iodide-125 in solution resulting from any internalisation 
showed that only 8-22 % of the supernatant activity was free iodine-125. From these 
data sets it seems reasonable to suggest that the amount of TSA internalisation over a 
two-hour period is in the order of 6-16 %. It is important to note that Internalisation is 
a rapid process which should occur within two hours 5. These assays suggest that the 
original results obtained using the acid-wash methods are inaccurate. Two publications 
were found detailing the problems associated with such a method and propose new 
44, methods to more accurately determine the level of ligand internalisation I 34s. Our 
data supports the claims of these two papers that low pH (pH 2.5 -2.8) glycine buffers 
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will not fully dissociate cell-surface receptor bound MAbs due to the interactions 
employed by the MAb to bind to the receptor. Though further investigations will prove 
necessary it is prudent to point out that both investigators recommend lowering the 
surface tension of the aqueous medium through the addition of organic solvents such 
as ethylene glycol or dimethyl suiphoxide will result in reversing the attractive van der 
Waals' force into a repulsive one or even reverse the electrostatic attractive 
component. Thus the reasoning for the reduced efficiency may be that the antigen-MAb 
interactions are usually a combination of van der Waals' and electrostatic (Coulombic) 
forces. To this end, therefore although bond dissociation in other systems may be 
possible solely by pH monitoring as is the case in the dissociation of DNA/anti-DNA 
complexes at high pH 346, both pH monitoring and lowering the surface tension of the 
aqueous medium appears to be necessary in order to reverse the HER2-TSA binding 34', 
348. Therefore it appears evident from the data presented in chapter 6 that initial results 
were proved incorrect and that the level of internalisation was much smaller than 
originally thought. Although further work in this area is necessary to provide a more 
accurate measure of the degree of TSA or trastuzumab internalisation, the results 
presented here do suggest that TSA is indeed a viable pretargeting agent. 
Able to be cleared to the liver rapidly with the use of a clearing agent and able to bind 
with multiple instances of effector molecule 
In order that TSA targeting and pretargeting with effector molecules could be 
performed in tumour models. Several attempts were made to generate SKBR3 breast 
tumour xenografts in nude mice. However after a three-month period the grafts had 
not taken, A subsequent literature review was performed to establish whether this was 
an established response in mice. Care et al concluded that SKBR3 alone would not grow 
in murine models, however homeobox gene HOXB7 transduced cells would develop 
xenografts 349. 
In order to derive a HERZ (c-erbB2) proto-oncogene positive tumour model, three new 
cell lines were investigated over a three month period. The cell lines investigated were 
BT 474 350, MDA-MB-435S and MDA-MB-361 351 , where all three lines were known to be 
HERZ positive. The only cell line to produce any sort of xenograft was MDA-MB-435S 
though the xenografts only reached a maximum size of 4 mm. Recently five 4 mm 
MDA-MB-435S xenografts were dissected into six parts and thirty mice were given the 
xenografts in the hope that smaller tumours grow more rapidly due to reduced need for 
vascularisation and diffusion. The xenografts grew much more rapidly and when the 
tumours had reached approximately 4 mm a biodistribution study was performed using 
the thirty mice. 125I-labelled TSA and '25I-trastuzumab were studied in the murine 
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tumour models where at six hours, twenty-four hours and forty-eight hours the tissues 
were isolated and counted to determine the degree of radioligand localisation. Blood 
clearance was faster with 125I-TSA than 125I-trastuzumab most probably due to the 
increased molecular weight of the conjugate. Liver uptake was initially high and 
reduced steadily indicating that clearance was occurring via the liver. This rate would 
be the same in a pretargeting context until a clearing agent was introduced, where 
much of the remaining blood-borne immunoconjugate would clear to the liver as 
described by Axworthy et al 214. Tumour uptake was found to be high and increased 
over time, though some degree of variation was noted which could be due to the 
variation in xenograft sizes which were in some instances quite marked. Due to the 
valency of radiolabelled biotin to TSA the amount of TSA that localises to the tumour 
has the potential to bring about a far higher tumour-radiation dose than with 
conventional RAIT. This study is worthy of more work to determine whether TSA is a 
viable pretargeting agent. 
Future work 
Due to the encouraging results from the biodistribution assay, a repeat assay is 
planned with subsequent pretargeting studies to follow. Various radioisotopes are 
planned for use to both image and deliver therapeutic doses to the tumour xenografts. 
It may also be possible in future studies to radiolabel either DLB or DBB with a positron 
emitting isotope for micro-PET analysis. The advantage with using PET for imaging is 
that increased resolution and importantly sensitivity of detection will be increased over 
conventional SPECT imaging. These increases in resolution and sensitivity are due to 
the lack of collimator and the increased response rates of the detection cells in the PET 
camera over the SPECT camera. Thus radioisotopes with suitable positron emmisions 
that can be chelated with DOTA such as 64Cu 340 or 67Ga 352 must be used In such an 
application. A range of therapeutic radioisotopes can be used with the DOTA chelate 
thus providing the opportunity to target different sizes of tumours or metastases by 
relating radioisotopes with higher LET's to micrometastases and radioisotopes with 
lower LET's to smaller tumours. Alternatively a "cocktail" of therapeutic radioisotopes 
with different LET's may be used to facilitate the maximum dose possible across the 
largest number of targeted tumour cells of a heterogeneous tumour to provide the 
highest radiation dose possible across all cells and give the best possible therapy. 
At this stage of the investigation it appears that DLB, DBB and TSA are potentially 
viable pretargeting agents. It remains to be seen whether an anti-HER2- 
streptavidin/biotin system can succeed to the clinic. 
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A6 Amino acid sequences of an IGG1 and stretavidin 
PR1A3 (light and heavy chains) 
DIQ MT QSPSSLSASVGD R' VTITCKAS QN VGTNVA 
WYQQKPGKAPKLLIYSASYRYSGVPSRFS GSGSG 
TDFT FT IS SLQPEDIATYYCHQYYTYP LF SFGQGT 
KVEIKRTVAAPSVFIFPPSDEQLKSGTASV VCLL 
NNFY PRE AKVQWKVDNALQSGNSQESV TE QDSK 
DSTYSLSSTLTLSKADY EK HKVYACEVTHQGLSS 
PVTKSFNRGEC VQLVQSGSELKKPGASVKVSCK 
ASGYTFTEFGMNWVRQAPGQGLEWMGWINTKTG 
EATYVEEFKGRFV F'S L DT SVSTAYLQISSLKADD 
TAVYY CA RWDFYDYVEAMDYWGQGTTVT VS SAS 
TKGPSVFPLAPSS KS TSG GT AALGCLVKDYFPEP 
VTedSWNS GA LTSGVHTFPAVLQSSGLYSLS SV VT 
VPSSSLGTQTYICNVNHKP SN TK V'D KKVEPKSCD 
KTHTCPPC PAP ELLGGPS VF LFPPKPKDTLM IS RT 
PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT 
KPREEQYNST. YRV VSVLTVLHQDWLNGKEYKCK 
VSNKALPAPIEKTISKAKGQPREP Q VYTLPPSRD 
ELTKNQVSLTC LV K G,. F YPSDIAVEWESNGQPENN 
YK TTPPVLDSDGSFFLYSKLTVD KS RWQQGNVFS 
CSVMHEALHNHY TQ KSLSLSPGK 
SA 
DPSKDS KAQVSAAEAG ITGTWYNQLG STFIVTAGAD GALTGTYESA VGNAESRYVL 
TGRYDSAPAT DGSGTALGWT VAWKNNYRNA HSATtWSGQY VGGAEARINT 
QWLLTSGTTE ANAWKSTLVG HDTFTKVKPS AASIDAAKKA GVNNGNPLDA VQQ 
TFIVTA ALTGTYE YVL TGRY TALGWT VAWK NA HSATTWSGQY RINT QWLLTS E 
ANAWK TLVG HDTFT 
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7. A novel pretargeting carrier molecule 
J. E. S. Hainsworth and S. J. Mather 
Nuclear Medicine Department, St Bartholomew's Hospital, London, 
UK 
A novel DOTA conjugated pretargeting radioimmu- 
notherapy carrier molecule has been developed with 
the aim of producing a cancer imaging and therapeutic 
agent with an improved biodistribution than existing 
products. The carrier molecule was synthesized from a 
resin bound lysine derivative to which biotin and DOTA 
were consecutively conjugated. Labelling with "'In and 
90Y yielded >95% labelled product without the need for 
purification. Experiments demonstrated that the `x'Y 
labelled DOTA-lysine-biotin (DLB) compound was as 
stable as 90Y labelled DOTA in acid stability tests. 
Labelled DLB bound completely to excess streptavidin, 
both in phosphate buffered saline and serum. Human 
serum protein binding was low, at 11%, ensuring rapid 
blood clearance in an in vivo context. Incubating the 
compound in fresh human serum for up to 24 h 
demonstrated complete resistance to any biotinidase 
activity. Biodistribution studies in norniol mice of ""Y 
labelled DLB showed minimal organ retention and very 
rapid blood clearance. Gut and kidneys showed reten- 
tions of 0.11% and 0.2% ID respectively at 24 h p. i. The 
molecule labels well, has been shown to be very stable, 
and, due to its relative hydrophilicity, has a very good 
biodistribuLion profile. With these points in mind the 
molecule looks like a promising agent for pretargeting. 
8. Methylcholine incorporation correlates with tumour 
proliferation 
F. Al-Saeedi, A. Welch and T. A. D. Smith 
Biomet ral Physics Department, Unirmrsity of Aberdeen, UK 
Purpose: To investigate the nature of incorporation of 
methylcholine into tumour cells and to determine its 
relationship with proliferation. 
Methods: To simulate, using cells in tissue culture 
flasks, the rapid blood clearance of "C-methylcholine in 
patients undergoing "C-methylcholine PET scans, tu- 
mour cells were pulsed with 3H-methylcholine, washed 
and chased with cold medium. Cells were extracted 
with organic and aqueous solvents to determine the intracellular location of the tracer. Tumour cells were 
also grown at different cell densities producing popula- tions of cells with different proliferative fractions (55"%, 
42% and 26%) and 'H-methylcholine incorporation 
determined. 
Nuclear Medicine Communications (2003) 24 
Results: During a 30 min incubation period of cells, 
pre-labelled for 10 min with 3H-methylcholine, in non- 
radioactive medium, about 20% of activity effluxed. Of 
the activity remaining in the cell only 15% was lipid 
soluble, that is, had been incorporated into phospholi- 
pids. 'H-methylcholine incorporation standardized to 
milligrams of protein, was highest in cells with the 
highest number of proliferating cells and vice versa. 
Conclusions (1) During the timescale of a 17C- 
methylcholme PET scan, most activity is not incorporated 
into phospholipid at least in tumour cells in vitro. (2) The 
uptake of radiolabelled methylcholine may he a measure 
of tumour cell proliferation 
9. The production of macroaggregated albumin from 
recombinant human albumin for lung perfusion 
imaging 
A. Hunt, M. Frier, R. Johnson, S. Berezenko and 
A. Perkins 
Academic Department of Medical Physics, Queen's Medical Centre, 
Nottingham, UK 
Human serum albumin (HSA) extracted from pooled 
blood donors is used in the production of "`1mTc labelled 
macroaggregated albumin (MAA) for lung perfusion 
imaging. However, concerns for the safety of blood 
derived products due to potential contamination by 
infective agents (e. g., nvCJD), make alternative produc- 
tion methods necessary. Recombinant DNA technology is 
a promising method of albumin production as it avoids 
problems associated with human derived }ISA. This 
paper presents results comparing MAA prepared from 
recombinant human albumin (rHA, Recombumin") 
(MAAr) with HSA MAA produced in-house and MAA 
produced commercially. ' "Tc-MAA was prepared using 
previously published production methods by heating a 
mixture of albumin and stannous chloride in acetate 
buffer (pH 5.4) at 70'C for 20 min. Parameters investi. 
'gated included aggregate size, radiolabelling efficiency, 
radiochemical and aggregate stability at 4'C and in vitro 
(in whole blood and plasma) at 37 C and Biodistribution 
studies. Results showed that MAAr could be produced 
with similar morphology, labelling efficiency and stabi- 
lity to MAA, suggesting the feasibility of using rHA as 
the base material for routine formulation and manufac- 
ture of lung perfusion agents. Our findings will be 
discussed with reference to the potential use of ri IA as a 
direct replacement for HSA in commercially available 
MAX 
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EVALUATION OF PET NUCLEOSIDE ANALOGUES IN TUMOUR 
CELLS 
J M. Grilles', N. Smith', H Willtam0°, P Julyan', a Hastings', G. Vat- 
dyanthanb and J. Zweit' 
'Y"RL'K (WIST R6ndtt"nun/ Turgrling and toms g Group. Pa, er- 
%ou insulate for (nmrr Rrwarth & North II'rst Sledua! Pittsa, s. 
C"hnsu,. ((ucpnn! NF/. S Trutt, IPthndnu Rruu/ Mans pester 6A, and 
'Dept n! Rad, oht v, DuAs Lniversut LfeJual Critter, Durham. VC. 
'77111.1 SA. 
Butkyround Thymtdmc analogues are currently being imesUgated 
for a number of PET applications including imaging of cell 
proliferation and gene expression We are interested in ex, umnmg 
the meats of "I labelled It'dR and FIAL' as potential in i rro markers 
of cell proliferation Two NSCLC cell lins. H4611 and H596 were 
chosen to assess total cellular uptake and DNA incorporation of ''01- 
111dR. '"1-Fl AT , 
'H-thým, dmr and 'H-FLT 
Rru. h The total cell uptake of both'll-thymtdme and'"1-lCdR. 
at hh was higher for 11460 than for 11596 whish is consistent with the 
faster growth rate of the I141>tl After 24h more than 15% of the total 
'I I-Ihvmtdme uptake was associated wwtth DNA for 11460 and >110', 
for H596, For "'I-l UdR. the incorporation into DNA of both cell 
line, increased from 1119 at 24h to a mammum of >90% by 49h for 
114(41 and >70% for H596 O%cr the whole incubation period. >90',. 
and > il)% of the total '-41-Fl NI J uptake was nuclear hound for 11460 
and 1-1596 cells respectively In contrast. DNA incorporation levels for 
'H-FLT were 16". and 12% li, r 11460 and 11596 over the same period. 
Conrhtrtvni This work demonstr tes the correlation of DNA 
uptake with the S-phase faction Both 'H-thyaudmc und'='1-lUdR 
have the closest correlation with the cell uptake whereas '11-FLT 
shows a negative correlation and 10l-Fl AC has no correlation. Thew 
prelmunarv results indicate that the total and nuclear incorporation of 
''al-ICdR were greater in the faster growing cell line. Further work is 
needed to highlight the specific merits of these nucleoside analogues in 
reflecting tumour DNA synthesis. 
VIRRAD, THE VIRTUAL RADIOPHARMACY: THE FIRST 
PROTOTYPE 
S. J. Mather and J. K. Sosabowski, on behalf of theVirRAD Consor- 
tium 
Orp, n/ .A mlenr NrJu'ne. Se &ýnhn/o, nen c Hupual, Gmdnn. I K. 
The purpose of the Vu RAD prnXa is to sce if we can use the 
worldwide web to bring together all of thou working in raahopharnacy 
and the rubopharmacrutical sciences into a virtual community %here 
they can learn, access information. exchange stews and discuss best 
practice The VirRAD project has been running for 1K monuhs now, and 
the first prototype is currenil being evaluated. This prototype consists 
of a communm site that provides communication tools and features 
such as a library, glossary, links to useful wcMncs and news. There is 
also a sample courseware section and access to a virtual ralbopharmacy 
laboratory. This presentation will provide an update on the progress of 
the project and the results of the user evaluation of the first prototype. 
A NOVEL PRETARGETING TRASTUZUMAB-STREPTAVIDIN 
CONJUGATE 
J. E S Hainsworth and S. J. Mather 
Sr Býurhu/wnr,, a /Iospool, Gxuton. G'A 
Aim The purpo. c of this study was to develop a pretargeting 
tra, tuiwnah streptawdm conjugate using photo-reduction as dc- 
Nuclear Medicine Communications 2004, Vol 25 No 4 413 
scnbcd by Mather es al III and to compare it with a chemically 
reduced monoclonal antibody (MAN) conjugation 
Stetluxit. Streptavidin denvatved with sulfosuconimidyl 4-(, V- 
maletmtdomethyltcyclohexane-t-cartnix) Lite was combined with re- 
duced trau tutumab in the pre once of stannous ions (photo-reduction) 
or mercaptoethanol (chemical reduction) Two butlers were studied: 
phosphate buffer and TSMZ (triethanolamne, sodium chloride. 
magnesium chloride and nits chloride) both at p11 7.3. Charactenot- 
aon of the conjug dc was performed using size exclusion IIPLC. SDS 
PAGE and mass spectrometry. 
Results Phosphate butkred conjugations produced very low yields 
(-5%), but TSMZ buffered solutions produced yields comparable to 
other studies. Both chemical and photo-reduction conjugation reac- 
(ions gave yields of up to 41)"4 consistently. Ratios of 1.2 
(MAIS ctrcptavidm) gave the best yield and stoa: htometry. IIPLC 
purification produced a product with greater than 99% purity and 
initial stability studies are encouraging. 
Gxawlmionr" The photo-reduction technique produces a MAI, 
conjugate with acceptable yields and comparable with chemical reduction 
methods The photo-reduction technique is a much simpler method and 
provides a rapid and reliable way to conjugate the two proteins. 
Reference 
I Mather SJ. Ellison D. Reduction-mediated tcchnetium-W)m 
labellutg of monoclonal annbodicc. J ASal. (feil 199(1; 11 692-697. 
COMPLEMENTARY ALTERNATIVE MEDICINE AND NUCLEAR 
MEDICINE THERAPYAND DIAGNOSIS 
U. Werneke and R. McCreadyb 
"Nomerron t'nnenm" Hospital, Lnndnn, and hRnra! Alarsden Ilacpual. 
Saun. UK. 
Purpose: A recent survey demonstrated that about 70% of patients 
attending a cancer hospital were taking alternatme medicines (CAMs). 
These medicines included herbal remedies. food supplements, vitamin 
preparationi and various other organiv and inorganic substances 
which could potentially ullcct the uptake and retention of radio- 
phannaccuticals 
bled- AA literature search was performed to disco er the nature, 
composition and potential ctlcts of sah alternative meheincs on un- 
scnlcd source radiotherapy and makar medicine diagnostic procedures. 
Rerun CAM. s acre found to contain a runt) of substances which 
could affect therapy and diagnosis. In thyroid cancer therapy iodine. 
lithium, selenium which could affect the turnover of radioiodinc. 
Herbal remedies include stimulant plants curb as tobacco, lobelia. 
gingko, ginseng all of which could äffen the uptake of ml lt . 
CAMS 
which could affect som: uostaun analogue therapy intude gingko. 
ginseng and ergot demuttves. Glomerular filtration rates can he 
alrnnd by a randy of CAMx including fish oils and L-argininc. 
Coruhniun It is important therefore to ask which GAMS patients 
are taking to order to acquire data which might explain unusual results 
in therapy and diagnosis. Patients should not alter their drug regime 
(including CAM. ) between GFR measurement and the admtntrtrution 
of clrcmothcrapy to prevent miscalculation of their doss. 
PREPARATION AND ANALYSIS OF ""TC MOXIFLOXACIN AS AN 
INFECTION SPECIFIC IMAGING AGENT 
R. Kashanf, M. S. Cooper and S. S. Das 
De/lit of Nwlenr Aledirinc and Mrdkal Mierohiulugr, St Burrhnh, - 
nh, 4'c llospiwf, Louh, n. UK. 
Aim: To prepare a nosel radiopharmaccuncul (ß"b"1 moxtfoxacinl 
as a potential bacteria specific infection imaging agent. 
A/rthodr Moxdloaacm was radiolabelled with "Tc by a number of 
ddlercnt methods. Variables included choice of co"hgand. choice of 
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